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 Abstract 
The ability to predict and control molecular arrangements without compromising 
the individual molecules themselves still remains an important goal in supramolecular 
chemistry. This can be accomplished by establishing a hierarchy of intermolecular 
interactions such as hydrogen and halogen bond, which may facilitate supramolecular 
assembly processes.  
Several acetaminopyridine/acetaminomethylpyridine supramolecular reactants 
(SR’s) were prepared with aliphatic carboxylic acids in order to determine patterns of 
molecular recognition preferences of the N-H moiety. The results obtained revealed the 
formation of molecular cocrystals through heteromeric O-H…N/N-H…O hydrogen 
bonds with the acetaminopyridine/acetaminomethylpyridine binding site. Furthermore, 
the SR’s also reacted with metal ions resulting in robust 1D and 2D metal-containing 
architectures. 
A series of pyridyl/pyrazine mono-N-oxide compounds were synthesized and 
reacted with a variety of halogenated benzoic acids, in order to assess the ability of these 
molecules to establish binding selectivity when both a hydrogen and halogen bond donor 
is present. The results obtained revealed that the pyridyl/carboxylic acid synthon formed 
7/7 times and halogen bonds (N-O…I or N-O…Br) extended the SR/acid dimers into 1D 
and 2D networks. These results were rationalized via charge calculations as well as 
through the hierarchical view of intermolecular interactions consisting of hydrogen and 
halogen bonds.  
Furthermore, a series of thienyl compounds were synthesized and allowed to react 
with halogen bond donors to determine whether the halogen bond is purely electrostatic 
or based on the hard and soft acids and bases principles. The results obtained showed that 
of the 34 reactions between a halogen bond donor and thienyl compounds, the halogen 
bond is predominantly electrostatic in nature. 
Finally, as a result of our improved understanding on molecular recognition, we 
were able to carry out systematic structure-property studies on a series of cocrystals of 
anti-cancer drug molecules with aliphatic carboxylic acids. This study revealed that 
systematic changes to the molecular nature of the co-crystallizing agent combined with 
 control over the way individual building blocks are organized within the crystalline 
lattice makes it possible to establish predictable links between molecular structure and 
macroscopic physical properties, such as melting behavior, solubility, dissolution rate, 
etc. 
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or based on the hard and soft acids and bases principles. The results obtained showed that 
of the 34 reactions between a halogen bond donor and thienyl compounds, the halogen 
bond is predominantly electrostatic in nature. 
Finally, as a result of our improved understanding on molecular recognition, we 
were able to carry out systematic structure-property studies on a series of cocrystals of 
anti-cancer drug molecules with aliphatic carboxylic acids. This study revealed that 
systematic changes to the molecular nature of the co-crystallizing agent combined with 
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CHAPTER 1 - From molecular recognition to fine-tuning 
physical properties of pharmaceutical compounds 
1.1 Introduction 
1.1.1 Molecular recognition 
Molecular recognition1 i.e. the way in which molecules interact and communicate 
with each other through non-covalent intermolecular forces2 is essential in biological 
systems as well as in areas of pharmaceutics, materials science and polymer chemistry. 
According to Jean-Marie Lehn, recognition involves complementarity interactions 
between associating partners, i.e. the information content of a receptor with respect to a 
given substrate.1 In essence, the recognition process extends over energetic features as 
well as over geometrical ones, which has being eloquently illustrated by Emil Fischer’s 
concept of the steric fit “lock and key” model.1,3 Further illustrating Lehn concept that 
recognition is binding with a purpose, similarly receptors are ligands with a purpose1 
Figure 1.1. 
 
Figure 1.1 Example of selective molecular recognition. 
 
Thus it is important to have a comprehensive understanding of non-covalent 
interactions, in order to reliably predict molecular organization, assembly and 
connectivity in the solid state as this will ultimately aid in controlling physical properties 
of bulk materials.4  
1.1.2 Generation of complementarity through self-assembly 
Self-assembly is a process of organizing molecular units into ordered structures 
through non-covalent interactions thereby generating supermolecules.5  It is a powerful 
 2 
strategy for the generation of structural and functional complexity. Several studies have 
shown that extended supramolecular architectures can be synthesized with the aid of 
complementary intermolecular interactions.6 Most of these supramolecular synthetic 
strategies employed are based on the combination of functional groups located on 
different molecules that prefer to interact with each other rather than with themselves.7,8  
Furthermore, the organization of different functional groups results from the 
molecular information stored in the component and from the active groups, which they 
bear. Thus generating molecular order is based on recognition-directed spontaneous 
assembly of one functional group from complementary molecular components, each of 
which presents two identical recognition sites,9 Figure 1.2.  
 
Figure 1.2 Schematic representation of the formation of an ordered structure through 
molecular-recognition assembly of two different molecular units.9 
 
The most famous and well-known example of self-assembly is the DNA double 
helix, a self-assembly of two complementary helical strands, held together through 
hydrogen bonding between base pairs,10 Figure 1.3.  
           
Figure 1.3 Example of self-assembly. 
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Other examples of self-assembly include inorganic and hydrogen-bonded 
multicomponent entities.11 Furthermore, these examples provide us with more insight into 
controlling molecular recognition and self-assembly, thereby allowing for further 
construction of supermolecules. 
1.1.3    Hydrogen bond in crystal engineering 
Hydrogen bonding, the master key for molecular recognition,12 is the most 
reliable directional interaction in supramolecular construction, and is highly significant in 
crystal engineering;13 the latter has been defined as “…the understanding of 
intermolecular interactions in the context of crystal packing and in the utilization of such 
understanding in the design of new solids with desirable physical and chemical 
properties.”14 
The field of crystal engineering is greatly indebted to the pioneering work of Etter 
and co-workers who began to focus attention on the ability of hydrogen bonds to help 
control molecular crystallizations.15 Moreover, this early work revealed that reliable 
hydrogen-bonding motifs are formed by many elementary functional groups frequently 
encountered in simple molecules. Together, these observations along with the hydrogen-
bond rules provide useful information about preferred connectivity patterns, hydrogen-
bond selectivity, and stereoelectronic properties.16 
The hydrogen-bond rules proposed by Etter are very useful and can be applied to 
organic hydrogen-bonded structures. The general rules state: 
1. all acidic hydrogens available in a molecule will be used in hydrogen 
bonding in the crystal structure of that compound.17 
2. all good acceptors will be used in hydrogen bonding when there are 
available hydrogen-bond donors.18 
3. the best hydrogen-bond donor and the best hydrogen-bond acceptor will 
preferentially form hydrogen bonds to one another.19 
These guidelines have set the stage for important advances in crystal engineering where 
structures are built from more sophisticated molecules, specifically designed to 
incorporate multiple sites of hydrogen bonding and oriented in arrays favoring the 
assembly of networks with predictable architectures,20 Figure 1.4. 
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Figure 1.4 Formation of a hexagonal network, broken lines represent directional 
intermolecular interactions.21 
 
Hydrogen bonds are usually written as D-H…A and normally involve an 
electronegative atom such as O or N as the acceptor (A) and an atom, as the donor (D) 
where D is more electronegative than A.22 Normal hydrogen bonds typically range in 
strength from approximately 4-60 kJ mol-1, although certain highly acidic compounds 
such as HF2- have hydrogen bond energies of up to 120 kJ mol-1.23 Whereas, the typical 
hydrogen bond distances are 2.50-2.80 Å (H…A), interactions in excess of 3.0 Å may 
also be significant.23  
The design step of crystal engineering utilizes the knowledge of non-covalent 
forces that mediate the formation of supramolecular synthons, which are “structural units 
within supermolecules which can be formed and/or assembled by known or conceivable 
intermolecular interactions.”24 
 Hydrogen-bonded supramolecular synthons are commonly used in crystal 
engineering, and an improved understanding of their geometries, and their frequency of 
occurrence in the presence of other hydrogen-bonding groups, will allow us to design and 
synthesize novel cocrystals. Supramolecular synthons are divided into two categories; 
homosynthons,25 which are composed of self-complementary functional groups, as 
exemplified by the carboxylic acid dimer 1 and the amide-amide dimer 2, and 
heterosynthons,25,26 which are composed of different but complementary functional 
groups 3-6, Figure 1.5. 
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Figure 1.5 Few examples of supramolecular synthons selected from the recent 
literature: homosynthons (1-2) and heterosynthons (3-6).25,26 
 
1.1.4 Co-crystallization a tool for probing intermolecular interaction 
Co-crystallization plays a vital role in probing intermolecular interactions 
between different molecules; these involve the deliberate bringing together of different 
molecular species within the same crystalline lattice without making or breaking covalent 
bonds.27 The overall aim of a co-crystallization reaction is to obtain a heteromeric 
compound, rather than a homomeric species (recrystallization), Figure 1.6.  
 
Figure 1.6 Recrystallization (homomeric intermolecular forces dominates) and co-
crystallization (heteromeric intermolecular forces dominates). 
 
Obtaining a heteromeric compound is easier said than done, because molecules by 
nature are inherently selfish and tend to stick with themselves. However, by developing 
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new systematic strategies we can increase the chances of obtaining a heteromeric 
product. With this in mind, one of the major goals of this dissertation is to probe for 
intermolecular recognition by conducting systematic studies on series of cocrystals. A 
cocrystal is a “structurally homogeneous crystalline material that contains two or more 
neutral building blocks that are present in definite stoichiometric amounts.”27,28 Two 
examples of a cocrystal are shown in Figure 1.7. 
 
   
   (a)                  (b) 
Figure 1.7 Two examples of a cocrystal (a) 3-(acetaminomethyl)pyridine succinic 
acid (1:1),11 (b) N,N'-1,6-hexanediylbis-4-pyridinecarboxamide suberic acid (1:1).29 
 
1.1.5  Molecular electrostatic potential as a tool for ranking   
  hydrogen/halogen bond donor and acceptor strength 
According to one of Etter’s rules “the best hydrogen bond donor and the best 
hydrogen-bond acceptor will preferentially form hydrogens to one another.”19 Therefore, 
it begs the question, how do we determine the strength of a given donor or acceptor 
molecule in order to determine the best donor and best acceptor?  
Hunter has shown that hydrogen bonding mainly involves electrostatic 
interactions and the molecular electrostatic potentials (MEP) of a given functional group 
which can be determined using low level of theoretical calculations provides a useful 
method for ranking different donors/acceptors.30 The association constants (K) have been 
measured for a wide variety of intermolecular interactions both in the gas phase and in 
solution. Furthermore, simple molecules such as benzoic acid or amino benzoic acid can 
be analyze in terms of pair-wise hydrogen-bonding interactions between the functional 
groups. These results can then be accounted for by the following relationship, Equation 
1.30 
log K = c1α2Hβ2H + c2   Equation 1 
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“Where c1 and c2 are constants that depend on the solvent and α2H and β2H are functional 
group constants that relate to the hydrogen-bond donor and hydrogen-bond acceptor 
properties of the molecules.”30 
 Therefore equation 1 can be correlated to the electrostatics of the hydrogen-
bonding interaction.31 Moreover, computed molecular properties such as atomic charge 
and electrostatic potential have been correlated to the values obtained for α2H and β2H.32 
 Furthermore, AM1 molecular electrostatic potential calculations carried out by 
Hunter, established that values obtained for α2H and β2H can be correlated with the 
experimentally determined values. Additionally, values of α (hydrogen bond donor) and 
β (hydrogen bond acceptor) can be calculated from the MEP by dividing by a correction 
factor of 52 kJ mol-1 resulting in: 
  α = Emax/52 kJ mol-1 = hydrogen bond donor constant 
β = -Emin/52 kJ mol-1 = hydrogen bond acceptor constant.30 
Hence MEPs can be used to rank the strength of hydrogen-bond donors and 
acceptors of a variety of functional groups, thus allowing us to probe the best-donor/best-
acceptor hypothesis.  
1.2 Halogen bonding as a complement to hydrogen bonding in crystal 
engineering 
The hydrogen bond occupies a position of central importance in chemistry, 
biology and materials science. Its properties, which include well-defined directionality 
and strength, as mentioned earlier, have lead to profound consequences for 
supramolecular chemistry in general. Although the hydrogen bond is generally accepted 
to be unique, recently Resnati and co-workers have demonstrated that noncovalent 
interactions of strength and directionality comparable to the hydrogen bond can be 
accomplished via halogen bonding (XB).33 
The term XB indicates any D…X-Y interaction in which X is an electrophilic 
halogen atom (Lewis acid, XB donor), D is a donor of electron density (Lewis base, XB 
acceptor), and Y is carbon, nitrogen, or halogen, Figure 1.8.34 
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D = N, O, S, Se  X = I, Br, Cl   Y = C, Halogen, N 
Figure 1.8 Schematic representation of XB. XB acceptors (D) are neutral or anionic 
species, while donors (X) are halogen atoms bound to a wide diversity of molecular 
arrays (Y).34 
 
Normally the energy of XB interaction spans a very wide range from 5-180 
kJmol-1, the weak Cl…Cl interaction between chlorocarbons and the very strong I-...I2 
interaction in the I-3 being the extremes.33 Moreover the interaction between the donor and 
the acceptor results in a shortening of the D…X distances and the stronger the interaction 
the shorter the D…X distance.33 
In addition, Hunter and co-workers have also used MEP calculations to show that 
XB have molecular recognition properties comparable to a moderate hydrogen-bond 
donor, and should therefore form complexes with strong hydrogen-bond acceptors such 
as pyridine.35  
1.3 The role of crystal engineering in pharmaceutical science 
Crystal engineering15,16,36 strategies have been used in understanding and 
predicting hydrogen-bonding interactions in active pharmaceutical ingredients (API). 
Pharmaceuticals are generally comprised of an API, a formulation containing inactive 
ingredients as a carrier system, and a package for market performance and appeal.  
A crystalline form of the API is strongly preferred because of their relative ease of 
isolation, and the physico-chemical stability that the crystalline solid state affords. The 
vast majority of API’s occur as solids; these include, salts, polymorphs, cocrystals and 
hydrates/solvates, 37 Figure 1.9. Nevertheless the use of crystalline materials can result in 
problems such as poor solubility properties or the existence of more than one crystalline 
form of an API.  However, crystal engineering affords a paradigm for rapid development 
of a fourth class of API’s; pharmaceutical cocrystals. 
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Figure 1.9 Pictures displaying the more common solid-state strategies and their 
respective components.38 
  
The form “pharmaceutical cocrystal” is commonplace and usually applies when an API is 
one of the molecules in the multicomponent crystal.37,38 Two examples of pharmaceutical 
cocrystals are shown in Figure 1.10. 
         
   (a)      (b) 
Figure 1.10 Examples of pharmaceutical cocrystals: (a) N,N'-1,6-hexanediylbis-4-
pyridinecarboxamide succinic acid;29 (b) N,N'-1,6-hexanediylbis-4-pyridinecarboxamide 
adipic acid.29 
 
1.3.1  Problems encountered during the development of API 
During the development and formulation of any API, several stringent 
performance parameters (e.g. solubility, dissolution rate, thermal stability, etc.) need to 
be carefully considered.39 It is thus not surprising that poor biopharmaceutical properties 
(opposed to toxicity or lack of efficacy, Figure 1.11)40 are the main reason that less than 
1% of active compounds eventually make it into the marketplace.41  
 10 
 
Figure 1.11 Reasons why compounds fail and slow down in development.39 
 
1.3.2  Fine tuning physico-chemical properties by pharmaceutical   
  cocrystal formation 
It has been well established that issues ranging from poor solubility and 
inadequate dissolution properties to lack of crystallinity and attendant instability plague 
the pharmaceutical industry.42 Recent studies, have shown that an opportunity exists to 
use co-crystallization to replace the solid forms of API that are being used, by taking 
advantage of supramolecular synthons.37 
1.3.2.1 Fine-tuning melting point behavior via co-crystallization 
The thermal stability (i.e. melting point) is a fundamental physical property. There 
have been several literature reports where co-crystallization was used as a tool in fine-
tune melting point behavior of an API. These results showed that the API melting point 
can typically be fine-tuned according to which coformer is chosen; therefore if a higher 
melting cocrystal is desired then a higher melting coformer should be selected and vice 
versa.43 
1.3.2.2 Modulating solubility via co-crystallization 
The aqueous solubility of a drug substance is one of the fundamental properties 
evaluated early in discovery. Majority of APIs fall into Biopharmaceutical Classification 
Scheme44 (BCS) classification II45 (low solubility, high permeability) furthermore 
aqueous solubility is a major indicator of the solubility in the intestinal fluids.46 To 
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generally describe solubility the Pharmacopoeia (USP) uses seven different solubility 
expressions as shown in Table 1.1. 
 
Table 1.1 Solubility Definitions46,47 
Descriptive term 
(solubility definition) 
Parts of solvent required 
for one part of solute 
Solubility range 
(mg/mL) 
Solubility assigned 
(mg/mL) 
Very soluble (vs) <1 >1000 1000 
Freely soluble (fs) From 1 to 10 100-1000 100 
Soluble (s) From 10 to 30 33-100 33 
Sparingly soluble (sps) From 30 to 1000 10-33 10 
Slightly soluble (ss) From 100 to 1000 1-10 1 
Very slightly soluble (vss) From 1000 to 10,000 0.1-1 0.1 
Practically insoluble (pi) ≥10,000 <0.1 0.01 
 
Pharmaceutical cocrystals have been demonstrated to profoundly modify the 
solubility of the parent API,29,Error! Bookmark not defined.43,44,47,48,49 and at least 90 APIs have 
been studied in the context of co-crystallization.  Often APIs that are targeted for 
pharmaceutical co-crystallization display undesirable solubility and possess multiple 
hydrogen bonding sites.50 
In fact, Bak and co-workers highlighted the ability of a series of pharmaceutical 
cocrystals for improving the solubility of the parent API. It was found that oral 
administration of the cocrystal showed a maximum plasma concentration 8 times greater 
compared to the oral administration of the pure API.43,51 Similarly, Childs et al48 
highlighted a cocrystal that exhibited approximately 4-fold increase in plasma 
concentration over the pure API after a single oral dose.  
1.4 Goals 
Understanding molecular recognition is important in the construction of new 
molecules. This can result in gaining control of intermolecular interactions, thereby 
providing opportunities to fine-tune specific properties (thermal stability, solubility, 
hygroscopicity, etc) of a variety of compounds. 
Therefore, this dissertation will focus on: 
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I. Understanding molecular recognition through systematic studies of 
 acetamidopyridine  
 Acetamidopyridine were of interest because pyridine derivatives exhibit high 
biological activity as is demonstrated in wide variety of pharmaceutical compounds.52 
Moreover the acetamide derivatives have shown to be effective inducers of cell growth.53 
Furthermore, by understanding the molecular recognition processes of this small 
molecule will provide us with valuable information, which can be used to understand 
larger and more complicated molecules. Therefore a series of acetamidopyridine 
derivatives will be designed and synthesized. Subsequent co-crystallizations with 
hydrogen-bond donors, will allow for a systematic study of molecular recognition 
preferences. Additionally, these supramolecular reagents will also be employed for 
organizing coordination complexes into extended architectures, using robust self-
complementary hydrogen-bonding capability. 
 
II. Balancing intermolecular hydrogen and halogen bonding 
 Halogen bonding has been shown to have similar strength and directionality as the 
hydrogen bond. To probe the strength of the halogen bond a collection of supramolecular 
reagents having the capability to participate in both hydrogen and halogen bonding will 
be tested. Additionally, Etter’s rule which states that the best hydrogen-bond donor will 
interact with the best hydrogen-bond acceptor, will be tested using MEPs in ranking the 
strength of the hydrogen and halogen bond, thus allowing for better predictability. 
 
III. Establishing the interaction of preference of the XB with thienyl compounds 
 A series of supramolecular reagents containing sulfur atoms will be synthesized. 
Subsequent co-crystallization reactions will be carried on these supramolecular reagents 
using a variety of halogen bond donors, in order to determine whether XB in these series 
is strictly electrostatic or a hard/soft acid and base interaction. 
 
IV. Applying molecular recognition in fine-tuning physicochemical properties 
 Finally, systematic studies will be carried out on a series of API’s with the 
ultimate goals of fine-tuning the melting behavior and aqueous solubility. 
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CHAPTER 2 - Exploring the hydrogen-bond preference of N-H 
moieties in cocrystals of 
acetamidopyridine/acetamidomethylpyridine  
2.1  Introduction 
2.1.1 Molecular recognition through intermolecular interaction 
In recent years, several efforts have been made to identify robust supramolecular 
synthons, and the reliability of homomeric self-complementary pair-wise hydrogen 
bonds, for example, amide…amide, carboxylic acid…carboxylic acid and 
oxime…oxime, have been established through extensive structural1 or database studies.2 
Some heteromeric pair-wise interactions are particularly robust, for example, carboxylic 
acid…pyridine,3 hydroxy…pyridine,4 and hydroxy…amine,5 which have allowed for the 
assembly of a wide range of binary cocrystals.  
However, to add more versatility and refinement to crystal engineering, it is 
necessary to further explore the possibility of “ranking” different supramolecular 
synthons. Thus to expand on this area we have employed a combination of two well-
known and robust synthons,6 the heteromeric carboxylic acid…pyridine interaction and 
the N-H…O (amide…carbonyl) interaction in an attempt to prepare binary cocrystals.  
The initial assembly of these cocrystals will be achieved by locating a carboxylic acid 
and a pyridyl moiety on different molecular fragments. Once this interaction is locked 
into place, the resulting binary aggregates can be further organized through N-H…O 
interactions. However, complications occur since the N-H donor has a choice of three 
different potential hydrogen-bond acceptors, it is not obvious how the competition 
between those three oxygen atoms will play out. 
We have carried out a systematic structural study on a family of 
acetamidopyridine compounds comprising of an amide moiety and an N-heterocyclic 
fragment, Figure 2.1.  This study will allow us to determine patterns of molecular 
recognition preferences of the N-H moiety based upon analysis of several new cocrystals 
as well as of relevant data obtained from the Cambridge Structural Database (CSD).7  
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Figure 2.1 Target compounds 3-acetamidopyridine 1, 4-acetamidopyridine 2, and 3-
acetamidomethylpyridine, 3. 
 
2.1.2    Controlling supramolecular structures through hydrogen  
  and coordination bonds 
 
Majority of crystal engineering has primarily focused on the syntheses of 
extended organic networks and transition metal based coordination polymers. Not enough 
work has been done on the construction of inorganic-organic hybrid materials with 
intermolecular forces;8 this is as a result of the daunting task of having precise control 
over its structural motifs.  The composite of inorganic-organic materials is important 
because it brings together synthetic flexibility as well as properties and reactivities 
inherent to the metal ions.  Some of the common reasons for incorporating metal ions into 
supramolecular networks are metal ions give access to physical properties that are less 
common in organic solids, such as magnetic properties, conductivity and catalytic 
activity. 
Metal ions also display a range of coordination geometries allowing for greater 
flexibility in constructing materials with specific dimensions and topologies. In fact, 
many reliable strategies based upon coordinate-covalent bonds have been employed in 
the syntheses of inorganic polymeric networks with predictable connectivity and 
dimensionality, typically through the use of bridging ligands such as 4,4-biypyridine, 
dicarboxylates, bis(amides), bis(lactams) and bis(pyridines).9 In addition, the strength and 
directionality of the hydrogen bond have offered supramolecular pathways towards the 
directed assembly of extended organic networks and multicomponent supermolecules.10 
This approach may in some case have certain advantages, as it combines the strength of 
the coordinate-covalent bond with the flexibility of the softer hydrogen-bond interactions, 
which can offer desirable physical properties such as enhanced solubility in a range of 
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organic solvents.  An important role in this approach is played by versatile bifunctional 
ligands that contain both metal-coordinating sites and functionalities that provide 
opportunities for organizing complex molecules into infinite architectures through 
supramolecular chemistry and non-covalent interactions. 
Compounds 1-3 were investigated for their ability to organize coordination 
complexes into extended architectures, using the robust self-complementary hydrogen-
bonding capability of the amide functionality (as a result of the strong N-H…O=C 
hydrogen bonds), and the reliable metal-coordinating ability of pyridine. Copper(II) 
1,1,1,5,5,5-hexafluoro-2,4-pentanedione [Cu(II)(hfacac)2], cobalt(II) 1,3-diphenyl-1,3-
propanedione [Co(II)(DBM)2] and nickel(II) 1,3-diphenyl-1,3-propanedione 
[Ni(II)(DBM)2] were utilized in this study due to the two dione anions occupying the four 
equatorial sites around the metal ion thereby producing an overall neutral metal-
containing building block.  Therefore leaving the two remaining axial sites to be utilized 
in constructing extended linear supramolecular architectures with the appropriate ligand, 
Figure 2.2. 
 
Figure 2.2 Metal(II) “paddlewheel” complexes with arrows indicating the two axial 
coordination sites. 
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2.2 Experimental  
2.2.1 Synthesis 
 
All chemicals were purchased from Aldrich, Fisher Scientific and used without 
further purification. Copper(II) 1,1,1,5,5,5-hexafluoro-2,4-pentanedione [Cu(II)(hfacac)2] 
was purchased from Alfa Aesar, whereas cobalt(II) 1,3-diphenyl-1,3-propanedione 
[Co(II)(DBM)2] and nickel(II) 1,3-diphenyl-1,3-propanedione [Ni(II)(DBM)2] were 
prepared according to the literature.11 Melting points were determined on a GallenKamp 
melting point apparatus in a capillary tube and are reported uncorrected. 1H and 13C NMR 
spectra were recorded on a Varian Unity plus 400 MHz or 200 MHz spectrometers in 
CDCl3 or DMSO-d6.  Compounds were prepared for infrared spectroscopic (IR) analysis 
as a mixture in KBr or on a ZnSe ATR crystal. 
 
2.2.1.1 Synthesis of 3-acetamidopyridine, 1 
 
 
 
1 was prepared by a previously reported method.12 3-Aminopyridine (1.882g, 20.0 
mmol) was dissolved in a mixture of pyridine (10 mL) and acetic anhydride (10 mL) and 
the resulting solution was stirred under a nitrogen atmosphere at room temperature for 24 
h. Water (10 mL) was added and the solution was evaporated in vacuo to dryness. The 
precipitate obtained was washed thoroughly with diethyl ether and recrystallized from 
methanol. The product isolated was a light peach solid (1.738g, 64%). M.p.: 133-134oC. 
1H NMR (δH; 200 MHz, CDCl3) 9.09 (br s, 1H), 8.6 (s, 1H), 8.34 (d, J = 4.8Hz, 1H), 8.21 
(d, J = 6.96Hz, 1H), 7.32 (m, J = 8.42Hz, 1H), 2.21 (s, 3H).  IR (KBr pellet) υ 1695 cm-1 
(C=O, s), 1533 cm-1 (Amide II, s). 
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2.2.1.2 Synthesis of 4-acetamidopyridine, 2 
 
 
4-Aminopyridine (1.882g, 20 mmol) was dissolved in a mixture of pyridine 
(10.00 mL) and acetic anhydride (10.8g, 106 mmol, 10 mL). The mixture was left to stir 
at room temperature for 24 h under a nitrogen atmosphere. Water (10 mL) was added 
and the solution was evaporated under reduced pressure to dryness. The precipitate 
obtained was washed thoroughly with diethyl ether and recrystallized from methanol. 
The product isolated was a light yellow solid (1.76g, 65%). M.p.: 144-146oC. 1H NMR 
(δH; 400 MHz, CDCl3): 8.52 (d, J = 12Hz, 1H), 7.5 (d, J = 12Hz, 1H), 2.23 (s, 3H); IR 
(KBr pellet) υ 1689 cm-1 (C=O), 1515cm-1 (Amide II, s). 
  
2.2.1.3  Synthesis of 3-(acetamidomethyl)pyridine, 3 
 
 
 
3-(Acetamidomethyl)pyridine was prepared by employing a modification of the 
previously reported procedure.13 Acetic anhydride (10 mL) was added very slowly into a 
mixture of pyridine (10 mL) and 3-(aminomethyl)pyridine (5.00 mL, 50.0 mmol) with 
continuous stirring and the resulting solution was refluxed for 1 h. Excess of acetic 
anhydride and acetic acid produced during the reaction were evaporated under reduced 
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pressure and the product thus obtained was recrystallized from diethyl ether. The 
product isolated was brown liquid (7.5g, 77%). 1H NMR (δH; 400 MHz, CDCl3): 8.45 (s, 
1H), 8.39 (d, J = 5.08 Hz 1H), 7.69 (d, J = 49.4 Hz, 1H), 7.40 (br s, 1H), 7.29 (m, J = 
7.81Hz, 1H), 4.362 (d, 2H), 1.98 (s, 3H). 
 
2.2.2 Synthesis of cocrystals and salts 
2.2.2.1  Synthesis of 4-acetamidopyridinium  hydrogenglutarate (1:2), 2HG 
2 (0.030g, 0.22mmol) was dissolved in 4 mL of acetonitrile. To this solution was 
added GLU (0.015g, 0.11 mmol) in 4 mL of acetonitrile. The resulting solution was 
heated and allowed to stand at room temperature for slow evaporation. Colorless prisms 
were obtained after five days. M.p.: 119-121oC; IR (KBr pellet) υ 2500 cm-1, 1850 cm-1 
(O-H…N), 1652 cm-1 (C=O acid, s), 1555 cm-1 (Amide II, s). 
2.2.2.2   Synthesis of 4-acetamidopyridine suberic acid (1:1), 2SUB 
2 (0.030g, 0.22 mmol) was dissolved in 5 mL of acetonitrile. To this solution was 
added SUB (0.038g, 0.22 mmol) in 5 mL of acetonitrile. The resulting solution was 
heated and left at room temperature for slow evaporation. Colorless plates were obtained 
after five days. M.p.: 129-130oC; IR (KBr pellet) υ 2520 cm-1, 1940 cm-1 (O-H…N), 
1691 cm-1 (C=O acid, s), 1589 cm-1 (C=O amide I, s), 1511 cm-1 (Amide II, s). 
2.2.2.3   Synthesis of 4-acetamidopyridine sebacic acid (1:1), 2SEB 
2 (0.03g, 0.22 mmol) was dissolved in 5 mL of acetonitrile. SEB (0.044g, 0.22 
mmol) dissolved in 7 mL of acetonitrile was added to the solution. The mixture was 
heated and left to evaporate at room temperature for five days; at which time colorless 
prisms were obtained. M.p.: 120-123oC; IR (KBr pellet) υ 2500 cm-1, 1850 cm-1 (O-
H…N, br), 1698 cm-1 (C=O acid, s), 1597 cm-1 (C=O amide I, s), 1514 cm-1 (Amide II, 
s). 
2.2.2.4  Synthesis of 3-(acetamidomethyl)pyridine succinic acid (1:1), 3SUC 
3 (0.015g, 0.099 mmol) was dissolved in 4 mL of ethanol and mixed with a 
solution of SUC (0.012g, 0.099 mmol) in 4 mL of ethanol was added and allowed to 
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stand at room temperature under slow evaporation. Colorless plates were obtained after 
ten days. M.p.: 79-81oC; IR (ZnSe ATR crystal) υ 2423cm-1, 1956cm-1 (O-H…N, br), 
1707cm-1 (C=O acid, s), 1543cm-1 (C=O amide, s). 
2.2.2.5  Synthesis of 3-(acetamidomethyl)pyridine 4-hydroxybenzoic acid (1:1),  
  3HBA 
A solution of 3 (0.015g, 0.099 mmol) in 4 mL of ethanol was mixed with a 
solution of HBA (0.014g, 0.099 mmol) in 4 mL of ethanol and allowed to stand at room 
temperature for slow evaporation. Transparent orange-brownish plates were obtained 
after eleven days. M.p.: 113-117oC; IR (ZnSe ATR crystal) υ 2627cm-1, 1928cm-1 (O-
H…N, br), 1675cm-1 (C=O acid, s), 1548cm-1 (C=O amide, s). 
2.2.3 Synthesis of Metal Complexes 
5.2.1.1  Synthesis of Co(3-acetamidopyridine)2(1,3-diphenyl-1,3-
 propanedionato)2, 1a 
A mixture of 1 (0.027 g, 0.200 mmol) in 7 mL of ethanol-acetonitrile (1:1) was 
added to a solution of Cobalt(II) 1,3-diphenyl-1,3-propanedione (0.028g, 0.010 mmol) in 
7 mL of ethanol-acetonitrile (1:1). The mixture was heated for 5 minutes to reduce the 
volume to 5 mL and then allowed to stand in screw cap vial at room temperature for ten 
days, at which time dark orange crystals appeared. IR (KBr pellet, cm-1) 3409m [υ (NH)], 
1672[υ(C=O)], 1570, 1553vs[υ(amide II)]. The confirmation of this complex was made 
from the X-ray structural results. 
 
2.2.3.2   Synthesis of Ni(3-acetamidopyridine)2(1,3-diphenyl-1,3-   
  propanedionato)2, 1b 
A solution of 1 (0.027g, 0.200 mmol) in 7 mL of methylene chloride was added to 
a mixture of Nickel(II) 1,3-diphenyl-1,3-propanedione (0.049g, 0.010 mmol) in 7 mL 
methylene chloride. The mixture was heated for 5 minutes and then allowed to stand at 
room temperature in a screw cap vial. After ten days light green crystals were obtained. 
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IR (ZnSe ATR crystal, cm-1) 3301m [υ(NH)], 1670[υ(C=O)], 1589, 1547vs [υ(amide 
II)]. The confirmation of this complex was made from the X-ray structural results. 
 2.2.3.3   Synthesis of Cu(4-acetoamidopyridine)2(1,1,1,5,5,5-hexafluoro-2,4- 
  pentanedione)2, 2a 
2 (0.03g, 0.20 mmol) was dissolved in 10 mL of methanol-acetonitrile (1:1) and 
was added to a solution of Cu(1,1,1,5,5,5-hexafluoro-2,4-pentanedione)2 (0.049g, 0.010 
mmol) in 10 mL methanol-acetonitrile (1:1). The resulting solution was shifted to a screw 
cap vial and allowed to stand at room temperature. Bright green needles were afforded in 
4 weeks. IR (ZnSe ATR crystal, cm-1) 3260m [υ (NH)], 1672[υ(C=O)], 1596, 
1514vs[υ(amide II)]. The confirmation of this complex was made from the X-ray 
structural results. 
2.2.3.4   Synthesis of Co(3-acetamidomethyl)pyridine)2(1,3-diphenyl-1,3-  
  propanedionato)2, 3a 
A solution of 3 (0.015g, 0.099 mmol) was dissolved in 4 mL acetonitrile and a 
solution of Co(II) 1,3-diphenyl-1,3-propanedione (0.023g, 0.049 mmol) in 4 mL of 
acetonitrile. The solution was heated and allowed to stand at ambient temperature in a 
screw cap vial. After 4 weeks transparent orange plates were obtained. IR (ZnSe ATR 
crystal, cm-1) 3436m [υ (NH)], 1652[υ(C=O)], 1554, 1521vs [υ(amide II)]. The 
confirmation of this complex was made from the X-ray structural results. 
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2.3 Results 
A summary of the crystallographic information for 2HG, 2SUB, 2SEB, 3SUC, 
3HBA and 1a-b, 2a, 3a are displayed in Table C.1 and all hydrogen-bond geometries for 
2HG, 2SUB, 2SEB, 3SUC, 3HBA and 1a-b, 2a, 3a are listed in Table 2.1. 
Table 2.1 Hydrogen-bond geometries for 2HG, 2SUB, 2SEB, 3SUC, 3HBA, 1a-b,  
  3a 
Structure  D-H…A d(D-H)/Å d(H…A)/Å d(D…A)/Å <(DHA)/o 
2HGi N(11)-H(11)...O(21) 0.88(3) 1.79(3) 2.677(2) 177(2) 
 O(25)-H(25)...O(21)#1 0.96(3) 1.58(3) 2.5309(19) 170(2) 
 N(14)-H(14)...O(26)#2 0.86(2) 1.97(2) 2.824(2) 177(2) 
     
 
2SUBii N(17)-H(17)...O(39)#1 0.877(13) 1.950(13) 2.8142(10) 
168.4(12) 
 N(27)-H(27)...O(32)#2 0.900(13) 2.018(13) 2.9156(9) 
174.2(12) 
 O(31)-H(31)...N(11) 1.036(19) 1.517(19) 2.5484(10) 
172.8(17) 
 O(38)-H(38)...N(21) 1.07(2)  1.48(2) 2.5454(9) 
173.8(18) 
     
 
2SEBiii O(21)-H(21)...N(11) 1.136(19) 1.421(19) 2.5516(15) 
172.5(17) 
 N(17)-H(17)...O(22)#2 0.845(19) 2.012(19) 2.8494(15) 
170.8(17) 
     
 
3SUCiv O(21)-H(21)...N(11) 0.965(13) 1.652(13) 2.6145(9) 
174.0(12) 
 N(17)-H(17)...O(18)#2 0.878(13) 1.971(13) 2.8259(10) 
164.3(12) 
     
 
3HBAv N(17)-H(17)...O(22)#1 0.858(16) 2.012(17) 2.8678(12) 
175.1(16) 
 O(21)-H(21)...O(18) 0.92(2) 1.63(2) 2.5467(11) 
175(2) 
 O(24)-H(24)...N(11)#2 0.82(2) 1.92(2) 2.7081(13) 
160(2) 
     
 
1avi N(47)-H(47)...O(47)#2 0.875(19) 2.052(19) 2.9245(14) 
174.5(18) 
     
 
1bvii N(13)-H(13)...O(17)#2 0.88(2) 2.10(2) 2.9696(18) 
173(2) 
     
 
3aviii N(48)-H(48)...O(48)#2 0.868(14) 2.191(15) 3.0576(12) 
176.0(13) 
i) #1 -x,-y,-z+2    #2 x+1,y+1,z-1 ii) #1 x-1/2,-y+1/2,z+1/2    #2 x+1/2,-y+3/2,z-1/2  iii) #2 -x+1/2,y-1/2,-z+1  iv) #2 x,y-1,z  v) #2 
x,-y+1/2,z-1/2 vi) #2 x,-y+3/2,z+1/2    vii) #2 x,-y+1/2,z-1/2   viii) #2 x,-y+3/2,z+1/2 
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2.3.1 Description of cocrystals 
2.3.1.1  Crystal structure 4-acetamidopyridinium hydrogenglutarate (1:2), 2HG 
The crystal structure determination of 2HG showed that a salt had formed 
resulting from proton transfer from one of the acid moieties of glutaric acid to the 
pyridine ring leading to a charge assisted N-H+…O- hydrogen bond as the driving force 
for the formation of the salt, Figure 2.3.  Also one oxygen is bifurcated and is 
participating in an O-H…O hydrogen bond with the remaining neutral carboxylic acid 
moiety resulting in a tetrameric pair of ions, Figure 2.4. The N-H amide moiety forms a 
hydrogen bond with a C=O moiety at the neutral end of the anion (N14-H14…O26, 
2.823 Å). These interactions connect adjacent tetramers into an infinite chain.   
 
Figure 2.3  Thermal ellipsoids (50%) and labeling scheme of the supramolecular 1:2 
trimer in 2HG. 
 
Figure 2.4 Two ion pairs connected into a tetramer in 2HG. 
 
2.3.1.2    Crystal structure of 4-acetamidopyridine suberic acid (1:1), 2SUB 
The asymmetric unit of 2SUB contains two molecules of 2 and one molecule of 
SUB.  The primary synthons in this structure are two unique O-H…N hydrogen bonds 
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resulting from the interactions between the dicarboxylic acid and the two 
acetamidopyridine molecules O(31)-H(31)...N(11), 2.5484(10)Å; and O(38)-
H(38)...N(21), 2.5454(9) Å, Figure 2.5.  Adjacent trimeric supermolecules are 
interconnected via an amide-carbonyl hydrogen bond with the C=O moiety as the 
acceptor located on the carboxylic acid. The result of this interaction is an infinite 2-D 
layer of orthogonal supermolecules Figure 2.6. 
 
Figure 2.5     Thermal ellipsoids and labeling scheme of 2SUB. 
 
 
Figure 2.6   2-D layer of 2SUB formed via N-H…O hydrogen bonds. 
 
2.3.1.3   Crystal structure of 4-acetaminopyridine sebacic acid (1:1), 2SEB 
The crystal structure of 2SEB has one molecule of 2 and half a molecule of SEB 
in the asymmetric unit. The trimeric supermolecule is constructed from symmetry related 
O-H..N hydrogen bonds between the O-H of the dicarboxylic acid and the pyridine atom 
(O21…N11, 2.5516(16) Å), Figure 2.7. Adjacent trimers are interconnected via an 
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amide-carbonyl hydrogen bond with the C=O moiety as the acceptor located on the 
carboxylic acid. The result of this interaction is an infinite 2-D layer of orthogonal 
supermolecules, Figure 2.8. 
 
Figure 2.7   Thermal ellipsoids (50%) and labeling scheme of the supramolecule 2:1 
trimer in 2SEB. 
 
 
Figure 2.8 Orientation of adjacent supramolecular trimer in 2SEB. 
 
2.3.1.4   Crystal structure of 3-(acetaminomethyl)pyridine succinic acid (1:1),  
  3SUC 
The asymmetric unit of 3SUC contains one molecule of 3 and half a molecule of 
SUC. Two symmetry related O-H…N hydrogen bonds are formed through the two O-H 
groups of the dicarboxylic acid and pyridine nitrogen atoms (O(21)-H(21)...N(11), 
2.6145(9) Å). The two pyridine rings in the trimer are coplanar with respect to one 
another as well as with the plane of SUC but the amide groups at both ends are 
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positioned in an up-down arrangement, Figure 2.9. Adjacent trimeric supermolecules 
produced from the primary hydrogen bonds are connected to one another via symmetry 
related hydrogen bonds involving H17 from the amide N-H group of one molecule and 
O18(#2) to an adjacent amide C=O group, N17...O18#2, 2.8259(10)Å. The overall result 
is an infinite 1-D ladder of trimers, Figure 2.10. 
 
Figure 2.9 Thermal ellipsoids (50%) and labeling scheme of the supramolecular 2 : 1 
trimer in 3SUC. 
 
 
Figure 2.10     Alignment of trimers by N-H…O hydrogen bonds resulting in infinite 
2-D ladders in 3SUC. 
 
2.3.1.5  Crystal structure of 3-(acetamidomethyl)pyridine 4-hydroxybenzoic acid  
  (1:1), 3HBA 
In the crystal structure of 3HBA, the asymmetric unit comprises two molecules of 
3 and one molecule of HBA. The primary synthons are the two unique O-H…N 
hydrogen bonds resulting from the interactions between the 4-hydroxybenzoic acid and 
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the 3-(acetamidomethyl)pyridine molecules (O(21)-H(21)...O(18), 2.5467(11) Å and 
O(24)-H(24)...N(11), 2.7081(13) Å, Figure 2.11. Adjacent trimeric supermolecules 
produced from the primary hydrogen bonds are further connected with one another via 
two unique hydrogen bonds, involving H17 from the amide N-H group and O22 on the 
acid C=O group N(17)-H(17)...O(22)#1, 2.7081(13) Å, resulting in an infinite 2-D ladder, 
Figure 2.12. 
 
Figure 2.11  Thermal ellipsoids (50%) and labeling scheme of the supramolecular 
trimer in 3HBA. 
 
 
Figure 2.12 Orientation of adjacent supramolecular trimers in 3HBA affected by N-
H…O=C (amide) hydrogen bonds. 
 
2.3.2 Description of Metal Complexes 
 
Table 2.2   Selected bond distances and angles for compounds 1a-b, 2d, 3c 
Compounds M(II)-N (Å) <N-M(II)-N (o) 
1a Co1-N41, 2.1865(10) 180.0 
1b Ni1-N11, 2.1189(2) 180 
2a Cu1-N11, 1.994(3) 179.999(1) 
3a Co1-N41, 2.1746(8) 180.0 
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2.3.2.1    Crystal structure of Co(3-acetamidopyridine)2(1,3-diphenyl-1,3-   
  propanedionato)2, 1a 
 
The centerpiece in the crystal structure of 1a is a hexa-coordinated cobalt(II) 
complex. Each metal complex is located on a crystallographic inversion center with an 
octahedral geometry constructed from two chelating 1,3-diphenyl-1,3-propanedionato 
anions and two 3-acetamidopyridine molecules coordinating through their pyridine 
nitrogen atoms with a Co-N distance of 2.1865(10) Å, Figure 2.13. 
 
Figure 2.13      Molecular geometry and thermal ellipsoids (50%) for the complex ion in 
1a. 
 
The pyridine rings of the two-amide ligands are planar with respect to one another 
and the amide groups in the complex are facing opposite directions. The chelate rings 
formed by the 1,3-diphenyl-1,3-propanedionato ligands have cis-angles ranging from 
88.88o to 91.12o, with the short angle, as expected, being associated with the bite of the 
chelate ring. The N-H group of one amide ligand and C=O group of the other group, in 
each metal complex, engages in self-complementary N-H…O hydrogen bonds with the 
neighboring molecules (N47...O47, 2.9245(14) Å), arranging in 1-D chain of complex 
molecules. The remaining amide N-H and carbonyl group, in each metal complex form 
symmetry related hydrogen bonds with neighboring chains producing an infinite 2-D 
sheet structure Figure 2.14. 
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Figure 2.14      2-D layer in the structure of 1a generated by symmetry-related N-H…O 
hydrogen bonds. 
 
2.3.2.2      Crystal structure of Ni(3-acetamidopyridine)2(1,3-diphenyl-1,3-  
  propanedionato)2, 1b 
The crystal structure of 1b has the nickel ions coordinated octahedrally by two 
unique 1,3-diphenyl-1,3-propanedionato ions and two 3-acetamidopyridine molecules. 
The two symmetry-related axial ligands display Ni-N distances of 2.1188(12) Å and the 
amide groups arranged in a trans fashion, Figure 2.15. 
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Figure 2.15        Molecular geometry and thermal ellipsoids (50%) for the complex 1b. 
 
Pyridine-based ligands on adjacent complex ions form intermolecular N-H…O=C 
hydrogen bonds, N13…O17, 2.9696(18) Å, resulting in a 2-D sheet structure, Figure 2.16. 
 
 
Figure 2.16    2-D layer in the crystal structure of 1b generated by symmetry-related N-
H…O hydrogen bonds. 
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2.3.2.3       Crystal structure of Cu(4-acetamidopyridine)2(1,1,1,5,5,5-hexafluoro- 
  2,4-pentanedione)2, 2a 
 
The crystal structure of 2a contains the expected six-coordinated copper (II) 
complex as well as one molecule of methanol and acetonitrile. The geometry at the Cu(II) 
center is a 4 + 2 coordination, resulting from two O,O'-chelating hexafluoro-2,4-
pentanedionato ions and two 4-acetamidopyridine ligands coordinated through their 
pyridine nitrogen atoms in trans positions, with Cu-N distance of 1.994(4) Å, Figure 2.17. 
 
Figure 2.17      Molecular geometry and thermal ellipsoids (50%) for the complex ion in 
2a (solvent molecules not shown). 
 
The N-H groups on both ligands engage in N-H…O hydrogen bonds with a C=O 
moiety from a ligand on a neighboring complex, producing an infinite 2-D layer, Figure 
2.18. 
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Figure 2.18    2-D layer in the structure of 2a generated by symmetry-related N-H…O 
hydrogen bonds. 
 
2.3.2.4       Crystal structure of Co((3-acetamidomethyl)pyridine)2(1,3-diphenyl-1,3- 
  propanedionato)2, 3a 
 
The central motif in the crystal structure of 3a is a 4 + 2 hexa-coordinate 
cobalt(II) complex where the metal ion is located on an inversion center. The two 
chelating 1,3-diphenyl-1,3-propanedionato anions occupy the equatorial plane, whereas 
the two 3-(acetamidomethyl)pyridine molecules complete the complex ion by 
coordinating through their pyridine nitrogen atoms with a Co-N of 2.1746(8) Å, Figure 
2.19.  
 
Figure 2.19    Molecular geometry and thermal ellipsoids (50%) for the complex ion in 
3a. 
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The pyridine rings of two amide ligands are coplanar and the amide groups in the 
complex are oriented trans with respect to the N-M(II) –N axis. The chelate rings formed 
by the anionic acac ligands have cis angles ranging from 89o to 92o, with the short angle, 
as expected, being associated with the bite of the chelate ring.  The N-H group of one 
amide ligand and the C=O group on a pyridyl ligand on an adjacent complex engage in 
self-complementary N-H…O hydrogen bonds, N48…O48, 2.191(15), resulting in an 
infinite 2-D sheet structure, Figure 2.20. 
 
 
Figure 2.20      2-D layer in the structure of 3a generated by symmetry-related N-H…O 
hydrogen bonds. 
 
2.4 Discussion 
2.4.1 Formation of acetamido/acetamidomethyl-pyridine cocrystals and salts 
Infrared spectroscopy plays a vital role in screening the formation of cocrystal; 
since the interaction between a N-heterocyclic compound and carboxylic acid show two 
broad stretches near 2450 cm-1 and 1900 cm-1, characteristic of O-H…N(py) hydrogen 
bonds.14 These stretches appeared in the vibrational spectra of all five compounds 
suggesting the presence of COOH….py intermolecular interactions. However, if the 
formation of a salt occurs it can be eliminated by looking at the conversion of the 
carbonyl to the carboxylate anion (COO-).  In the vibrational spectra of compounds 
2SUB, 2SEB, 3SUC, and 3HBA the carbonyl stretch appears above 1670 cm-1; whereas, 
in compound 2HG the carbonyl stretch is shifted to a lower wavenumber, below 1660 
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cm-1 suggesting the presence of COO- anions, Table 2.3. Furthermore, single-crystal 
structural determinations carried out on 2HG, 2SUB, 2SEB, 3SUC, and 3HBA 
confirmed the assignments made on the basis of the vibrational spectroscopy.  
 
Table 2.3 Summary of IR data for compounds 2HG, 2SUB, 2SEB, 3SUC, and  
  3HBA 
Compounds 2HG 2SUB 2SEB 3SUC 3HBA 
Observed COOH/COO- Stretch (cm-1) 1652 1691 1698 1707 1675 
Product Salt Cocrystal Cocrystal Cocrystal Cocrystal 
 
The distinction between cocrystal and salts can also be determined upon selective 
intermolecular distances and angles. In the crystal structures of 2SUB, 2SEB, 3SUC, and 
3HBA each carboxylic acid contains distinctly different C-O bond distances 
corresponding to the C=O (1.217-1.224 Å) and C-O(H) (1.300-1.317 Å) covalent bonds. 
Furthermore, the C-N-C endocyclic bond angle of the heterocyclic moieties fall in the 
range of 114.4o-119.6o, which is indicative of a non-ionized pyridine unit. In contrast, in 
the structure of 2HG the carboxylate C-O bond distances are more similar (1.27/1.23 Å). 
In addition, the C-N-C endocyclic bond angle of the heterocyclic moiety is 121.1o, which 
is typical for a pyridinium cation.14 
2.4.2 Intermolecular interactions 
The five crystal structures obtained exhibit similar primary trimeric 
supermolecules constructed through the expected intermolecular O-H…N synthon 
between the dicarboxylic acid and pyridine except for structure 3HBA. In addition to the 
primary hydrogen bonding within each trimer, the N-H moiety in each acetamido group 
is further involved in the formation of hydrogen bonds with a neighboring molecule; in 
all five structures the amide C=O moiety act as the hydrogen bond acceptor. Besides the 
primary interaction that takes place between the carboxylic acid or carboxylate and 
acetamido/acetamidomethylpyridine, four other types of motifs are possible in this series 
of compounds, Figure 2.21. The frequency of occurrence of each type of motif is 
summarized in Table 2.4. 
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Figure 2.21 Expected primary acid…pyridine synthons (I). Three possible interactions 
involving the N-H hydrogen bond with the amide C=O (II), with the acid C=O (III), with 
the acid O-H (IV). 
 
The binding motif in the crystal structure of 3HBA is different when compared to 
the other cocrystals mentioned above, in that the phenolic hydroxy group forms a 
hydrogen bond to the pyridyl-N, while the carboxylic acid forms a hydrogen bond with 
the amide (N-H) group on the ligand. This binding preference is not surprising based on 
the molecular electrostatic potential (MEP) charge calculation carried out indicating that 
the phenolic hydroxy group is a better donor when compare to the carboxylic acid.15 
Moreover, there have been other similar cases of this interaction between phenolic 
hydroxy groups and isonicotinamide, where the phenol…pyridine interaction prevailed in 
the presence of COOH groups.16 This ‘low-yield’ adduct 3HBA provides more examples 
with acid…amide synthon III (Figure 2.21) without acid…pyridine recognition I (Figure 
2.21).  Furthermore, MEP charge calculations can be employed for assigning (and ranking) 
the relative hydrogen-bond donor/acceptor strengths across a wide range of chemical 
functionalities.  
Overall, pyridine…carboxylic acid intermolecular interactions were observed 
approximately 90% of the time in this study. Thus this interaction may be employed in 
subsequent supramolecular synthetic strategies. 
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Table 2.4   Summary of structural motifs 
Ligands Carboxylic 
acid/carboxylate 
Structure Structural motif 
 
hydrogenglutarate 
suberic acid 
sebacic acid 
2HG 
2SUB 
2SEB 
I, III 
I, III 
I, III 
 
succinic acid 
4-hydroxybenzoic acid 
3SUC 
3HBA 
I, II 
III 
 
2.4.3 Structural comparison with CSD 
A search for relevant pyridine…carboxylic acid cocrystals in the CSD7 revealed 
that this interaction occurs around 91% of the time, which was demonstrated in four out 
of the five structures herein.  The self-complementarity of monoacetylated amides is 
generally a reliable motif with the combination of functionalities present. This 
intermolecular compability of the amide N-H and the amide C=O may therefore be 
employed in subsequent supramolecular synthetic strategies based upon a hierarchy of 
hydrogen bond interactions even in the presence of potentially competitive hydrogen 
bond acceptors. 
2.4.4 Metal coordination abilities of acetamido/acetamidomethyl-pyridine moieties  
Single-crystal X-ray analysis of 1a-b, 2a, and 3a, has demonstrated that the self-
complementary N-H…O=C intermolecular ligand…ligand hydrogen bond interaction is 
present. The O,O'-chelating anions employed, hexafluoro-2,4-pentanedionate and 1,3-
diphenyl-1,3-propanedionate, occupy the four equatorial positions around the metal(II) 
ions, when the amide moiety is located further away from the equatorial plane as 
demonstrated by the meta- and para-substituted pyridine-based ligands, it gives the N-H 
moiety the structural freedom to select a hydrogen bond acceptor, the carbonyl moiety the 
preferred interaction site in each of the complexes, Figure 2.22. 
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Figure 2.22   Pictorial representation of the desired coordination chemistry around the 
M(II) centers after compound binds; as well as the possible hydrogen bond interactions.  
 
 The nature of the metal ion does not affect the resulting structure notably because 
in each case, the metal ion is ‘strapped into’ a fixed geometry dictated by the two anionic 
chelating ligands.  The importance of using chelating ligands for controlling the 
coordination geometry, and thereby the structural role of the complex ion itself, is 
illustrated by a previously reported crystal structure of a five coordinate Cu(II) complex 
compromising of two 4-acetamidopyridine, two acetate ions and a water molecule in the 
first coordination sphere; in this case the amide…amide hydrogen bond is disrupted by 
the water molecule, and the result is a complex 3-D architecture.17 
The self-complementary acetamido moiety has also been demonstrated in the 
preparation of a series of silver(I)-containing 2-D architectures,18 indicating that the 
particular supramolecular synthon is robust enough to organize relatively large complex 
ions into desired extended networks.  A search of the CSD showed other examples of 
amido functional groups containing Ag(I) ions, where those structures also contained 
extended networks assembled via self-complementary N-H…O=C hydrogen bonds.19 
Other examples include nicotinamide and isonicotinamide with Cu(II) ions to produce 2-
D network and similar 2-D networks with open channels have been constructed from 
Ni(II), Cu(II) and Co(II).20  
The structures presented here support the idea that control at both the molecular 
and supramolecular level can be achieved by combining reliable supramolecular reagents 
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with coordination complexes where the coordination geometry is strictly controlled by 
the aid of suitable chelating ligands. 
 
2.5 Conclusion 
In summary the self-complementarity of monoacetylated amides is generally a 
reliable motif for the construction of other supermolecules, with the combination of 
functionalities present in 2HG, 2SUB, 2SEB, 3SUC, and 3HBA despite the potential 
competition from a C=O moiety located on the carboxylic acid. This intermolecular 
compatibility of the amide N-H and the amide C=O may therefore be employed in 
subsequent supramolecular synthetic strategies based upon a hierarchy of hydrogen bond 
interactions.  
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CHAPTER 3 - Balancing intermolecular hydrogen and 
halogen bonding interactions using pyridine/pyrazine mono-N-
oxides 
3.1 Introduction 
An important aspect of organic supramolecular chemistry is the design of discrete 
building blocks with intermolecular preferences that can be utilized for the directed 
assembly of homomeric1 and heteromeric2 solid-state architectures with predictable and 
desirable connectivities.  In supramolecular chemistry, carboxylic acids have traditionally 
been used because they readily aggregate as homomeric dimers.  However, the 
acid…pyridine heterosynthon is the most frequently occurring hydrogen bond motif in 
the Cambridge Structural Database (CSD), and has occurrence probability of over 90%3 
compared to <50% frequency for other hydrogen bond synthons4 such as, acid…acid, 
amide…amide and acid…amide, Figure 3.1.  
 
Figure 3.1 Strong hydrogen bond homosynthons and heterosynthons with their 
frequency. 
 
Although the above synthons are well established and dependable tools within 
crystal engineering, other synthons such as pyrazine/4,4'-bipyridine mono N-
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oxide…carboxylic acid and mono N-oxide…halogen (I or Br) have not been utilized, 
although they can form extended supramolecular architectures.5 
 Constructing new supramolecular products is often predictable when there are 
only two individual entities, containing only one complementary moiety; however 
predictability becomes more complicated when the number of interactive moieties on each 
reactant leads to an increased possibility of synthons. A 2010 search of the CSD6 
reported no assembly formed through a combination of hydrogen and halogen bonds with 
mono N-oxide derivatives; however there are approximately twenty examples of self 
assembly involving a dioxide moiety and a hydrogen-bond, and only one example where 
self assembly is through halogen bonding.6  
 A notable example is the carboxamide–pyridine N-oxide synthon, which takes 
advantage of the strong N-H…O- hydrogen bond.7 In fact pyridine N-oxide (N+-O-) is a 
stronger acceptor than pyridyl N because of its anionic character; for example the pKHB 
values of pyridine N, and N-oxide O- are 1.86 and 2.70 (increasing basicity)7 and 
moreover, electrostatic surface potential charges at the electronegative atoms N -43.7, O -
47.4, and O- -53.3 kcal mol-1 parallel the same trend.5 Hence in terms of energy, the 
amide…N-oxide two point heterosynthon of N-H…O- and C-H…O hydrogen bond is 
more stable than the constituent N-H…O amide dimer, Figure 3.2. 
 
Figure 3.2 Two point heterosynthon of N-H…O- and N-H…O amide dimer. 
 
 Another notable example is the case of 4,4'-bipyridine and 4,4'-bipyridine dioxide 
hydrocarbon modules where the electron donor moiety (i.e. oxygen atom) can effectively 
drive the perfluorocarbon halides-hydrocarbon self-assembly processes, as well as be 
more effective in the formation of the halogen bonded adducts than corresponding 
nitrogen substituted modules, Figure 3.3.8  
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Figure 3.3 Halide-hydrocarbon self-assembly processes. 
 
Furthermore, the strength of the halogen bond donor can be reinforced upon fluorination 
of the molecule, which can lead to an increase in the electron-acceptor capabilities of the 
iodine or bromine atoms.9 
 With the above concepts in mind, pyrazine and 4,4'-bipyridine mono N-oxide 
moieties have the capabilities to provide ideal molecular recognition sites for promoting 
both hydrogen and halogen bonding in a controllable and predictable manner. Therefore, 
we will focus on the design and synthesis of supramolecular architectures formed through 
hydrogen and halogen bonds using pyrazine and 4,4'-bipyridine mono N-oxide 
derivatives. Based on electrostatic surface potentials the higher charge will determine the 
interaction preferences between the different species.  Therefore, we synthesized three 
mono N-oxide moieties 4, 5, and 6, Figure 3.4, and allowed them to react with a variety of 
hydrogen and halogen donor species. 
 
Figure 3.4 Target compounds showing best acceptor site (A1) and second best 
acceptor site (A2). 
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A series of semi-empirical PM310 calculations will be employed to calculate the 
charges on 4, 5, and 6 as well as on the hydrogen and halogen bond reactants. The overall 
goals of this chapter are: 
  1. To carry out a series of semi-empirical PM3 calculations in order  
   to rank the binding sites in terms of charge.  
  2. To determine whether the combination of hydrogen and halogen  
   bonds can be use to construct predictable assemblies with mono N- 
   oxide derivatives. 
  3. Establish a balance between the hydrogen bond and halogen bond. 
   
3.2 Experimental  
3.2.1 Synthesis 
 
All chemicals, unless noted, were purchased from Aldrich and used without 
further purification. Column chromatography was carried out on silica gel (150 Å pore 
size) from Analtech Inc. Melting points were determined on a GallenKamp melting point 
apparatus in a capillary tube and are reported uncorrected. 1H and 13C NMR spectra were 
recorded on a Varian Unity plus 400 MHz or 200 MHz spectrometers in DMSO-d6. 
Compounds were prepared for infrared spectroscopic (IR) analysis as a mixture in KBr or 
on a ZnSe ATR crystal. 
 
3.2.1.1  Synthesis of pyrazine mono N-oxide, 411 
 
A solution of 30% hydrogen peroxide (1.42g, 0.042 mol) in 10 mL of acetic acid 
was added dropwise using a drop funnel over a period of 2.5 hr to a solution of pyrazine 
(1.00g, 0.013 mol) in 12.5 mL of acetic acid at 70-80oC. Heating was continued for about 
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5 hours. Acetic acid was removed on a rotary evaporator, and then 10 mL of water was 
added followed by evaporation. The residue was dissolved in 50 mL of hot chloroform 
and dried with a mixture of sodium sulfate and sodium carbonate and the solvent 
removed on a rotary evaporator. The residue was chromatographed on silica with 9:1 
chloroform-methanol as the eluant. Product 4 was isolated as a white powder and 
recrystallization from methanol gave needle-like crystals, (1.2g, 72%). M.p.: 113-115oC 
(Lit. m.p.: 113-114oC);11 1H NMR (δH; 400 MHz, DMSO-d6): 8.66 (d, 2H, J = 4Hz), 8.36 
(d, 2H, J = 4Hz); 13C NMR (δC; 200 MHz, DMSO-d6): 158, 144; IR (KBr pellet): υ 
3430, 2914, 1596, 1470, 1433, 1312(N+-O-), 1213, 1005, 861, 540, 477 cm-1. 
 
3.2.1.2  Synthesis of tetramethylpyrazine mono N-oxide, 511 
 
A solution of 30% hydrogen peroxide (1.42g, 0.042 mol) in 10 mL of acetic acid 
was added dropwise using a drop funnel over a period of 2.5 hr to a solution of 
tetramethylpyrazine (1.77g, 0.013 mol) in 12.5 mL of acetic acid at 70-80oC, with heating 
continued for about 5 hr. Acetic acid was removed using a rotary evaporator, 10 mL of 
water was added followed by evaporation. The residue was dissolved in 50 mL of hot 
chloroform and dried with a mixture of sodium sulfate and sodium carbonate and the 
solvent removed on a rotary evaporator. The residue was chromatographed on silica with 
9:1 chloroform-methanol as the eluant. Product 5 was isolated as a white powder and 
recrystallization from methanol gave micro size crystalline particles, (1.2g, 61%). M.p.: 
98-100oC; 1H NMR (δH; 200 MHz, DMSO-d6): 2.43 (d, 6H), 2.32 (d, 6H); 13C NMR (δC; 
200 MHz, DMSO-d6): 150, 138, 21, 12; IR (KBr pellet): υ 3462, 2914, 1572, 1472, 1320 
(N+-O-), 1138, 1004, 922, 691 cm-1. 
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3.2.1.3  Synthesis of 4,4'-bipyridine mono N-oxide, 611 
 
6 was prepared by employing a modification of the previously reported 
procedure.11 A mixture of 4,4ʹ′-bipyridine (2.00g, 12.82 mmol), 30% hydrogen peroxide 
(1.33g, 39 mmol) and glacial acetic acid (8 mL) was stirred in a round bottom flask for 
18 hours at 70oC. After cooling the reaction mixture the solvent was removed via a rotary 
evaporator and diluted with 20 mL water. The solution was basified with excess sodium 
carbonate (2g) and extracted with chloroform (3 x 50 mL). The organic layers were 
combined and then concentrated under reduced pressure using a rotary evaporator. 6 was 
further purified via column chromatography with a 3:1 ethyl acetate-methanol mixture 
producing an off-white solid, (1.1g, 52%). M.p.: 170-171oC; 1H NMR (δH; 400 MHz, 
DMSO-d6): 8.70 (d, 2H, J = 12Hz), 8.36 (d, 2H, J = 12Hz), 7.94 (d, 2H, J = 12 Hz), 7.83 
(d, 2H, J = 21 Hz); 13C NMR (δC; 400 MHz, DMSO-d6): 150, 142, 139, 133, 124 120; IR 
(KBr pellet): υ 3222, 2910, 1600, 1515, 1482, 1410, 1253 (N+-O-), 1228, 1191, 1029, 
851, 821, 714, 651, 580 cm-1. 
3.2.2 Synthesis of cocrystals 
3.2.2.1  Synthesis of pyrazine mono N-oxide 4-iodotetrafluorobenzoic acid (1:1),  
  4IF4BA  
4 (15 mg, 0.163 mmol) and IF4BA (52 mg, 0.163 mmol) were placed in a beaker 
and dissolved in 4 mL of acetonitrile. After five days of slow evaporation, light yellow 
needle-shaped crystals were obtained. M.p.: 122-124oC; IR (KBr pellet) υ 2561 and 1931 
cm-1 (O-H…N, br), 1712 cm-1 (C=O, s), 1293 cm-1 (N+-O-, s), 1022 and 979 cm-1 (C-I, s) 
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3.2.2.2  Synthesis of pyrazine mono N-oxide 1,3,5-trifluorotriiodobenzene (1:1), 
 4I3F3B  
4 (15 mg, 0.163 mmol) and I3F3B (166 mg, 0.163 mmol) were placed in a beaker 
and dissolved in 4 mL of ethyl acetate. After ten days of slow evaporation, transparent 
plate-like crystals were obtained. M.p.: 155-156oC; IR (ZnSe crystal) υ 1292 cm-1 (N+-O-, 
s), 1046 cm-1 (C-I, s). 
3.2.2.3  Synthesis of pyrazine mono N-oxide 4-hydroxybenzoic acid (1:1), 4HBA  
4 (15 mg, 0.163 mmol) and HBA (45 mg, 0.163 mmol) were placed in a beaker 
and dissolved in 4 mL of acetonitrile and 2.00 mL methanol. After fifteen days of slow 
evaporation, transparent plate-like crystals were obtained. M.p.: 194-196oC; IR (KBr 
pellet) υ 2484 and 1928 cm-1 (O-H…N, br), 1695 cm-1 (C=O, s), 1244 cm-1 (N+-O-, s). 
3.2.2.4  Synthesis of tetramethylpyrazine mono N-oxide 4-iodotetrafluorobenzoic 
  acid (1:1), 5IF4BA  
5 (15 mg, 0.110 mmol) and IF4BA (35 mg, 0.110 mmol) were placed in a beaker 
and dissolved in 5 mL of ethanol. After thirteen days of slow evaporation, transparent 
plate-like crystals were obtained. M.p.: 177-178oC; IR (ZnSe crystal) υ 2441 and 1918 
cm-1 (O-H…N, br), 1732 cm-1 (C=O, s), 1298 cm-1 (N+-O-, s), 979 cm-1 (C-I, s). 
3.2.2.5  Synthesis of tetramethylpyrazine mono N-oxide 4-
 bromotetrafluorobenzoic acid (1:1), 5BrF4BA 
5 (15 mg, 0.110 mmol) and BrF4BA (30 mg, 0.110 mmol) were placed in beaker 
a and dissolved in 5 mL of ethanol. After fifteen days of slow evaporation, transparent 
plate-like crystals were obtained. M.p.: 113-115oC; IR (KBr pellet) υ 2448 and 1911 cm-1 
(O-H…N, br), 1732 cm-1 (C=O, s), 1301 cm-1 (N+-O-, s), 990 cm-1 (C-Br, s). 
3.2.2.6  Synthesis of tetramethylpyrazine mono N-oxide 4-aminobenzoic acid  
  (1:2), 5ABA  
5 (15 mg, 0.110 mmol) and ABA (30 mg, 0.220 mmol) were placed in a beaker 
and dissolved in 5 mL of ethanol. After thirteen days of slow evaporation, transparent 
plate-like crystals were obtained. M.p.: 178-179oC; IR (KBr pellet) υ 2554 and 1900 cm-1 
(O-H…N, br), 1655 cm-1 (C=O, s), 1290 cm-1 (N+-O-, s). 
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3.2.2.7  Synthesis of 4,4'-bipyridine mono N-oxide 4-iodobenzoic acid (1:1),  
  6IBA  
6 (15 mg, 0.091 mmol) and IBA (23 mg, 0.091 mmol) were placed in a beaker 
and dissolved in 2 mL of acetonitrile. After ten days of slow evaporation, transparent 
needle-like crystals were obtained. M.p.: 168-170oC; IR (KBr pellet) υ 2550 and 1926 
cm-1 (O-H…N, br), 1680 cm-1 (C=O, s), 1220 cm-1 (N+-O-, s), 815 cm-1 (C-I, s). 
3.2.2.8  Synthesis of 4,4'-bipyridine mono N-oxide 4-aminobenzoic acid (1:1), 
 6ABA  
6 (15 mg, 0.091 mmol) and ABA (13 mg, 0.091 mmol) were placed in a beaker 
and dissolved in 2 mL of acetonitrile. After fifteen days of slow evaporation, transparent 
needle-like crystals were obtained. M.p.: 197-198oC; IR (KBr pellet) υ 2448 and 1961 
cm-1 (O-H…N, br), 1662 cm-1 (C=O, s), 1265 cm-1 (N+-O-, s). 
3.2.2.9  Semi-empirical PM3 calculations 
Compounds 4(pyrazine mono N-oxide) 5(tetramethylpyrazine mono N-oxide) 
and, 6(4,4'-bipyridine mono N-oxide) molecular structures were constructed using 
Spartan ’06 (Wavefunction, Inc. Irvine, CA). All three molecules were optimized using 
Semi-empirical PM3 with the maxima and minima in the electrostatic potential surface 
(0.002 e/au isosurface) determined using a positive point charge in the vacuum as a 
probe.  
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3.3  Results 
A summary of the crystallographic information for 4IF4BA, 4I3F3BA, 4HBA, 
5IF4BA, 5BrF4BA, 5ABA, 6IBA, and 6ABA are displayed in Table C.2 and all 
hydrogen-bond geometries for 4IF4BA, 4I3F3BA, 4HBA, 5IF4BA, 5BrF4BA, 5ABA, 
6IBA, and 6ABA are listed in Table 3.1. 
 
Table 3.1 Hydrogen-bond geometries for 4IF4BA, 4I3F3BA, 4HBA, 5IF4BA, 
5BrF4BA, 5ABA, 6IBA, and 6ABA 
Structure  D-H…A d(D-H)/Å d(H…A)/Å d(D…A)/Å <(DHA)/o 
4 IF4BA O(11)-H(11)…N(24) 0.84 1.85 2.6470(14) 157.3 
      
4 HBA i O(21)-H(21)…N(14) 0.965(16) 1.756(16) 2.7203(11) 177.0(15) 
 O(24)-H(24)…O(11)#1 0.897(16) 1.7563(17) 2.6442(11) 166.8(15) 
      
5 IF4BA ii O(31A)-H(31A)…N(14) 0.84 1.87 2.681)4) 161.2 
 O(31B)-H(31B)…N(14) 0.84 1.99 2.715(3) 144.8 
 O(31C)-
H(31C)…O(11)#1 
0.84 1.65 2.485(11) 175.1 
      
5 BrF4BA iii O(31A)-H(31A)…N(14) 0.84 1.90 2.711(5) 161.4 
 O(31B)-H(31B)…N(14) 0.84 1.81 2.594(8) 154.2 
 O(31C)-
H(31C)…O(11)#1 
0.84 1.82 2.662(8) 179.6 
      
5 ABA iv N(34)-H(34A)…O(11) 0.885(17) 1.956(17) 2.8220(16) 165.8(15) 
 N(44)-H(44A)…N(14) 0.906(15) 2.139(15) 3.0437(14) 177.0(13) 
 N(44)-
H(44B)…O(32)#1 
0.876(15) 2.290(15) 3.0713(14) 148.6(13) 
 O(31)-H(31)…O(32)#2 0.895(16) 1,724(16) 2.642(11) 172.4(15) 
 O(41)-H(41)…O(42)#3 1.259(16) 1.327(16) 2.5849(12) 176.7(13) 
      
6 IBA O(31)-H(31)…O(11) 0.84 1.76 2.556(2) 158.0 
      
6 ABA v O(31)-H(31)…N(21) 1.01(2) 1.64(2) 2.6440(19) 175.2(16) 
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Structure  D-H…A d(D-H)/Å d(H…A)/Å d(D…A)/Å <(DHA)/o 
6 ABA v N(34)-
H(34A)…N(34)#1 
0.87(2) 2.33(2) 3.183(2) 164.5(17) 
 N(34)-
H(34B)…O(11)#2 
0.89(2) 1.98(2) 2.869(2) 176.5(19) 
i)  #1 x+2,y-1,z    ii) #1 x+1,-y+3/2,z+1/2     iii)  #1 x-1,-y+1/2,z-1/2 iv)  #1 -x+1,y+1/2,-z+1/2    #2 -
x+2,-y+1,-z+1    #3 -x-1,-y,-z      v) #1 -x+1/2,y+1/2,-z+3/2    #2 x+1/2,-y+1/2,z+1/2      
 
3.3.1 Molecular Electrostatic Potential Calculations 
        
          (a)       (b)                     (c) 
Figure 3.5 Electrostatic potentials of (a) pyrazine mono N-oxide, (b) 4,4'-bipyridine 
mono N-oxide, (c) tetramethylpyrazine mono N-oxide. 
 
Table 3.2 shows the results of the electrostatic potentials calculated for the mono 
N-oxides as well as the donor ligands used in this study, and Figure 3.5 shows the 
electrostatic potential diagrams for each type of mono N-oxides. 
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Table 3.2 Electrostatic potentials of all acceptor and donor ligands used in this study 
3.3.2 Crystal structure of pyrazine mono N-oxide 4-iodotetrafluorobenzoic acid (1:1), 
4IF4BA  
In the crystal structure of 4IF4BA the asymmetric unit consists of one molecule of 
4 and one molecule of IF4BA; forming a hydrogen bond between the carboxylic acid and 
the pyrazine-N moiety, (O11…N24) 2.6470(14) Å, Figure 3.6. The architecture is further 
extend into an infinite 1-D chain through the iodine atom and the pyrazine mono N-oxide 
oxygen with, N+-O-…I distance of 2.814 Å, Figure 3.7. 
 
Figure 3.6 Thermal ellipsoids (50%) of the 1:1 binary cocrystal of 4IF4BA. 
 
Figure 3.7 1-D chain of 4IF4BA held together via O-H…N hydrogen bond and N-
O…I halogen bond. 
  E 
(kJ/mol
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) 
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(kJ/mol) 
E 
(kJ/mol) 
E 
(kJ/mol) 
E 
(kJ/mol) 
E 
(kJ/mol) 
E 
(kJ/mol) 
E 
(kJ/mol) 
Compounds (N+-O-) (N) (COOH) (OH) (NH2) (IF4BA) (IBA) (BrF4BA
) 
(I3F3B) 
Pyrazine mono N-oxide -282 -238 - - - - - - - 
Tetramethylpyrazine 
mono N-oxide 
-297 -253 - - - - - - - 
Bipyridyl mono N-oxide -300 -253 - - - - - - - 
4-Iodotetrafluorobenzoic 
acid 
- - 143 - - 219 - - - 
4-Iodobenzoic acid - - 123 - - - 130 - - 
4-
Bromotetrafluorobenzoic 
acid 
- - 146 - - - - 160 - 
1,3,5-
trifluorotriiodobenzene 
- - - - - - - - 191 
4-Hydroxybenzoic acid - - 111 165 - - - - - 
4-Aminobenzoic acid - - 114 - 145 - - - - 
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3.3.3    Crystal structure of pyrazine mono N-oxide 1,3,5-trifluorotriiodobenzene  
 (1:1), 4I3F3B  
The asymmetric unit of 4I3F3B contains one molecule of 4 and one molecule of 
I3F3B. The supermolecule is constructed through the interaction of one of the iodo-
moiety of the I3F3B and O atom of 4 with a bond distance of 2.69Å, Figure 3.8.  
 
Figure 3.8 Thermal ellipsoids and labeling scheme of 4I3F3B. 
 
Furthermore, the structure is extremely disordered making it difficult to observe any short 
contacts between the pyrazine mono N-oxide nitrogen atom and any of the iodo-moiety. 
The ideal interaction that should be observed is a halogen bond between the N-oxide 
oxygen and nitrogen atom as is shown in Figure 3.9, resulting in an infinite 1-D chain. 
 
Figure 3.9 1-D chain of 4I3F3B as a result of halogen bonding. 
 
Nevertheless, a ring-like system is formed through halogen bonds between the N-
oxide oxygen as well as through some short contacts between the iodine groups, with an 
I-I bond distance of 3.95Å and an angle of 120o, Figure 3.10. 
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Figure 3.10 Ring-like arrangement in 4I3F3B formed via N+-O-…I and I…I halogen 
bonds. 
 
3.3.4 Crystal structure of pyrazine mono N-oxide 4-hydroxybenzoic acid (1:1), 4HBA  
The crystal structure of 4HBA has one molecule of 4 and one molecule of HBA 
in the asymmetric unit.  This supermolecule is constructed through O-H…N hydrogen 
bonds between the O-H of the carboxylic acid group and the pyrazine nitrogen atom 
O21…N14, 2.7203(11) Å, Figure 3.11.  The structure is further expanded into an infinite 
1-D chain via the phenolic hydroxy group hydrogen bond to the oxygen atom of pyrazine 
mono N-oxide, O24…O11#1, 2.6442(11) Å, Figure 3.12. 
 
 
Figure 3.11  Thermal ellipsoids (50%) and labeling scheme of the unique molecules in 
4HBA. 
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Figure 3.12 1-D chain of 4HBA held to via O-H…N and O-H…O hydrogen bonds. 
 
3.3.5 Crystal structure of tetramethylpyrazine mono N-oxide 4-iodotetrafluorobenzoic 
acid (1:1), 5IF4BA  
The crystal structure of 5IF4BA contains one molecule 5 and one molecule of 
IF4BA in the asymmetric unit.  The structure exhibits some disorder; nonetheless the 
supermolecule is constructed through O-H…N hydrogen bonds between the O-H of the 
acid and the tetramethylpyrazine mono N-oxide nitrogen atom O31A…N14, 2.681(4) Å, 
Figure 3.13. The structure is further extended into an infinite 1-D chain through the 
assistance of a halogen bond formed between the N+-O- of the tetramethylpyrazine mono 
N-oxide and the 4-iodotetrafluorobenzoic acid moiety, Figure 3.14. 
 
Figure 3.13 Thermal ellipsoids (50%) and labeling scheme of the supramolecule 
5IF4BA. 
 
 
Figure 3.14 1-D chain of 5IF4BA held together via hydrogen and halogen bonding. 
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3.3.6  Crystal structure of tetramethylpyrazine mono N-oxide 4-   
  bromotetrafluorobenzoic acid (1:1), 5BrF4BA  
The asymmetric unit of 5BrF4BA contains one molecule of 5 and one molecule of 
BrF4BA; similar to 5IF4BA the crystal structure of 5BrF4BA is also disordered. The 
disorder resulted in the hydroxy group of the acid forming a hydrogen bond with the 
tetramethylpyrazine mono N-oxide O31A…N14, 2.711(5) Å, Figure 3.15. The 
architecture is further extended into this 1-D chain with the aid of halogen bonds formed 
through the bromo-substituent of the acid, Figure 3.16. 
 
Figure 3.15 Thermal ellipsoids (50%) and labeling scheme of the supramolecule 
5BrF4BA. 
 
 
Figure 3.16 Alignment of binaries by O-H…N hydrogen bonds and C-Br…O halogen 
bonds resulting in infinite 1-D chain in 5BrF4BA. 
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3.3.7  Crystal structure of tetramethylpyrazine mono N-oxide 4-aminobenzoic  
  acid (1:2), 5ABA  
In the crystal structure of 5ABA, the main motif comprises of hydrogen-bonding 
interactions between the amino group and the tetramethylpyrazine mono N-oxide moiety, 
with bond distances of N34…O34A, 2.8220(16) Å and N44…N14, 3.0437(14) Å 
respectively, Figure 3.17.  The structure is further connected through self-complementary 
acid-acid dimers, O-H…O hydrogen bonds with bond distances of O31…O(32), 
2.642(11) Å and O41…O(42), 2.5849(12) Å respectively, resulting in an infinite 1-D 
chain, Figure 3.18. 
 
Figure 3.17 Thermal ellipsoids (50%) and labeling scheme of the supramolecule 
5ABA. 
 
 
Figure 3.18 1-D chain of 5ABA held together by N-H…O, N-H…N and an acid-acid 
dimer hydrogen bond. 
 
 
 
 60 
3.3.8 Crystal structure of bipyridyl mono N-oxide 4-iodobenzoic acid (1:1), 6IBA  
The crystal structure of 6IBA contains one molecule of 6 and one molecule of 
IBA in the asymmetric unit cell. The supermolecule is constructed from O-H…O 
hydrogen bonds between the O-H of the acid and the O atom of the N-oxide moiety 
resulting in bond distance of O31…O11, 2.556(2) Å, Figure 3.19. The architecture is 
further expanded through interactions between the iodo-moiety and the N atom having 
the lowest charge resulting in an infinite 1-D chain, Figure 3.20. 
 
 
Figure 3.19 Thermal ellipsoids (50%) and labeling scheme of the supermolecule in 
6IBA. 
 
 
Figure 3.20 1-D chain of 6IBA held together by O-H…O hydrogen bond and C-
Br…N halogen bond. 
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3.3.9 Crystal structure of bipyridyl mono N-oxide 4-aminobenzoic acid (1:1), 6ABA  
The asymmetric unit cell of 6ABA contains molecule of 6 and one molecule of 
ABA, held together by O-H…N with bond distance of O31…N21, 2.6440(19) Å, Figure 
3.21. The structure is further extended into an infinite 1-D chain held together by N-
H…N and N-H…O hydrogen bonds with bond distances of N34…N34, 2.869(2) and 
N34…O11, 3.183(2) Å, respectively, Figure 3.22. 
 
 
Figure 3.21 Thermal ellipsoids (50%) and labeling scheme of the supramolecule in 
6ABA. 
 
 
Figure 3.22 Alignment of binaries by N-H…O and O-H…N hydrogen bonds resulting 
in infinite 1-D chain in 6ABA. 
 
3.4 Discussion 
3.4.1 Characterization of mono N-oxide cocrystals through IR spectroscopy 
The results of the co-crystallization reactions were first screened using IR 
spectroscopy, paying particular attention to the O-H…N hydrogen-bond interactions, 
shifts in the C-X (X = I or Br) band for conformation of halogen bonding, as well as to 
any significant shifts in the N+-O- band.  In the case of hydrogen bond formation, as 
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mentioned earlier, two broad stretches near 2450 cm-1 and 1900 cm-1 are observed. The 
N+-O- stretches for uncomplexed 4, 5 and 6 are as follows: 1312, 1320 and 1253 cm-1 
respectively; and upon complexation with the halogenated or non-halogenated benzoic 
acid the band due to N+-O- stretch shifts toward shorter wavenumbers, Table 3.3. 
 
Table 3.3 IR summary of uncomplexed and complexed N+-O- and O-H…N 
interactions for compounds 4-6 and 4IF4BA, 4I3F3B, 4HBA, 5IF4BA, 5BrF4BA, 5ABA, 
6IBA, 6ABA. 
 
Compounds Uncomplexed 
N+-O- (cm-1) 
Complexed 
 N+-O- (cm-1) 
O-H…N (cm-1) 
4 1312 - - 
4 IF4BA - 1293 2561 & 1931 
4 I3F3B - 1292 - 
4 HBA - 1276 2484 & 1928 
5 1320 - - 
5 IF4BA - 1298 2441 & 1918 
5 BrF4BA - 1301 2448 & 1911 
5 ABA - 1290 2554 & 1900 
6 1253 - - 
6 IBA - 1220 2550 & 1926 
6 ABA - 1225 2448 & 1961 
 
The changes observed in the IR after complexation between the N-oxides and 
halogenated benzoic acids in 4IF4BA-4I3F3B, 5IF4BA- 5BrF4BA could be as a result of 
the electron withdrawing capabilities of the fluorine atoms on benzoic acid ring, thus 
resulting in a shift to a lower wavenumber. Similar trends were also observed in 4HBA 
with the bands due N+-O- stretch shifts towards a lower wavenumber with a difference  
(of 36 cm-1) when compared to the uncomplexed N-oxide moiety.   
These changes along with the principle that pyridine nitrogen and carboxylic 
acids tend to form strong hydrogen bonds,12 suggests that in the case of the N-oxide 
moieties a shift in the N+-O- band may indicate a formation of either a halogen-bond or a 
hydrogen-bond between the oxygen atom of the N-oxide.  
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3.4.2 Evaluating the capability of mono N-oxide functionality to form predictable 
assembles through hydrogen and halogen-bonds 
Since there are no reported cocrystals of 4,4'-bipyridine or pyrazine mono N-
oxide derivatives, it is important to examine the ability of these mono N-oxides to act as a 
hydrogen or halogen bond acceptors. It is also essential to establish how effective the 
mono N-oxides are when compared to the 4,4'-bipyridine or pyrazine nitrogen atom in 
hydrogen or halogen bonding. In the case of pyrazine mono N-oxide for example, two 
possible interactions could take place, first the acid can form a hydrogen bond with the 
pyrazine nitrogen leaving the pyrazine mono N-oxide oxygen to interact with either a 
hydrogen or halogen atom or vice versa, Figure 3.23. The binding interaction 
demonstrates that the pyrazine N-oxide oxygen is ‘active’, and can compete successfully 
with the pyrazine nitrogen atom for the incoming halogen or acid moiety. 
 
Figure 3.23 Possible binding interactions between pyrazine mono N-oxide and a 
halogenated species. 
 
Nangia et al, have reported a system consisting of both a 4,4'-bipyridine and a 
4,4'-bipyridine dioxide, which demonstrate the ability of the oxygen atom of the dioxide 
to participate in hydrogen bonding with a carboxylic acid, resulting in a zigzag tape 
structure.13 This further shows that in a given system containing both nitrogen atom and 
oxygen atom that the oxygen will participate in some form of non-covalent interaction. 
 
3.4.3 Establishing a balance between hydrogen and halogen bonding 
In all the eight cocrystals obtained, seven possess the O-H…N heterosynthon. In 
five of the eight structures 4IF4BA-4I3F3B, 5IF4BA- 5BrF4BA and 6IBA halogen bonds 
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i.e. N+-O-…I, N+-O-…Br or N…I extend the structures into polymeric networks. The 
halogen bonding patterns and distances for each crystal structure is displayed in Table 
3.4. 
 
Table 3.4 Halogen bonding patterns observed in crystal structures 4IF4BA, 
4I3F3BA, 5IF4BA, 5BrF4BA, and 6IBA 
Structure # Donor moieties Halogen bonds Type of halogen 
bonds 
Halogen bond 
distance (Å) 
4IF4BA IF4BA yes N+-O-…I 2.81 
4I3F3B I3F3B yes N+-O-…I 2.69 
5IF4BA IF4BA yes N+-O-…I 2.77 
5BrF4BA BrF4BA yes N+-O-…Br 2.83 
6IBA IBA yes N…I 2.94 
 
 A comparison of structures 4IF4BA and 6IBA revealed that the halogen bond 
distance is shorter as a result of fluorination of the aryl ring in 4IF4BA. The binding 
interaction observed in 6IBA is different to that of 4IF4BA, because the N-oxide oxygen 
in 4IF4BA forms a halogen bond with iodine group, whereas in 6IBA the halogen bond is 
formed with 4,4'-bipyridine nitrogen and the N-oxide group participates in a hydrogen 
bond. This connectivity is as a result of the iodine atom in 4IF4BA being activated by 
fluorine, subsequently resulting in the formation of a halogen bond between the N-oxide 
oxygen. Moreover in 5IF4BA and 5BrF4BA, connectivity is as a result of aryl ring being 
fluorinated.  Furthermore, in the absence of fluorinated groups on the aryl ring the 
hydroxy group of the acid forms a hydrogen bond with the N-oxide oxygen leaving the 
halogen to form a halogen bond with the nitrogen atom. Therefore a combination of 
hydrogen and halogen bonding provides an additional control on the syntheses and self-
assembly of supermolecules, thus creating a versatile strategy for bringing together 
molecular building blocks. 
 
3.4.4  Hierarchy of hydrogen bond and halogen bond binding preferences  
  based on MEP 
 PM3 electrostatic potential surfaces were calculated in order to rank the binding 
preference of 4, 5 and 6 with a variety of hydrogen and halogen donating compounds. 
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Each molecule (4, 5 and 6) has two separate charges, pyrazine/4,4'-bipyridine N-oxide 
oxygen atoms (A1) and pyrazine/4,4'-bipyridine N-oxide nitrogen atoms (A2), Figure 
3.24. 
 
A1 kJ/mol         -283       -297  -300 
A2 kJ/mol         -238       -253  -253 
Figure 3.24 Calculated electrostatic potential surfaces for a variety of mono N-oxide 
derivatives. 
 
 Four of the eight crystal structures obtained in this study contained a combination of 
hydrogen and halogen bonding moieties, 4IF4BA, 5IF4BA, 5BrF4BA, and 6IBA, based 
on the semi-empirical PM3 calculations carried out our experimental results match the 
predicted outcome as seen in Figure 3.25.  
 
Figure 3.25 Interactions observed in crystal structures between mono N-oxides and a 
combination of hydrogen bond (HB) and halogen bond (XB) donors. 
In the case where the best donor went for the second best acceptor structure 6IBA, the 
charges between the carboxyl acid moiety and the halogen differ by 7kJ/mol. This 
difference may be so small that the two binding sites cannot be distinguished, Table 3.2. 
Another reason may be due to the geometric match between the bipyridyl mono N-oxide 
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ring and the carboxylic acid. The aromatic C-H proton may aid this interaction, and hence 
making this the preferred site for carboxylic acid. From the crystal structure the carbonyl 
group and the adjacent C-H proton are almost co-planar, further confirming why this 
interaction may have occurred Figure 3.25. 
              
Figure 3.26 Compound 6IBA showing C-H proton co-planarity to carbonyl group. 
 
The three other structures obtained 4HBA, 5ABA and 6ABA showed similar 
trends, in that the best donor in all three cases went for the best acceptor leaving the 
carboxylic acid to interact with the pyrazine/4,4'-bipyridine nitrogen atom.  In addition, 
similar examples of molecules having two different functionality bearing two different 
MEP charges, displayed comparable interactions; the molecule having the highest charge 
(i.e. the best donor) formed a hydrogen bond with the best acceptor molecule, again 
leaving the second best donor to interact with the second best acceptor.14   
In terms of compound 5ABA the interaction observed did not totally follow the 
charges, the amine group being the best donor did form a hydrogen bond with the N-
oxide moiety; however instead of the carboxylic acid forming a hydrogen bond with the 
available tetramethylpyrazine nitrogen atom, an acid-acid dimer homosynthon occurred, 
Figure 3.26.   
 
Figure 3.27 Acid-acid homosynthon of 5ABA. 
 
This could be due to the 1:2 stoichiometry, and it is also possible that a 1:1 cocrystal may 
have a structure with carboxylic acid tetramethylpyrazine nitrogen synthon on the other 
side, as there is neither steric hindrance nor intramolecular hydrogen bonding 
complication in 5ABA. In fact, crystal structures reported with barbituric acid and 
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quinoxaline N,N'-dioxide demonstrate similar interactions in that an amide-amide 
homosynthon was observed despite the availability of the other N-oxide the amide dimer 
was the preferred interaction.5 
 
3.5  Conclusion 
This study has demonstrated that a combination of hydrogen and halogen bond 
can be used to construct predictable assemblies with mono N-oxide derivatives. We were 
also able to further show that the electron accepting ability of the 4-iodobenzoic acid 
molecules can be increased upon fluorination when comparing structures 6IBA and 
4IF4BA. In addition, when given the choice the pyrazine or 4,4'-bipyridine mono N-oxide 
nitrogen will form a hydrogen bond with incoming acid, thus leaving the halogen to form 
a halogen atom with the N-oxide oxygen, as demonstrated in 4IF4BA, and 5IF4BA, 
5BrF4BA. 
Finally, semi-empirical PM3 charge calculations can be used as a tool in 
determining the interaction preferences between different species. The semi-empirical 
PM3 charge calculations done supported the experimental results that was obtained, in 
that, seven out of eight time the molecule predicted to be the best donor did interact with 
other molecule predicted to be the best acceptor.  Suggesting a high selectivity of A1 and 
A2 and further confirming that semi-empirical PM3 charge calculations can be used as an 
aide in ranking binding preferences of a wide variety of molecules. 
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CHAPTER 4 - Probing halogen bonding interactions in 
cocrystals of thiophene/thiophane compounds 
4.1 Introduction 
Hydrogen bonding,1 is the most frequently used tool for assembling organic 
molecules in solid, liquid, or gas phases, and it plays an important role in stabilizing 
supramolecular aggregates even in water. Halogen bonding2 has also been shown to have 
similar strength, selectivity, and directionality. For these reasons, halogen bonding 
provides an additional opportunity for designing functional solid-state architectures.3  
In Chapter 3 we showed examples of halogen bonding between oxygen atoms in a 
series of mono N-oxides, which aid in the formation of 1-D chains, Figure 4.1. 
 
Figure 4.1 Example of an infinite 1-D held together via both hydrogen and halogen 
bonds.4 
 
4.1.1 Theory behind the halogen bond 
As mentioned earlier, halogen bonding (XB) is a noncovalent interaction that is in 
some ways analogous to hydrogen bonding. A puzzling aspect of halogen bonding is that 
halogen atoms are themselves usually viewed as having partial negative charges. Why 
then would they interact non-covalently with a heteroatom (N, O, S)?  This can be 
explained either in terms of electrostatic potentials or the hard/soft acid and base (HSAB) 
principle.  
4.1.1.1 Electrostatic potentials and halogen bonding 
When atoms combine to form a molecule the accompanying rearrangements of 
electronic charge normally produce one or more regions of negative charge.5  
Electrostatic potential calculations on CF4 reveal that the fluorine hemisphere is 
negative. However when chlorine is substituted for fluorine, Figure 4.2, a positive 
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potential develops on the outmost portion of its surface, around its intersection with the 
C-Cl axis, this positive region, which is centered on the C-X axis is referred to as the “σ-
hole”.5 In general, the positive potential along the C-X axis increases on moving from F 
to I and the electrostatic potential remains negative all round the F atom,6 Figure 4.2. 
Therefore, it is these positive regions that are responsible for XB capabilities of CF3Cl, 
CF3Br and CF3I as well as of other halogen-bonding molecules. 
 
 
Figure 4.2 Molecular electrostatic potential of: CF4 (top left), CF3Cl (top right), 
CF3Br (bottom left), CF3I (bottom right).5,6 
 
Additionally, each atom X in the molecules CF3X, is involve in C-X bonding 
orbital, σCX, which also possess three unshared pairs of electrons, two in the p-orbitals 
perpendicular to the C-X axis and the third in the s-orbital. The electronic configuration 
s2p2xp2yp1z is similar to a single atom X in these molecules, with two filled p-orbitals and 
one half-filled,5 Figure 4.3. 
 
 
Figure 4.3 Schematic representation of halogen bonding.5 
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4.1.1.2 Hard and soft acid and base interaction and halogen bonding 
In 1963, Pearson7 brought forth a unifying concept by which chemical 
reactivities, selectivities and stabilities of compounds may be readily rationalized. 
Chemical entities including atoms, molecules, and ions are categorized as “hard” or 
“soft” Lewis acids or bases. The “hard” species in general have small atomic radii, and 
low polarizability, whereas “soft” ones possess the opposite characteristics. 
Since the softness of a species is governed by its size, charge and other attached 
groups, a group having a heavier central atom is the softer base; therefore as anticipated 
sulfur would be a softer base than oxygen. For example, systems such as 1,4-thioxane (I) 
and thiomorpholine (II), Figure 4.4 serve as good models for the consideration of 
competitive interactions from the standpoint of the HSAB principle.8 
 
(I)                     (II)                     
Figure 4.4 Models for competitive interaction based on HSAB principle: (I) thioxane; 
(II) thiomorpholine.8 
 
Compound (I) contains atoms belonging to the same group, so that the interaction 
should be preferentially located at the oxygen atom (hard center) with a hard acid and at 
the sulfur center in cased interaction with soft acids.8 Likewise, in compound (II) the 
sulfur having the softer center would be a favorable interaction with a softer acid. 
In terms of the halogens, from fluorine, a very hard acid through less hard 
chlorine, bromine to iodine, a soft acid; reactions are more favorable for ‘hard-hard’ and 
‘soft-soft’ interactions than for a mix of hard and soft.9 Therefore, based on the HSAB 
principles a sulfur…iodine interaction would be more favored over a nitrogen…iodine 
interaction. Furthermore, in the case of halogens, polarization effects are important for 
sulfur, which is known to form short directional contacts of the type S…Cl.10 
Recently there have been reports of S…I interactions in solids based on 
tetrathiafulavalenes and related compounds.11 Other examples that have been reported 
involving halogen bonding between organoiodines and sulfur include the antithyroid 
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drugs, methylmecaptoimidazole,12 thiomorpholine,13 thioxane13 and most recently a 
thiourea system, Figure 4.5.14 
 
Figure 4.5 Examples of S…I interactions. 
 
4.1.1.3 Understanding the type of interactions in halogen bonding 
In order to expand and further understand the interactions taking place in a 
halogen bonding system, we synthesized a series of thiophene and thiophane compounds; 
in order to probe whether or not the halogen bond is dominated purely by electrostatic or 
the HSAB principles. The compounds of interest are seven different thienyl moieties 8, 9, 
12, 13, 16, 17, and 19 Figure 4.6, which we react with a variety of hydrogen and halogen 
bond donors. 
 
 
Figure 4.6 Target compounds. 
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The overall goals of this chapter are: 
1. To synthesize a series of thiophene and thiophane compounds. 
2. To synthesize a series of cocrystals using different halogen and hydrogen 
bond donors. 
3. To establish whether the halogen bond is primarily an electrostatic or a 
HSAB interaction. 
4.2 Experimental 
4.2.1 Synthesis 
All chemicals, unless noted, were purchased from Aldrich and used without 
further purification. Column chromatography was carried out on silica gel (150 Å pore 
size) from Analtech Inc. Melting points were determined on a GallenKamp melting point 
apparatus in a capillary tube and are uncorrected. 1H and 13C NMR spectra were recorded 
on a Varian Unity plus 400 MHz or 200 MHz spectrometers in CDCl3, DMSO-d6, and 
CD3OD-d4. Compounds were prepared for infrared spectroscopic (IR) analysis as a 
mixture in KBr or on a ZnSe ATR crystal. Electrospray Ionization – Ion-Trap Mass 
Spectrometry (ESI-IT-MS) was carried out on a Bruker Daltonics Esquire 3000 Plus. 
4.2.2 Synthesis of 3-thienylboronic acid, 715 
 
To a dry round bottom flask equipped with a magnetic stirrer and septum toluene 
(32 mL) and tetrahydrofuran (THF) (8 mL) were added under a nitrogen atmosphere. 
This was followed b the addition of triisopropylborate (5.1 mL, 22 mmol) and 3-
bromothiophene (1.89 mL, 20 mmol). The mixture was cooled to -70oC using a dry 
ice/acetone bath. n-Butyllithium (1.6M hexane, 9.6 mL) was added dropwise via a 
syringe pump over 1hr and the reaction mixture was stirred for an additional 30 minutes 
while maintaining the temperature at -70oC, after which the acetone bath was removed 
and the reaction was allowed to warm up to -20oC before a 2N hydrochloric acid (20 mL) 
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was added. When the reaction reached room temperature it was transferred to a 
separatory funnel. Organic layers were dried over magnesium sulfate and evaporated on a 
rotary evaporator producing a white solid. 7 was recrystallized from acetonitrile as a 
white crystalline material, (2.56g, 61%). M.p.: 153-154oC; (Lit. m.p.: 152-154oC).15 1H 
NMR (δH; 200 MHz, CD3OD-d4): 7.84 (m, 1H), 7.36 (s, 2H). 
4.2.3 Synthesis of 3-(thiophen-3-yl)pyridine, 816  
 
A mixture of 3-bromopyridine (0.99g, 6.4 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.18g, 0.26 mmol) in 20 mL of acetonitrile and 
20 mL of water was stirred under nitrogen atmosphere for 10 minutes. To that mixture 7 
(1.00g, 7.8 mmol) and sodium carbonate (1.01g, 9.5 mmol) were added and the reaction 
mixture was allowed to reflux at 70oC and monitored by TLC. After 4 days, water was 
added and the mixture was extracted with ethyl acetate producing a light brown liquid. 
The residue was chromatographed on silica using 7:3 hexanes-ethyl acetate as the eluant. 
8 was isolated as a light yellow powder and recrystallized from ethanol to produce a 
crystalline material, (0.85g, 83%). M.p.: 73-76oC; (Lit. m.p.: 76-77oC).17 1H NMR (δH; 
400 MHz, CDCl3): 8.88 (s, 1H), 8.55 (d, 1H, J = 4Hz), 7.87 (d, 1H, J = 8Hz), 7.53 (s, 
1H), 7.41 (m, 1H), 7.34 (m, 1H), 7.32 (m, 1H); 13C NMR (δC; 400 MHz, CDCl3): 148, 
139, 133, 131, 127, 123, 121, 119; IR: 3075, 1576, 1474, 1430, 1321, 1258, 1180, 1018, 
860, 782, 700, 640 cm-1. 
 
4.2.4 Synthesis of N-(5-(thiophen-3-yl)pyridin-2-yl)acetamide, 918 
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2-Acetamido-5-bromopyridine (1.12g, 5 mmol) and 7 (0.77g, 6 mmol) were 
dissolved in ethylene glycol dimethylether (20 mL) the mixture was degassed with 
dinitrogen for 10 minutes, after which 2N sodium carbonate (5 mL) and 
tetrakis(triphenylphosphine)palladium(0) (0.35g, 0.30 mmol) were added and the reaction 
was left to reflux at 70oC and monitored by TLC. After 3 days, the reaction mixture was 
allowed to cool to room temperature. The reaction mixture was filtered and the filtrate 
extracted with ether. The combined ether layers were washed with saturated aqueous 
sodium chloride (2 x 100 mL) and water (3 x 100 mL), and dried over magnesium 
sulfate. The ether was evaporated and the residue was chromatographed on silica with 9:1 
hexanes-ethyl acetate as the eluant. 9 was isolated as a light yellow solid, (0.57g, 52%). 
M.p.: 131-133oC. 1H NMR (δH; 400 MHz, CDCl3): 9.10 (s, 1H), 8.52 (d, 1H, J = 4Hz), 
8.29 (d, 1H, J = 4Hz), 7.92 (s, 1H), 7.45 (m, 1H), 7.36 (m, 1H), 2.23 (s, 3H); 13C NMR 
(δC; 400 MHz, CDCl3): 169, 150, 141, 138, 136, 128, 127, 125, 120, 114, 24; IR: 2934, 
1683, 1586, 1529, 1405, 1302, 1310, 1214, 1000, 848, 758, 735, 697, 652 cm-1. 
4.2.5 Synthesis of trimethyl(2-(thiophen-3-yl)ethynyl)silane, 1019 
 
Trimethyl(2-(thiophen-3-yl)ethylnyl)silane was prepared by employing a 
modification of the previously reported procedure.19 3-Bromothiophene (6.15g, 37.7 
mmol), trimethylsilylacetylene (4.12g, 41.54 mmol), triphenyl phosphine (0.07g, 0.267 
mmol), copper iodide (0.01g, 0.05 mmol), and tetrakis(triphenylphosphine)palladium(0) 
(0.261g, 0.22 mmol) were added to a dry round bottom flask, to which THF (50 mL) and 
triethylamine (16 mL) were added followed by degassing with nitrogen for 15 minutes. 
Reaction mixture was refluxed at 70oC under a N2 atmosphere and monitored by TLC. 
After 53 hrs no significant changes were observed in TLC, therefore the reaction was 
allowed to cool to room temperature. The solution was diluted with 100 mL of 
hexanes/ethyl acetate (1:1) and washed with water (3 x 100 mL), then washed with 
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saturated aqueous sodium chloride (1 x 100 mL). The organic layer was dried over 
sodium sulfate. The solvent was removed on a rotary evaporator and the residue was 
chromatographed on silica with hexanes-ethyl acetate (10:2) as eluant. 10 was isolated as 
a red liquid, (6.79g, 81%); 1H NMR (δH; 200 MHz, CDCl3): 7.46 (m, 1H), 7.20 (m, 1H), 
7.11 (m, 1H), 0.28 (s, 9H). 
4.2.6 Synthesis of 3-ethynylthiophene, 1119 
 
3-Ethylnythiophene was prepared by employing a modification of the previously 
reported procedure.19 A mixture of 10 (1.80g, 0.01 mmol) and potassium carbonate 
(1.04g, 7.5 mmol) was stirred in methanol (30 mL) at room temperature for 2hrs. The 
reaction mixture was then diluted with dichloromethane (100 mL), washed with water (3 
x 50 mL) and dried over magnesium sulfate. The solvent was removed under reduced 
pressure via a rotary evaporator producing a light brown liquid (0.464g, 52%).  1H NMR 
(δH; 200 MHz, CDCl3): 7.51 (s, 1H), 7.23 (m, 1H), 7.15 (m, 1H), 3.03 (s, 1H). 
Note: The compound was used immediately without further purification because 
it decomposed on silica gel during column chromatography as well as when left at room 
temperature or in the refrigerator within a 24hr period. 
4.2.7 Synthesis of 3-(2-(thiophen-3-yl)ethynyl)pyridine, 1219 
 
12 was prepared by employing a modification of the previously reported 
procedure.19 A mixture of 11 (2.1g, 17 mmol) and 3-bromopyridine (1.47 mL, 15 mmol), 
copper(I) iodide (0.03g, 0.16 mmol), triphenyl phosphine (0.09g, 0.34 mmol), and 
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bis(triphenylphosphine)palladium(II) dichloride (0.25g, 0.36 mmol) was added to a dry 
round bottom flask. THF (60 mL) and triethylamine (15 mL) were added and degassed 
with dinitrogen for 10 minutes. The reaction mixture was allowed to reflux at 70oC under 
a nitrogen atmosphere and monitored by TLC. After 36hrs the reaction was allowed to 
cool to room temperature and diluted with ethyl acetate (100 mL) and washed with water 
(3 x 100 mL), and saturated aqueous sodium chloride (1 x 100 mL). The organic layer 
was dried over magnesium sulfate. The solvent was removed on a rotary evaporator and 
the residue was chromatographed on silica with 9:1 hexanes-ethyl acetate as eluant, to 
produce 12 as a dark brown powder. 12 dissolved in methanol and subjected to activated 
carbon wash producing a light brown powder, (1.95g, 70%). M.p.: 60-62oC; 1H NMR 
(δH; 200 MHz, CDCl3): 8.75 (s, 1H), 8.52 (d, 1H, J = 4Hz), 7.75 (d, 1H, J = 4Hz), 7.75 (s, 
1H), 7.28 (t, 1H), 7.21 (m, 2H); 13C NMR (δC; 400 MHz, CDCl3): 152, 151, 148, 138, 
129, 125, 123, 121, 120, 87, 85; IR: 3125, 1552, 1468, 1409, 1182, 1027, 872, 788, 703, 
624 cm-1. 
4.2.8 Synthesis of N-(5-(2-thiophen-3-yl)ethynyl)pyridin-2-yl)acetamide, 1319 
 
11 was prepared by employing a modification of the previously reported 
procedure.19 A mixture of 11 (0.464g, 3.86 mmol) and 2-acetamido-5-bromopyridine 
(0.430g, 2 mmol), copper(I) iodide (0.004g, 0.021 mmol), triphenyl phosphine (0.03g, 
0.11 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.03g, 0.043 mmol) 
were added to a dry round bottom flask. THF (10 mL) and triethylamine (5 mL) were 
added and degassed with dinitrogen for 10 minutes. The reaction mixture was allowed to 
reflux at 70oC under a nitrogen atmosphere and monitored by TLC. After 36hrs reaction 
was allowed to cool to room temperature and diluted with ethyl acetate (50 mL) and 
washed with water (3 x 50 mL) then washed with saturated aqueous sodium chloride (1 x 
50 mL). The organic layer was dried over magnesium sulfate. The solvent was removed 
on a rotary evaporator and the residue was chromatographed on silica with 9:1 hexanes-
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ethyl acetate as eluant, producing 13 as a light brown powder, (0.23g, 48%). M.p.: 196-
198oC; 1H NMR (δH; 200 MHz, CDCl3): 8.75 (s, 1H), 8.52 (d, 1H, J = 4Hz), 7.75 (d, 1H, 
J = 4Hz), 7.75 (s, 1H), 7.28 (t, 1H), 7.21 (m, 2H); 13C NMR (δC; 400 MHz, CDCl3): 169, 
150, 148, 141, 129, 125, 121, 116, 115, 114, 87, 85, 24; IR: 2940, 1661, 1672, 1530, 
1455, 1367, 1300, 1092, 1002, 828, 778, 704, 623 cm-1. 
4.2.9 Synthesis of 3-bromo-2,5-dimethylthiophene, 1420 
 
To 50 mL of a glacial acetic acid solution containing 2,5-dimethylthiophene (1.14 
mL, 10 mmol), N-bromosuccinimide (NBS) (1.78g, 10 mmol) was slowly added at room 
temperature. The reaction mixture was stirred for 3hrs, after which it was poured onto 
excess ice-cold water and extracted with dichloromethane. The organic layer was washed 
with aqueous sodium carbonate (3 x 50 mL) and water (5 x 50 mL) and dried over 
magnesium sulfate, and concentrated under reduced pressure via a rotary evaporator. The 
residue was purified by column chromatography with hexanes as eluant. 14 was isolated 
as a colorless oil, (1.30g, 68%). 1H NMR (δH; 200 MHz, CDCl3): 6.58 (s, 1H), 2.43 (s, 
3H), 2.36 (s, 3H). 
 
4.2.10  Synthesis of 2,5-dimethylthiophen-3-yl-boronic acid, 1521 
 
 
n-Butyllithium (1.6M in hexanes, 9.7 mL, 15.6 mmol) was slowly added to a 
stirred solution of 14 (2.9g, 14.1 mmol) in anhydrous THF (40 mL) under nitrogen 
atmosphere at -78oC. The reaction mixture was then stirred at this temperature for 90 
minutes. A solution of triisopropyl borate (3.26 mL, 14.2 mmol) was added over 15 
minutes. After stirring for 5hrs, 2M aqueous hydrochloric acid solution was added and 
the reaction mixture was stirred at room temperature for 10 hrs. The reaction mixture was 
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extracted with diethyl ether and the combined extracts were washed with water (3 x 100 
mL). The product was obtained by extracting the ethereal layer with aqueous sodium 
hydroxide solution (2M, 20 mL) followed by acidification with hydrochloric acid (12M) 
to commence the precipitation of 15 as a white powder, (1.10g, 68%). M.p.: 180-182oC, 
(Lit. m.p.: 180-183oC);22 1H NMR (δH; 200 MHz, DMSO-d6): 7.75 (s, -OH), 6.85 (s, 1H), 
2.37 (s, 3H), 2.33 (s, 3H). 
4.2.11  Synthesis of 3-(2,5-dimethylthiophen-3-yl)pyridine, 1618 
 
3-Bromopyridine (0.54g, 3.7 mmol) and 15 (0.73g, 4.7 mmol) were dissolved in 
20 mL ethylene glycol dimethylether, the reaction mixture was degassed with dinitrogen 
for 10 minutes, after which 2N sodium carbonate (10 mL) and 
tetrakis(triphenylphosphine)palladium(0) (0.1g, 0.86 mmol) were added and the reaction 
mixture was left to reflux at 70oC and monitored by TLC. After 3 days, the reaction was 
allowed to cool to room temperature. The reaction mixture was filtered and the filtrate 
extracted with ether. The combined ether layer were washed with a saturated solution of 
sodium chloride (2 x 50 mL) and water (3 x 100 mL), and dried over magnesium sulfate. 
The ether was evaporated and the residue was chromatographed on silica with 9:1 
hexanes-ethyl acetate as the eluant. 16 was isolated as a light yellow oil, (0.70g, 77%). 1H 
NMR (δH; 200 MHz, CDCl3): 8.63 (s, 1H), 8.52 (d, 1H, J = 4Hz), 7.34 (t, 1H), 7.67 (d, 
1H, J = 4Hz), 6.68 (s, 1H), 2.40 (s, 6H); 13C NMR (δC; 149, 147, 136, 135, 134, 133, 132, 
126, 123, 15, 14; IR: 1556, 1454, 1410, 1300, 1239, 1202, 1008, 840, 762, 680, 620 cm-1. 
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4.2.12  Synthesis of N-(5-(2,5-dimethylthiophen-3-yl)pyridin-2-yl)acetamide,  
  1718 
 
17 was prepared by employing a modification of the previously reported 
procedure.18 2-Acetamido-5-bromopyridine (1.00g, 6.4 mmol) and 15 (1.2g, 5.4 mmol) 
were dissolved in 30.00 mL ethylene glycol dimethylether, the solution was degassed 
with dinitrogen for 10 minutes, after which 2N sodium carbonate (15 mL) and 
tetrakis(triphenylphosphine)palladium(0) (0.2g, 1.7 mmol) were added and the reaction 
mixture was allowed to reflux at 70oC and monitored by TLC. After 3 days, the reaction 
mixture was allowed to cool to room temperature, filtered and extracted with ether. The 
combined ether phases were washed with a saturated solution of sodium chloride (2 x 50 
mL) and water (3 x 100 mL), and dried over magnesium sulfate. The ether was 
evaporated and the residue was chromatographed on silica with 7:3 hexanes-ethyl acetate 
as the eluant. 17 was isolated as a white solid, (1.33g, 68%). M.p. 141-142oC. 1H NMR 
(δH; 200 MHz, CDCl3): 9.17 (s, 1H), 8.29 (d, 1H, J = 2Hz), 7.73 (d, 1H, J = 2Hz), 6.67 (s, 
1H), 2.45 (d, 6H), 2.22 (s, 3H); 13C NMR (δC; 400 MHz, CDCl3): 169, 150, 147, 138, 
136, 134, 132, 129, 128, 114, 24, 15, 14; IR: 3400, 1684, 1586, 1528, 1435, 1397, 1364, 
1312, 1260, 1139, 850, 813, 724, 680 cm-1. 
4.2.13  Synthesis of 2-chlorothiophane, 1823 
 
To a stirred solution of thiophane (1.12mL, 10 mmol) in benzene (10.00 mL) was 
added N-chlorosuccinimide (NCS) (0.75g, 0.06 mmol) in small portions over a period of 
5 minutes. Reaction temperature was maintained at 10-20oC using an ice bath. After 
addition of NCS, stirring was continued for 2 hrs, after which the solution was filtered 
and the solvent was removed via rotary evaporator to produce 18 as a yellow liquid. 18 
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was purified via column chromatography using hexanes as eluant to yield a light yellow 
liquid, (0.65g, 88%). 1H NMR (δH; 200 MHz, CDCl3): 5.98 (s, 1H), 3.29 (t, 2H), 2.89 (m, 
2H), 2.11-1.84 (m, 2H). 
Note: Compound 18 was immediately used, as it decomposed upon storage at 
room temperature and in the fridge.  
 
4.2.14   Synthesis of 1-(thiophane)-1H-benzimidazole, 1924 
 
To a round bottom flask, containing benzimidazole (1g, 8 mmol) dissolved in 
THF (50 mL) was added sodium hydroxide pellets (10g, 250 mmol) and the mixture was 
stirred at room temperature for 2hrs. This was followed by the addition of 18 (0.49g, 4.00 
mmol) in THF (25 mL) and the reaction mixture was stirred at room temperature for 2 
days. Upon completion water was added and the layers were separated and dried over 
magnesium sulfate, and the solvent removed via rotary evaporator resulting in a light 
yellow solid, (0.4g, 48%). M.p.: 80-82oC. 1H NMR (δH; 200 MHz, CDCl3): 8.28 (s, 1H), 
7.80 (m, 1H), 7.44 (m, 1H), 7.29 (m, 2H), 6.00 (m, 1H), 3.29 (m, 2H), 2.96 (m, 2H), 2.37 
(m, 2H); 13C NMR (δC; 400 MHz, CDCl3): 144, 141, 132, 122, 120, 110, 63, 38, 33, 28; 
ESI-IT-MS m/z 205 [19+H]; IR: 1925, 2851, 1456, 1396, 1268, 1244, 1201, 1123, 1004, 
877, 767 cm-1. 
4.2 Synthesis of cocrystals  
The synthesis of a small number of cocrystals is presented here. Co-
crystallizations were set up in a 1:1 ratio with halogens/carboxylic acids and thiophene 
derivatives using a variety of solvents including; ethanol, methanol, nitromethane, 
acetonitrile as well as a combination of 1:1 methanol-nitromethane, ethanol-nitromethane 
and ethyl acetate-nitromethane. Only crystals suitable for X-ray crystallography are 
presented here. All solids obtained were analyzed by IR spectroscopy, results are shown 
in Table 4.4-4.5.  
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4.3.1.1  Synthesis of 3-(thiophen-3-yl)pyridine succinic acid (2:1), 8SUC 
8 (0.015g, 0.093 mmol) was dissolved in 4 mL of ethanol in a 100 mL beaker. To 
this a solution of SUC (0.011g, 0.093 mmol) in 4 mL ethanol was added. Colorless plates 
were obtained via slow evaporation after 10 days. M.p.: 109-110oC; IR (KBr pellet): ν 
2481 cm-1, 1944 cm-1 (O-H…N, br), 1700 cm-1 (C=O acid, s). 
4.3.1.2  Synthesis of 3-(thiophen-3-yl)pyridine 4-iodobenzoic acid (1:1), 8IBA 
8 (0.015g, 0.093 mmol) was dissolved in 2 mL of nitromethane in a 100 mL 
beaker. To this a solution of IBA (0.023g, 0.093 mmol) in 2 mL of nitromethane was 
added. The solution was left at ambient temperature to undergo slow evaporation. After 5 
days colorless plate-like crystals were obtained. M.p.: 195-195oC; IR (ZnSe ATR 
crystal): ν 2541 cm-1, 1901 cm-1 (O-H..N, br), 1670 cm-1 (C=O acid, s), 1006 cm-1, 751 
cm-1 (C-I). 
4.3.2  Hartree–Fock 6-31G* calculations 
Compounds 8 3-(thiophen-3-yl)pyridine, 9 N-(5-(thiophen-3-yl)pyridin-2-
yl)acetamide, 12 3-(2-(thiophen-3-yl)ethynyl)pyridine, 13 N-(5-(2-thiophen-3-
yl)ethynyl)pyridin-2-yl)acetamide, 16 3-(2,5-dimethylthiophen-3-yl)pyridine, 17 N-(5-
(2,5-dimethylthiophen-3-yl)pyridin-2-yl)acetamide, and 19 1-(thiophane)-1H-
benzoimidazole (Figure 4.7) molecular structures were constructed using Spartan ’06 
(Wavefunction, Inc. Irvine, CA). All seven molecules were optimized using Hartree-Fock 
6-31G*, with the maxima and minima in the electrostatic potential surface (0.002 e/au 
isosurface) determined using a positive point charge in the vacuum as a probe.  
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4.4 Results and Discussion 
4.4.1 Calculations 
 
Figure 4.7 Electrostatic potential calculations of 8, 9, 12, 13, 16, 17, 19, units in 
(kJmol-1). 
 
Table 4.1 shows the results of the electrostatic potentials calculated for the thienyl 
derivatives used in this study, and Figure 4.7 shows the electrostatic potential surfaces for 
each acceptor ligands, with A1 having highest charge thereby being the best acceptor and 
A2 the second best acceptor. 
 
Table 4.1 Electrostatic potentials of heterocycles 8, 9, 12, 13, 16, 17, 19 
Heterocycle MEP A1/kJmol-1 MEP A2/kJmol-1 
3-(thiophen-3-yl)pyridine,  8 -197 -64 
N-(5(thiophen-3-yl)pyridin-2-yl)acetamide, 9 -251 -64 
3(2-(thiophen-3-yl)ethynyl)pyridine, 12 -193 -64 
N-(5-(2-thiophen-3-yl)ethynyl)pyridin-2-yl)acetamide, 13 -231 -70 
3-(2,5-dimethylthiophen-3-yl)pyridine, 16 -201 -75 
N-(5-(2,5,-dimethylthiophen-3-yl)pyridin-2-yl)acetamide, 17 -240 -82 
1-(thiophane)-1H-benzoimidazole, 19 -220 -96 
 
Hartree-Fock 6-31G* electrostatic potential calculations were conducted in order 
to rank the binding preferences, as well as to establish whether XB interactions of 8, 9, 
12, 13, 16, 17, 19 are dominated by electrostatic or HSAB interactions. Each molecule 
has two separate acceptor sites, the pyridine nitrogen atoms (A1) and the thienyl sulfur 
atoms (A2), Table 4.1.  Compounds 16, 17 and 19 were synthesized in order to increase 
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the charge on the sulfur atom, therefore increasing the ability of the sulfur atoms to 
participate in some form of non-covalent interaction.  Thus by adding electron-donating 
groups such as methyl groups we were able to increase the charge on the sulfur atom by 
approximately 11 kJmol-1. Likewise, changing from an aromatic system to an aliphatic 
system 19, we were able to increase the charge by approximate 20 kJmol-1 on the sulfur 
atom. 
The charges of donor compounds we employed are shown in Table 4.2, with the 
D1 being the acidic proton and D2 the halogen atom in cases where both an acid and 
halogen atom is present.  
 
Table 4.2 Electrostatic potentials of hydrogen/halogen bonding donor atoms 
Donor compounds MEP D1/kJmol-1 MEP D2/kJmol-1 
4-iodobenzoic acid 130 123 
4-iodotetrafluorobenzoic acid 219 143 
4-bromotetrafluorobenzoic acid 160 146 
1,4-diiodobenzene - 124 
1,4-diiodotetrafluorobenzene - 207 
1-bromo-4-iodotetrafluorobenzene - 202(I) & 142(Br) 
 
Based on the calculated electrostatic potentials and the HSAB theory, the 
anticipated interactions between the donor and acceptor molecule involving a halogen 
bond is shown in Figure 4.8-4.9. 
 
       
Figure 4.8 Anticipated interaction if electrostatic interaction dominates. 
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Figure 4.9 Expected intermolecular interactions if HSAB theory dominates 
 
However if the interactions are comparable, then both the sulfur and nitrogen 
should participate in halogen bonding, Figure 4.10. 
 
 
Figure 4.10 Anticipated interaction if sulfur and nitrogen are comparable acceptors. 
 
In the case where we have both a hydrogen bond and halogen bond donor, the 
anticipated interactions between the acceptors and donors are shown in Figure 4.11. 
    
 
            
Figure 4.11 Anticipated hydrogen and halogen bonding. 
 
4.4.2 IR spectroscopy 
Infrared spectroscopy is an effective tool for investigating hydrogen and halogen 
bonding interactions25 through the study of vibrational motions in terms of intensity and 
shift. The IR spectroscopy data for uncomplexed compounds used in this study are shown 
in Table 4.3. 
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Table 4.3 IR stretches of uncomplexed halogen donors 
Compounds C-I/C-Br stretches  
(cm-1) 
4-iodobenzoic acid 1007 & 753 
4-iodotetrafluorobenzoic acid 1468 & 978 
4-bromotetrafluorobenzoic acid 1473 & 983 
1.4-diiodobenzene 1066 & 794 
1,4-diiodotetrafluorobenzene 1457 & 938 
1-bromo-4-iodotetrafluorobenzene 1470 & 947 
 
The data obtained from IR spectroscopy performed on solids from the 
supramolecular reactions with dicarboxylic acids are shown in Table 4.4. 
 
Table 4.4 IR data (position of O-H…N stretches) from co-crystallization 
experiments. 
Compounds Dicarboxylic acids O-H…N band cm-1 Cocrystal formation 
 
8 
succinic acid 
adipic acid 
suberic acid 
sebacic acid 
2481 & 1994 
2530 & 1895 
2530 & 1926 
2530 & 1905 
yes 
yes 
yes 
yes 
 
9 
succinic acid 
adipic acid 
suberic acid 
sebacic acid 
2501 & 1920 
2487 & 1910 
2340 & 1874 
2530 & 1926 
yes 
yes 
yes 
yes 
 
12 
succinic acid 
adipic acid 
suberic acid 
sebacic acid 
2550 & 1899 
2668 & 1920 
2509 & 1910 
2340 & 1874 
yes 
yes 
yes 
yes 
 
Based on IR data collected from co-crystallization reactions with aliphatic 
dicarboxylic acids and 8, 9 and 12, twelve out of twelve times the typical stretch at 
approximately 2500 and 1900 cm-1, indicative of O-H…N heterocycle hydrogen bonds 
was observed.  However, we were unable to tell whether or not sulfur is participating in 
hydrogen bonding with dicarboxylic acids from the infrared spectra. No significant shifts 
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in the C-S stretch were observed when the IR of the starting materials was compared with 
that of the product.  Although 8, 9, and 12 are able to form cocrystals with dicarboxylic 
acid based on infrared spectroscopy, we cannot conclude that the sulfur atom is 
participating in any form of non-covalent interaction. 
Similarly, the data obtained from IR spectroscopy performed on solids from the 
supramolecular reactions with an acid-halogen and halogen bond donors are shown in 
Table 4.5. 
 
Table 4.5 IR data (position of O-H…N and C-I/Br stretches) from co-crystallization 
experiments 
Compounds Acid/halogen O-H…N 
band 
cm-1 
C-I/Br 
band  
cm-1 
Formation of 
C-X…N/S 
Cocrystal 
formation 
 
               8 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2541 & 1901 
2500 & 1900 
2498 & 1952 
- 
- 
- 
1006 & 751 
1466 & 938 
1470 & 980 
1066 & 775 
1451 & 930 
1450 & 931 
no 
yes 
no 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
 
                     9 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2533 & 1936 
1903 
2496 & 1956 
- 
- 
- 
1006 & 752 
1462 & 972 
1473 & 982 
1066 & 795 
1451 & 929 
1460 & 963 
no 
yes 
no 
no 
yes 
yes 
yes 
yes 
yes 
no 
yes 
yes 
 
12 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2549 & 1932 
2459 & 1911 
2516 & 1948 
- 
- 
- 
1006 & 752 
1466 & 935 
1461 & 972 
1066 & 791 
1449 & 931 
1463 & 935 
no  
yes 
yes 
no 
yes 
yes 
yes 
yes 
yes 
no 
yes 
yes 
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Compounds 
 
Acid/halogen 
O-H…N 
band 
cm-1 
C-I/Br 
band  
cm-1 
Formation of 
C-X…N/S 
Cocrystal 
formation 
 
13 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2498 & 1897 
2381 & 1916 
2501 & 1952 
- 
- 
- 
1002 & 750 
1455 & 974 
1473 & 980 
1066 & 779 
1455 & 931 
1455 & 972 
no 
yes 
no 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
 
16 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2498 & 1896 
2500 & 1924 
2471 & 1912 
- 
- 
- 
1007 & 752 
1453 & 970 
1468 & 975 
1064 & 794 
1449 & 931 
1453 & 970 
no 
yes 
yes 
no 
yes 
yes 
yes 
yes 
yes 
no 
yes 
yes 
 
17 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2553 & 1901 
2498 & 1897 
2498 & 1944 
- 
- 
- 
1006 & 751 
1455 & 973 
1471 & 979 
1066 & 796 
1454 & 929 
1458 & 966 
no 
yes 
no 
no 
yes 
yes 
yes 
yes 
yes 
no 
yes 
yes 
 
19 
4-iodobenzoic acid 
4-iodotetrafluorobenzoic acid 
4-bromotetrafluorobenzoic acid 
1,4-diiodobenzene 
1,4-diiodotetrafluorobenzene 
1-bromo-4-
iodotetrafluorobenzene 
2569 & 1920 
2489 & 1944 
2569 & 1916 
- 
- 
- 
1005 & 738 
1455 & 974 
1457 & 976 
1009 & 736 
1448 & 934 
1460 & 934 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
 
Of the twenty-one co-crystallization reactions with an acid-halogen molecule, 
twenty-one out of twenty-one times O-H…N (~2500 and 1900 cm-1) interactions were 
observed in the infrared spectra. However if the halogen atom participated in halogen 
bonding changes in C-X stretches would undergo a decrease by 7-15 cm-1. Of the twenty-
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one reactions 11/21 times a shift in the C-X stretch was observed suggesting that maybe 
the sulfur atom is participating in halogen bonding.  
 To further establish whether the sulfur atom in this study is participating in 
halogen bonding another set of co-crystallization reactions were carried out using only di-
halogenated compounds. Of the twenty-one reactions seventeen of those reactions 
showed a decrease in either the C-I or C-Br stretches indicating that halogen bonding is 
taking place. Since both nitrogen and sulfur atoms, are present in these complexes it is 
difficult to establish whether both sulfur and nitrogen is participating in halogen bonding 
based on the infrared evidence. 
Therefore to establish the participation of sulfur atom in halogen bonding we 
carried out grinding experiments with 2,5-dimethylthiophene and thiophane using I2F4B 
as our cocrystal former, Figure 4.12. 
 
 
(a)     (b) 
Figure 4.12 Halogen bonding between: (a) 2,5-dimethylthiophene-I2F4B, (b) 
thiophane-I2F4B. 
 
Based on the infrared evidence (Figure 4.13-4.14) no significant changes in the C-I 
stretch was observed, suggesting that the sulfur atom in these series is not participating in 
halogen bonding. 
 90 
 
Figure 4.13 IR spectra of grinding experiment with 2,5-dimethylthiophene-I2F4B: top 
(2,5-dimethylthiophene), middle (I2F4B), bottom (2,5-dimethylthiophene-I2F4B). 
 
 
Figure 4.14 IR spectra of grinding experiment with thiophane- I2F4B: top (I2F4B) and 
bottom (thiophane-I2F4B). 
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4.4.3 Characterization of 9 and 17 
9 and 17 were prepared in good yields, crystals suitable for single-crystal X-ray 
crystallography of 9 and 17 were grown by slow evaporation of saturated ethyl acetate 
solution at room temperature over 36 hrs, Figure 4.15. 
 
9      17 
Figure 4.15 Thermal ellipsoids plot (50 % probability level) of 9 and 17. 
 
The crystal structure determination confirms that both 9 and 17 participate in self-
complementary amide-pyridine interaction through N-H…N hydrogen bonds, Figure 
4.16. 
    
9                     17 
Figure 4.16 Self-complementary pyridine-amide interaction in 9 and 17. 
 
Unfortunately, crystals suitable for X-ray diffraction were not obtained for 
compounds 8, 12, 13, 16 and 19, however combination of 1H and 13C NMR along with 
mass spectrometry confirm the identity of the resulting products. 
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4.4.4 Crystal structure descriptions  
A summary of the crystallographic information for 9, 17, 8SUC and 8IBA is 
displayed in Table C.3 and all hydrogen-bond geometries for 9, 17, 8SUC and 8IBA are 
listed in Table 4.6. 
 
Table 4.6 Hydrogen-bond geometries for 9, 17, 8SUC and 8IBA 
Structure D-H…A d(D-H)/Å d(H…A)/Å d(D…A)/Å <(DHA)o 
9i N(11)-H(11)…N(21)#1 0.78(2) 2.34(2) 3.1082(17) 170(2) 
17ii N(22)-H(22)…N(21)#1 0.885(16) 2.333(16) 3.1984(14) 165.9(14) 
8SUC O(31)-H(31)…N(21) 0.889(16) 1.766(16) 2.6517(10) 174.8(15) 
8IBA O(11)-H(11)…N(21) 0.84 1.89 2.623(4) 144.7 
i) #1 -x+2,-y+1,-z    ii) #1 -x-1,-y,-z+1 
 
4.4.4.1  Crystal structure of 8SUC 
The crystal structure of 8SUC contains one molecule of 8 and half a molecule of 
SUC in the asymmetric unit; the structure also displays disorder, Figure 4.17.  The 
architecture shows the pyridyl nitrogen hydrogen bonding to the carboxylic acid resulting 
in a trimer, Figure 4.18. Moreover, the sulfur atom does not participate in any form of 
non-covalent interactions. 
 
Figure 4.17 Thermal ellipsoid plot (50% probability) of 8SUC. 
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Figure 4.18 Trimer of 8SUC held together by O-H…N hydrogen bonds. 
 
4.4.4.2  Crystal structure of 8IBA 
The asymmetric unit of 8IBA contains one molecule of 8 and one molecule of 
IBA, Figure 4.19. 
 
Figure 4.19 Thermal ellipsoid (50% probability) of 8IBA. 
 
The overall architecture reveals O-H…N hydrogen bonding between the pyridine 
nitrogen atom and the carboxylic acid, Figure 4.20.  
 
Figure 4.20 1:2 cocrystal of 8IBA held together by O-H…N and I…O interactions. 
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Additionally, a halogen bond between the iodine and oxygen atom of the hydroxy 
group is observed with a bond distance of 3.263Å, and bond angle of 160.75o. The typical 
bond distance observed for halogen bonding involving an oxygen atom (I…O) normally 
ranges between 3.04-3.37Å26 whereas the typical bond angle for contacts with 
nucleophiles such as oxygens and nitrogen primarily range between 160o and 180o.27 
As with the previous structures the sulfur atom does not participate in any non-
covalent interactions. 
4.5 Conclusion  
Based on the molecular electrostatic potential calculations conducted the pyridyl 
and benzimidazole nitrogen having the highest charge formed hydrogen bond with 
incoming donor molecules 33/33 times (100% success rate). 
Additionally, from IR evidence we can conclude that the sulfur atom in 2,5-
dimethylthiophene and thiophane did not participate in halogen bonding, therefore in this 
series the halogen bonding interaction is not dominated by HSAB principles. 
Furthermore, from the twenty-one reactions, seventeen of those showed 
significant shifts in the C-X band, indicating that the formation of halogen bond between 
the nitrogen or oxygen atom present in the system, thereby confirming that halogen bond 
is purely electrostatic. This is further demonstrated in 8IBA, where instead of forming a 
halogen bond with the sulfur atom, the iodine being the softer acid formed a halogen 
bond with oxygen a harder base, further confirming that within these series of compounds 
the dominating interaction is based on electrostatics and not HSAB principles. 
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CHAPTER 5 - Exploring the co-crystallizing and melting 
capabilities of pyridylcarboxaldehyde hydrazones  
5.1 Introduction 
The arrangement of molecules in a crystal determines many fundamental 
properties such as melting behavior, solubility, hygroscopicity and mechanical strength. 
These properties can affect the performance of a solid drug.  The shape and particle size 
of the solid drug can influence pharmaceutical operations, such as filtration, washing, 
drying, milling, mixing, tableting, dissolution, recrystallization of a suspension and 
lyophilization.1 Therefore, the ability to control, predict, and change the crystal structure 
of both known and unknown compounds would contribute significantly to both 
manufacturers and consumers of solid specialty chemicals.2  
Current approaches used in changing the physical properties of APIs have 
drawbacks such as structural changes that may take place upon formation of a new 
crystalline phase, which can be very drastic (i.e. limiting the fine-tuning of the physical 
properties) or highly unpredictable. For example, several pharmaceutical crystals such as 
theophylline,3 carbamazepine4 and phenobarbital5 have been reported to undergo a 
variety of phase transformations thereby affecting the stability and bioavailability of the 
drug. As a result, the transformation of a biologically active drug into a viable product is 
often extremely time consuming, expensive and inefficient. 
An alternative approach to over-come this problem is utilizing co-crystallization 
techniques to form cocrystals6 of APIs using predesigned, inexpensive and readily 
available small molecules. This can provide a means for making subtle changes to bulk 
physical properties without tampering with the pharmacological behavior of the 
compound at the molecular level and may therefore provide new opportunities for 
addressing issues related to the dissolution characteristics, hygroscopicity, drug delivery, 
processability and melting behavior. 
A survey of cocrystal formation in the CSD7 revealed that most cocrystals have 
been prepared using a combination of functional groups located on a variety of molecules 
such that they would prefer to bind in a heteromeric fashion, Figure 5.1, rather than in a 
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homomeric manner.8,9,10 These particular moieties are ubiquitous in biochemistry as well 
as in materials science and display favorable geometric and electronic complementarity.  
 
 
Figure 5.1 Examples of cocrystals constructed via heteromeric intermolecular 
interactions. 
 
 A notable example is isonicotinamide, which has been shown to form cocrystals 
readily with a variety of carboxylic acids, Figure 5.2.11 We anticipate that having the 
isonicotinamide derivative, as part of a scaffold in our molecules can result in the 
formation of cocrystals with a variety of carboxylic acids. 
 
Figure 5.2  Anticipated heteromeric interaction between organic acids and 
isonicotinamide derivatives. 
 
 The compounds of interest to us are a family of hydrazones, which possesses 
chelating abilities for the treatment of iron-overload disease and acts as agents with 
considerable anti-tumor activity.12 Therefore, we designed and synthesized 
supramolecular architectures with a variety of carboxylic acids using four members of the 
hydrazone family 20, 21, 23 and 24 Figure 5.3.   
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Figure 5.3 Target family of hydrazone compounds. 
 
The overall goals of this chapter are: 
 1. To synthesize and characterize a series of hydrazones. 
 2. To determine whether we can synthesize a series of cocrystals with  
  predictable and reliable patterns of behavior. 
3. To establish whether the melting point of the cocrystal can be correlated  
  with the nature of the co-crystallizing agent. 
5.2 Experimental 
5.2.1 Synthesis 
 
All chemicals, unless noted were purchased from Aldrich and used without 
further purification. Melting points were determined on a GallenKamp melting point 
apparatus in a capillary tube and are uncorrected. 1H and 13C NMR spectra were recorded 
on a Varian Unity plus 400 MHz or 200 MHz spectrometers in CDCl3 or DMSO-d6. 
Compounds were prepared for infrared spectroscopic (FT-IR) analysis as a mixture in 
KBr or on a ZnSe ATR crystal.  The target compounds were prepared in good yields by 
Schiff base condensation between the corresponding aldehydes and acid hydrazides. 
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5.2.1.1  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2013 
 
 
2-Pyridine carboxaldehyde (5.40g, 0.050 mol) and isonicotinic acid hydrazide 
(6.86g, 0.050 mol) were dissolved in 35 mL of ethanol. Solution was refluxed at 70oC 
using a Dean Stark apparatus for 2hrs.  The refluxed solution was allowed to cool and left 
standing at room temperature for 24hrs, during which the product precipitated. The 
product was isolated by filtration then recrystallized from methanol as a white solid, 
(6.76g, 60%). M.p.: 168-171oC; (Lit m.p. 168-170oC).14 1H NMR (δH; 400 MHz, DMSO-
d6): 12.29 (s, -CONH-), 8.81 (d, 2H, J = 8Hz), 8.63 (d, 1H, J = 4Hz), 8.49 (s, -N=CH-), 
8.00 (d, 1H, J = 8 Hz); 7.91 (d, 1H, J = 8Hz), 7.86 (d, 2H, J = 8Hz), 7.44 (t, 1H, J = 
12Hz); 13C NMR (δC; 400 MHz, DMSO-d6): 161, 152, 150, 149, 140, 137, 136, 124, 121, 
120; IR (KBr pellet): υ 3288 (N-H), 1667 (C=O), 1544 (C=N), 1463, 1403, 1275( C-O), 
1145, 752, 685 cm-1. 
 
5.2.1.2  Synthesis of 4-pyridylcarboxaldehyde isonicotinoylhydrazone, 2113 
 
4-Pyridine carboxaldehyde (3.21g. 0.030 mol) and isonicotinic acid hydrazide 
(4.11g, 0.030 mol) were dissolved in 30 mL of ethanol. The solution was refluxed at 
70oC using a Dean Stark apparatus for 2hrs.  The refluxed solution was allowed to cool 
and left standing at room temperature for 24hrs, during which the product precipitated. 
The product was isolated by filtration then recrystallized from methanol as a white solid, 
(5.34g, 79%). M.p.: 241-242oC. 1H NMR (δH; 400 MHz, DMSO-d6): 12.35 (s, -CONH), 
8.80 (d, 2H, J = 8Hz), 8.64 (d, 2H, J = 4Hz), 8.44 (s, -N=CH-), 7.85 (d, 2H, J = 4 Hz), 
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7.65 (d, 2H, J = 4Hz); 13C NMR (δC; 400 MHz, DMSO-d6): 162, 150, 146, 141, 140, 121; 
IR (KBr pellet): υ 3288 (N-H), 1669 (C=O), 1536 (C=N), 1460, 1280 (C-O) cm-1. 
5.2.1.3  Synthesis of picolinohydrazide, 2215 
 
  
 A suspension of methyl picolinate (3.02g, 0.022 mol) and hydrazine (5.00g, 0.156 
mol) in 150 mL methanol was refluxed under nitrogen atmosphere for 10 hrs. The 
reaction was then allowed to cool to room temperature. The solvent was removed on a 
rotary evaporator and a light pink solid was obtained. Recrystallization from warm ethyl 
acetate resulted in the product as a white solid, (2.51g, 83%). M.p.: 102-104oC; (Lit m.p. 
102-103oC).15 1H NMR (δH; 400 MHz, CDCl3): 9.06 (s, 1H), 8.53 (d, 1H, J = 5Hz), 8.13 
(d, 1H, J = 8Hz), 7.88 (t, 1H), 7.46(t, 1H), 4.11 (s, 2H); IR (KBr pellet): υ 3309, 3206, 
1675, 1521, 1000 cm-1. 
5.2.1.4  Synthesis of 4-pyridylcarboxaldehyde picolinoylhydrazone, 2313 
 
4-Pyridine carboxaldehyde (2.14g 0.020 mol) and 22 (2.74g, 0.020 mol) were 
dissolved in 25 mL of ethanol. The solution was refluxed at 70oC using a Dean Stark 
apparatus for 2hrs.  The refluxed solution was allowed to cool and left standing at room 
temperature for 24hrs, during which the product precipitated. The product was isolated by 
filtration and further purified via recrystallization from methanol to give an off white 
solid, (2.74g, 61%). M.p. 204-206oC. 1H NMR (δH; 400 MHz, DMSO-d6): 12.45 (s, -
CONH-), 8.67 (d, 2H, J = 8Hz), 8.63 (d, 2H, J = 8Hz), 8.16 (d, 1H, J = 8Hz), 8.03 (d, 1H, 
J = 12 Hz), 7.62 (m, 3H); 13C NMR (δC; 400 MHz, DMSO-d6): 160, 150, 149, 146, 141, 
138, 127, 122, 120; IR (KBr pellet): υ 3282 (N-H), 3018, 1684 (C=O), 1510 (C=N), 
1355, 1141 cm-1. 
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5.2.1.5  Synthesis of 3-pyridylcarboxaldehyde nicotinoylhydrazone, 2413 
 
3-Pyridine carboxaldehyde (3.21g 0.030 mol) and nicotinic hydrazide (4.11g, 
0.030 mol) were dissolved in 30 mL of ethanol. The solution was refluxed at 70oC using 
a Dean Stark apparatus for 2hrs.  The refluxed solution was allowed to cool and left 
standing at room temperature for 24hrs, during which the product precipitated. The 
product was isolated by filtration followed by recrystallized from methanol to give the 
product as a white solid, (5.28g, 78%). M.p.: 222-224oC. 1H NMR (δH; 400 MHz, 
DMSO-d6): 12.23 (s, -CONH-), 9.11 (s, 1H), 8.87 (s, -N=CH-), 8.77 (d, 1H, J = 4 Hz), 
8.60 (s, 1H), 8.50 (d, 1H, J = 4Hz), 8.28 (d, 1H, J = 4Hz), 8.14 (d 1H, J = 4Hz), 7.56 (t, 
1H), 7.46 (t, 1H); 13C NMR (δC; 400 MHz, DMSO-d6): 162, 152, 150, 148, 145, 125, 
133, 130, 129, 124, 123; IR (KBr pellet): υ 3232 (N-H), 2824, 1694 (C=O), 1549 (C=N), 
1281 (C-O), 1141, 1027, 818 cm-1. 
5.2.1.6  Synthesis of 2-pyridinylidene benzoylhydrazine, 2516 
 
To a solution of benzoic hydrazide (0.110g, 0.830 mmol) in absolute ethanol (7 
mL) containing 2 drops of 37% hydrochloric acid was added to 2-pyridine 
carboxaldehyde (0.093g, 0.870 mmol). The mixture was stirred at 30oC for 24hrs. The 
reaction mixture was poured into cold water and neutralized with 10% aqueous sodium 
bicarbonate solution. Using a stirring rod to scratch the beaker resulted in formation of a 
white precipitate, which was filtered off and dried, (0.131g, 70%). M.p.: 166-168oC; (Lit 
m.p. 166-168oC).16 1H NMR (δH; 400 MHz, DMSO-d6): 12.09 (s, 1H), 8.62 (d, 1H, J = 
9.6Hz), 8.49 (s, -N=CH), 7.98 (m, 4H), 7.61 (m, 3H), 7.42 (t, 1H, J = 12.4Hz); IR (ATR 
ZnSe crystal): υ 3403 (N-H), 2982, 1666 (C=O), 1576 (C=N), 1290 (C-O), 1141, 1076, 
776 cm-1. 
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5.2.2   Synthesis of cocrystals 
5.2.2.1  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone octanoic  
  acid hydrate (1:1), 20OCT 
20 (0.030g, 0.133 mmol) and octanoic acid (0.038g, 0.266 mmol) were added to a 
beaker along with 4 mL of ethanol. The mixture was heated gently until components 
were in solution. Colorless plates suitable for X-ray diffraction were obtained after 
twenty days via slow evaporation of ethanol. M.p.: 72-74oC. IR (KBr pellet): υ 2533 cm-
1, 1951 cm-1 (O-H…N, br), 1667 cm-1 (C=O acid, s). 
5.2.2.2  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone hexanoic  
  acid hydrate (1:1), 20HEX 
20 (0.030g, 0.133 mmol) was dissolved in 4 mL of ethanol and added to beaker 
containing hexanoic acid (0.031g, 0.266 mmol) in 4 mL of ethanol. The mixture was left 
at ambient temperature to undergo slow evaporation. After ten days colorless plates were 
obtained. M.p.: 77-79oC. IR (KBr pellet): υ 2525 cm-1, 1900 cm-1 (O-H…N, br), 1675 
cm-1 (C=O acid, s). 
5.2.2.3  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone fumaric  
  acid (1:1), 20FUM 
20 (0.0565g, 0.245 mmol) was dissolved in 4 mL of ethanol and added to beaker 
containing fumaric acid (0.029g, 0.245 mmol) in 4 mL of ethanol. The mixture was 
allowed to slowly evaporate at room temperature. After seven days light orange prism 
were obtained. M.p.: 208-210oC. IR (KBr pellet): υ 2510 cm-1, 1884 cm-1 (O-H…N, br), 
1674 cm-1 (C=O acid, s). 
5.2.2.4  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone adipic acid 
  hydrate (1:1), 20ADI 
20 (0.029g, 0.130 mmol) was dissolved in 4 mL of nitromethane and added to 
solution of adipic acid (0.019g, 0.130 mmol) in 4 mL of nitromethane and allowed to 
slow evaporate at room temperature. After twenty days colorless prism were obtained. 
M.p.: 112-114oC. IR (KBr pellet): υ 2451 cm-1, 1933 cm-1 (O-H…N, br), 1676 cm-1 
(C=O acid, s). 
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5.2.2.5  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone suberic  
  acid hydrate (1:1), 20SUB 
A solution of 20 (0.025g, 0.109 mmol) in 4 mL of ethanol was mixed with a 
solution of suberic acid (0.019g, 0.109 mmol) in 4 mL of ethanol and allowed to stand at 
room temperature for slow evaporation. Colorless prisms were obtained after eleven 
days. M.p.: 134-136oC. IR (KBr pellet): υ 2461 cm-1, 1953 cm-1 (O-H…N, br), 1679 cm-1 
(C=O, s). 
5.2.2.6  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone sebacic  
  acid dihydrate (1:1), 20SEB 
A solution of 20 (0.030g, 0.133 mmol) in 4 mL of nitromethane was mixed with a 
solution of suberic acid (0.027g, 0.133 mmol) in 4 mL of nitromethane and allowed to 
stand at room temperature for slow evaporation. Colorless prisms were obtained after five 
days. M.p.: 105-106oC. IR (KBr pellet): υ 2561 cm-1, 1933 cm-1 (O-H…N, br), 1693 cm-1 
(C=O, s). 
5.2.2.7  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone 
   3-fluorobenzoic acid hydrate (1:1) 20FBA 
 
In a test tube containing 20 (0.019g, 0.086 mmol) in 2 mL of ethanol was added 
to 3-fluorobenzoic acid (0.024g, 0.171 mmol) in 2 mL of ethanol. The solution was 
placed at room temperature to undergo slow evaporation. After ten days colorless plates 
were obtained. M.p.: 117-119oC. IR (KBr pellet): υ 2544 cm-1, 1923 cm-1 (O-H…N, br), 
1669 cm-1 (C=O, s). 
5.2.2.8  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone 4-
 nitrobenzoic  acid hydrate (1:1) 20NBA 
A solution of 20 (0.014g, 0.0.059 mmol) in 2 mL of ethanol was added to a 
solution of 4-nitrobenzoic acid (0.020g, 0.119 mmol) in 2 mL of ethanol and allowed to 
stand at room temperature for slow evaporation in a test tube. After eleven days colorless 
prisms were obtained. M.p.: 210-212oC. IR (KBr pellet): υ 2361 cm-1, 1943 cm-1 (O-
H…N, br), 1669 cm-1 (C=O, s). 
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5.2.2.9  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone 2,4- 
  difluorobenzoic acid hydrate (1:1), 20F2BA 
In a test tube containing 20 (0.030g, 0.133 mmol) in 2 mL of ethanol was added 
to 2,4-difluorobenzoic acid (0.084g, 0.531 mmol) in 2 mL of ethanol. The solution was 
placed at room temperature to undergo slow evaporation. Colorless plate-like crystals 
were obtained after twenty days. M.p.: 154-156oC. IR (KBr pellet): υ 2498 cm-1, 1900 
cm-1 (O-H…N, br), 1684 cm-1 (C=O, s). 
5.2.2.10  Synthesis of 2-pyridylcarboxaldehyde isonicotinoylhydrazone 4-  
  aminobenzoic acid hydrate (1:1) 20ABA 
In a beaker containing 20 (0.015g, 0.070 mmol) in 3 mL of ethanol-acetonitrile 4-
aminobenzoic acid (0.010g, 0.070 mmol) in 3 mL of ethanol-acetonitrile was added. The 
solution was placed at room temperature to undergo slow evaporation. Transparent 
orange block-like crystals were obtained after fifteen days. M.p.: 105-107oC. IR (KBr 
pellet): υ 2489 cm-1, 1879 cm-1 (O-H…N, br), 1684c m-1 (C=O acid, s), 3416 cm-1 (NH2 
acid, s). 
5.2.2.11  Synthesis of 4-pyridylcarboxaldehyde isonicotinoylhydrazone succinic  
  acid dihydrate (1:1), 21SUC 
21 (0.030g, 0.133 mmol) was gently heated in 4 mL of ethanol and added to a 
solution containing succinic acid (0.0157g, 0.133 mmol) in 4 mL of ethanol. The solution 
was left to stand at room temperature for slow evaporation. After nine days colorless 
plate-like crystals were obtained. M.p.: 212-214oC. IR (KBr pellet): υ 2431 cm-1, 1948 
cm-1 (O-H…N, br), 1679 cm-1 (C=O acid, s). 
5.2.2.12  Synthesis of 4-pyridylcarboxaldehyde isonicotinoylhydrazone adipic  
  acid hydrate (1:1), 21ADI 
A solution of 21 (0.030g, 0.133mmol) in 4 mL of ethanol was gently heated and 
added to a solution of adipic acid (0.019g, 0.133mmol) in 4 mL of ethanol. The mixture 
was allowed to stand at ambient temperature. After nine days colorless plate-like crystals 
were obtained. M.p.: 190-192oC. IR (KBr pellet): υ 2476 cm-1, 1903 cm-1 (O-H…N, br), 
1677 cm-1 (C=O acid, s). 
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5.2.2.13 Synthesis of 4-pyridylcarboxaldehyde isonicotinoylhydrazone suberic  
  acid hydrate (1:1), 21SUB  
21  (0.030g, 0.133 mmol) was dissolved in 1 mL methanol-1 mL ethyl acetate and 
added to a beaker containing suberic acid (0.023g, 0.133 mmol) in 1 mL methanol-1 mL 
ethyl acetate.  The solution was allowed to stand at room temperature for slow 
evaporation. After twelve days colorless plates were obtained. M.p.: 179-181oC. IR (KBr 
pellet): υ 2500 cm-1, 1900 cm-1 (O-H…N, br), 1678 cm-1 (C=O acid, s). 
5.2.2.14 Synthesis of 4-pyridylcarboxaldehyde picolinoylhydrazone fumaric acid  
  (1:1), 23FUM 
23 (0.030g, 0.133 mmol) was dissolved in 4 mL of ethanol and added to a beaker 
containing fumaric acid (0.015g, 0.133 mmol) in 4 mL of ethanol. The solution was left 
to stand at room temperature for slow evaporation. Colorless prisms were obtained ten 
days later. M.p.: 207-209oC. IR (KBr pellet): υ 2498 cm-1, 1924 cm-1 (O-H…N, br), 1695 
cm-1 (C=O acid, s). 
5.2.2.15 Synthesis of 4-pyridylcarboxaldehyde picolinoylhydrazone glutaric acid  
  (1:1), 23GLU 
23 (0.030g, 0.133 mmol) was dissolved in 4 mL of ethanol and added to a beaker 
containing glutaric acid (0.018g, 0.133 mmol) in 4 mL of ethanol. The solution was left 
to stand at room temperature for slow evaporation. After eight days colorless plate-like 
crystals were obtained. M.p.: 156-157oC. IR (KBr pellet): υ 2484 cm-1, 1928 cm-1 (O-
H…N, br), 1715 cm-1 (C=O acid, s). 
5.2.2.16 Synthesis of 3-pyridylcarboxaldehyde nicotinoylhydrazone adipic acid  
  dihydrate (1:1), 24ADI 
A solution of 24 (0.030g, 0.133 mmol) in 4 mL of ethanol was gently heated and 
added to a solution of adipic acid (0.019g, 0.133 mmol) in 4 mL of ethanol. The solution 
was allowed to stand at ambient temperature for slow evaporation. After ten days 
colorless prisms were obtained. M.p.: 139-141oC. IR (KBr pellet): υ 2495 cm-1, 1918 cm-
1 (O-H…N, br), 1669 cm-1 (C=O acid, s). 
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5.2.2.17 Synthesis of 3-pyridylcarboxaldehyde nicotinoylhydrazone suberic acid  
  hydrate (1:1), 24SUB 
24 (0.030g, 0.133 mmol) was dissolved in 4 mL of ethanol by gentle heating and 
added to beaker containing suberic acid (0.023g, 0.133 mmol) in 4 mL of ethanol. The 
solution was allowed to stand at room temperature for slow evaporation.  Colorless plate-
like crystals were obtained twelve days later. M.p.: 152-154oC. IR (KBr pellet): 2475 cm-
1, 1924 cm-1 (O-H…N, br), 1670 cm-1 (C=O acid, s). 
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5.4 Results 
A summary of the crystallographic information for 20OCT, 20HEX, 20FUM, 
20ADI, 20SUB, 20SEB, 20FBA, 20NBA, 20F2BA, 20ABA, 21SUC, 21ADI, 21SUB, 
23FUM, 23GLU 24ADI and 24SUB are displayed in Table C.3 and all the hydrogen-
bond geometries are listed in Table 5.1. 
 
Table 5.1 Hydrogen-bond geometries for 20OCT, 20HEX, 20FUM, 20ADI, 
20SUB, 20SEB, 20FBA, 20NBA, 20F2BA, 20ABA, 21SUC, 21ADI, 21SUB, 23FUM, 
23GLU, 24ADI, 24SUB 
Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
20OCTi O(31)-H(31)...N(21) 1.00(4) 1.60(4) 2.597(3) 178(3) 
 N(27)-H(27)...O(1S)#1 0.82(3) 2.01(3) 2.815(3) 166(3) 
 O(1S)-H(1A)...O(32) 0.81(3) 1.97(3) 2.758(3) 164(3) 
 O(1S)-H(1B)...O(27)#2 0.97(4) 1.81(4) 2.767(3) 168(3) 
      
20HEXii O(1S)-H(1A)...O(17)#1 0.80(3) 1.98(3) 2.778(3) 177(3) 
 O(1S)-H(1B)...O(32)#2 0.94(3) 1.85(3) 2.760(3) 161(3) 
 O(31)-H(31)...N(11) 1.04(4) 1.56(4) 2.590(3) 171(3) 
 N(17)-H(17)...O(1S) 0.74(3) 2.09(3) 2.815(3) 165(3) 
      
20FUMiii O(31)-H(31)...N(11) 0.952(18) 1.666(18) 2.6167(15) 176.0(16) 
 N(17)-H(17)...O(17)#2 0.870(17) 2.396(17) 3.2462(15) 165.6(15) 
      
20ADIiv O(31)-H(31)...N(11) 1.01(3) 1.60(3) 2.6035(19) 174(2) 
 O(1S)-H(1A)...O(17)#2 0.81(2) 2.00(2) 2.7649(17) 157(2) 
 O(1S)-H(1B)...O(32)#3 0.88(3) 1.93(3) 2.7744(19) 161(2) 
 N(17)-H(17)...O(1S) 0.84(2) 1.96(2) 2.7928(19) 168(2) 
      
20SUBv O(31)-H(31)...N(11) 0.90(4) 1.69(4) 2.593(3) 173(3) 
 O(1S)-H(1A)...O(17) 0.88(4) 1.93(4) 2.760(3) 157(3) 
 O(1S)-H(1B)...O(32)#2 0.79(4) 1.99(4) 2.753(3) 163(4) 
      
20SEBvi N171-H171...O(1S) 0.893(15) 1.934(15) 2.8216(15) 172.6(14) 
 N172-H172...O(2S) 0.863(14) 1.932(15) 2.7831(14) 168.4(13) 
 O(1S)-H(1A)...O171#1 0.866(17) 2.007(18) 2.8318(14) 158.9(15) 
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Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
 O(1S)-H(1B)...O(32)#2 0.856(18) 1.946(18) 2.7946(15) 170.8(16) 
20SEBvi O(2S)-H(2A)...O172#3 0.846(18) 1.943(18) 2.7612(13) 162.3(15) 
 O(2S)-H(2B)...O(41)#4 0.824(17) 1.975(18) 2.7749(14) 163.2(16) 
      
20FBAvii N(17)-H(17)...O(1S) 0.94(3) 1.90(3) 2.826(4) 167(3) 
 O(1S)-H(1A)...O(32)#1 0.94(4) 1.87(4) 2.791(4) 165(3) 
 O(1S)-H(1B)...O(17)#2 0.81(4) 2.04(4) 2.817(3) 161(4) 
 O(31)-H(31)...N(11) 1.08(4) 1.51(4) 2.552(4) 159(3) 
      
20NBAviii O(1S)-H(1A)...O(17) 0.796(10) 2.138(18) 2.875(3) 154(3) 
 O(1S)-H(1B)...O(1S)#1 0.786(10) 2.27(4) 2.904(6) 139(5) 
 O(31)-H(31)...N(11) 0.94(5) 1.69(5) 2.624(3) 172(4) 
      
20F2BAix O(1S)-H(1A)...O(17) 0.84(2) 2.13(2) 2.8653(15) 146(2) 
 O(1S)-H(1B)...N(21)#1 0.82(2) 2.34(2) 2.9844(19) 136(2) 
 O(31)-H(31)...N(11) 1.11(2) 1.53(2) 2.6337(15) 172.1(18) 
 N(17)-H(17)...O(1S)#2 0.88(2) 1.95(2) 2.8264(16) 178(2) 
      
20ABAx O(31)-H(31)...N(11) 0.90(2) 1.73(2) 2.6349(17) 176.7(18) 
 N(17)-H(17)...O(1S) 0.915(18) 2.001(18) 2.8570(18) 155.1(15) 
 O(1S)-H(1A)...O(17)#1 0.91(2) 2.26(2) 3.0533(19) 145.2(17) 
 O(1S)-H(1B)...N(21)#2 1.01(2) 1.82(2) 2.8274(19) 176.8(17) 
      
21SUCxi O(31)-H(31)...N(11) 0.97(2) 1.65(2) 2.612(2) 174(2) 
 O(1S)-H(1A)...O(17) 0.92(3) 1.92(3) 2.804(2) 160(2) 
 O(2S)-H(2A)...O(32) 0.88(3) 1.86(3) 2.718(2) 166(2) 
 N(17)-H(17)...O(2S)#1 0.83(2) 1.98(2) 2.766(2) 157.4(19) 
 O(34)-H(34)...N(21)#2 1.11(2) 1.45(2) 2.5566(18) 173.7(18) 
 O(1S)-H(1B)...O(35)#3 0.79(3) 1.99(3) 2.775(2) 170(3) 
 O(2S)-H(2B)...O(1S)#4 0.86(3) 1.85(3) 2.717(2) 177(2) 
      
21ADIxii N(17)-H(17)...O(1S) 0.860(19) 2.09(2) 2.9376(18) 167.9(17) 
 O(31)-H(31)...N(11) 0.87(2) 1.77(2) 2.6269(17) 170(2) 
 O(36)-H(36)...N(21)#1 0.94(2) 1.69(2) 2.6269(17) 175.6(19) 
 O(1S)-H(1A)...O(32)#2 0.87(2) 1.97(2) 2.7950(19) 158.6(19) 
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Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
 O(1S)-H(1B)...O(17)#3 0.78(2) 2.13(2) 2.8689(16) 156(2) 
21SUBxiii O(31)-H(31)...N(11) 0.93(3) 1.74(3) 2.641(3) 166(3) 
 O(38)-H(38)...N(21)#1 0.94(3) 1.74(3) 2.666(3) 172(3) 
 O(1S)-H(1A)...O(17) 0.86(3) 2.05(3) 2.873(3) 161(3) 
 O(1S)-H(1B)...O(32)#2 0.87(3) 1.95(3) 2.795(3) 165(3) 
 N(17)-H(17)...O(1S)#3 0.86(3) 2.11(3) 2.942(3) 165(2) 
      
23FUM O(31)-H(31)...N(21) 1.113(13) 1.472(13) 2.5845(9) 177.8(11) 
      
23GLUxiv O(31)-H(31)...O(17) 0.86(2) 1.84(2) 2.6783(18) 166(2) 
 O(35)-H(35)...N(21)#1 1.04(2) 1.62(2) 2.6628(18) 175.5(18) 
      
24ADIxv N(17A)-H(17A)...O(1A) 0.88 2.15 2.993(4) 160.6 
 N(27B)-
H(27B)...O(1B)#1 
0.88 1.95 2.758(11) 152.6 
      
24SUBxvi N(17)-H(17)...O(1S)#1 0.848(16) 2.111(16) 2.9541(14) 172.9(14) 
 O(31)-H(31)...N(11) 0.903(17) 1.776(17) 2.6597(13) 165.2(15) 
 O(38)-H(38)...N(21)#2 0.902(16) 1.752(17) 2.6447(13) 170.0(15) 
 O(1S)-H(1A)...O(17) 0.812(18) 2.147(18) 2.9187(13) 158.8(16) 
 O(1S)-H(1B)...O(32)#3 0.864(18) 2.023(18) 2.8728(14) 167.7(15) 
i) #1 -x+1,-y,-z+1    #2 -x,-y,-z+1      ii) #1 x+1,y,z    #2 -x+1,-y,-z      iii) #2 x-1/2,-y+1/2,z-1/2   iv)#1 -x,-y+2,-z+2    
#2 x-1,y,z    #3 -x,-y+1,-z+1      v) #2 -x+1,-y,-z+1   vi) #1 x-1,y,z    #2 -x+2,-y,-z+1    #3 x+1,y,z    #4 -x,-y+2,-z      
vii) #1 -x+2,-y+1,-z+1    #2 x+1,y,z    viii) #1 -x+2,-y,-z+1      ix) #1 x+1/2,y+1/2,z    #2 -x+1/2,y-1/2,-z+1/2    x) 
#1 -x+1,-y+1,-z+1    #2 -x,-y+1,-z+1      xi) #1 x-1,y,z    #2 x+3/2,-y+3/2,z-1/2    #3 x-1/2,-y+3/2,z+1/2     #4 -
x+1,-y+1,-z+1      xii) #1 x-2,y+1,z+1    #2 -x,-y+1,-z    #3 x-1,y,z     xiii) #1 x-2,y+2,z-1    #2 -x+1,-y+1,-z+1    #3 x-
1,y,z       xiv) #1 x+1/2,y,-z+1/2   xv) #1 x-1,y,z  xvi) #1 x+1,y,z    #2 x-2,y-1,z-1    #3 -x+1,-y+1,-z+2      
 
5.4.1 Crystal structure of 20OCT 
The crystal structure of 20OCT contains one molecule of 20, one molecule of 
OCT and one water molecule with an O-H…N interaction between the carboxylic acid 
and the pyridine nitrogen atom of 20, Figure 5.4.  The crystal structure is further extended 
into a 1-D layer through hydrogen bonds between a water molecule and the adjacent 
carbonyl and amide hydrogen of 20, Figure 5.5. A water molecule is also hydrogen 
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bonded to the carbonyl of the acid, with hydrogen bond distances in Table 5.1. No short 
contacts were observed with the pyridine nitrogen atom in the ortho position of 20. 
 
Figure 5.4 Thermal ellipsoids (50%) and labeling scheme of 20OCT. 
 
 
Figure 5.5 Hydrated cocrystal of 20OCT depicting O-H…N and N-H…O 
interactions resulting in a 1-D motif. 
 
5.4.2 Crystal structure of 20HEX 
The asymmetric unit of 20HEX contains one molecule of 20, one molecule of 
HEX and a water molecule, held together by O-H…N hydrogen bonds between the 
carboxylic acid and the pyridine nitrogen of 20, Figure 5.6.  
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Figure 5.6 Thermal ellipsoids (50%) and labeling of 20HEX. 
 
The structure is further extended into a 1-D array via the aid of the water 
molecule hydrogen bonded to the carbonyl and amide of 20, Figure 5.7. Furthermore, as 
observed in 20OCT there were no short contacts observed with the pyridine nitrogen 
atom in the ortho position of 20HEX. Additionally, as observed in the 20OCT the water 
molecule also forms a hydrogen bond with the carbonyl of an acid.   
 
Figure 5.7 1-D layer of 20HEX held together by both O-H…N and N-H…O 
hydrogen bonds. 
 
5.4.3 Crystal structure of 20FUM 
The asymmetric unit of 20FUM contains one molecule of 20 and one molecule of 
FUM, held together by O-H…N hydrogen bonds between the pyridine nitrogen in the 
para position and the hydroxy group of acid, Figure 5.8. The structure is further 
expanded into a trimer via hydrogen bond interactions between the pyridine nitrogen and 
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carboxylic acid, Figure 5.9. However, as observed in the first two structures the pyridine 
nitrogen in the ortho-position does not participate in any distinct non-covalent 
interactions.  Unlike the two previous structures 20FUM does not contain a water 
molecule in the crystalline lattice. 
 
Figure 5.8 Thermal ellipsoids (50%) and labeling scheme of 20FUM. 
 
 
Figure 5.9 Trimer of 20FUM held together by O-H…N hydrogen bond. 
 
5.4.4 Crystal structure of 20ADI 
The crystal structure of 20ADI contains one molecule of 20, one molecule of ADI 
and one water molecule in the asymmetric unit.  The supermolecule is constructed 
through O-H…N hydrogen bonds between the carboxylic acid and the para position 
nitrogen atom on 20, Figure 5.10.  A 2-D sheet is formed though hydrogen bonds from 
the water molecule, to the carbonyl and amide hydrogen, Figure 5.11. No short contacts 
were observed between the acid and the pyridine nitrogen in the ortho position of 20. 
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Figure 5.10 Thermal ellipsoids (50%) and labeling of 20ADI. 
 
 
Figure 5.11 2-D sheet of 20ADI held to together by O-H…N, O…H-O, N-H…O 
interactions. 
 
5.4.5 Crystal structure of 20SUB 
The crystal structure of 20SUB contains one molecule of 20, one molecule of 
SUB and one water molecule in the asymmetric unit. The structure display hydrogen 
bonding interactions between the para-position pyridine nitrogen and the carboxylic acid, 
a water molecule is hydrogen bonded to the carbonyl group of 20, Figure 5.12, the bond 
distances is shown in Table 5.1. The structure is further extended into a 2-D sheet via the 
aid of a hydrogen bond between the water molecule and the carbonyl and amide 
hydrogen of 20 Figure 5.13, similar to what was observed in 20ADI. Note that the 
carbonyl of the acid also forms a hydrogen bond with the water molecule as previously 
observed. 
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Figure 5.12 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
20SUB. 
 
 
Figure 5.13 2-D sheet of 20SUB held together via O-H…N, O-H…O and N-H…O 
hydrogen bonds. 
 
5.4.6 Crystal structure of 20SEB 
The asymmetric unit of 20SEB contains one molecule of 20, one molecule of 
SEB and one water molecule. As with the two previous structures 20ADI and 20SUB, 
the carboxylic acid forms a hydrogen bond with the para-position pyridine nitrogen, 
Figure 5.14. The water molecule aids in the formation of a 2-D sheet through non-
covalent interaction with the carbonyl and amide, Figure 5.15. Again, the ortho-position 
pyridine nitrogen of 20 shows no distinct non-covalent interaction. 
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Figure 5.14 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
20SEB. 
 
 
Figure 5.15 2-D sheet of 20SEB displaying O-H…N, O-H…O and N-H…O non-
covalent interactions. 
 
5.4.7 Crystal structure of 20FBA 
The crystal structure of 20FBA consists of one molecule of 20, one molecule of 
FBA and one water molecule in the asymmetric unit. The supermolecule is constructed 
through O-H…N hydrogen bonds between the carboxylic acid and the para-position 
pyridine nitrogen atom of 20, Figure 5.16. 
 
Figure 5.16 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
20FBA. 
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The architecture of 20FBA is similar to 20OCT and 20HEX, in that the water molecule 
helps to extend the structure in 1-D layer by interacting with the carbonyl and amide 
hydrogen, Figure 5.17. 
  
     
Figure 5.17 1-D layer motif of 20FBA, held together via O-H…N, N-H…O 
interactions. 
5.4.8 Crystal structure of 20NBA 
The asymmetric unit of 20NBA consists of one molecule of 20, one molecule of 
NBA and one water molecule, the structure is also disordered.  The primary interaction 
observed in this structure is a hydrogen bond between the pyridine nitrogen in the para-
position of 20 and the carboxylic acid, Figure 5.18. 
 
Figure 5.18 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
20NBA. 
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The structure is further extended into a 1-D step-like motif, with interactions 
similar to 20FBA, in that the disordered water molecule forms a hydrogen bond with the 
amide hydrogen and carbonyl thus aiding the extension of the structure, Figure 5.19.  
 
 
Figure 5.19 1-D step-like motif of 20NBA displaying O-H…N and N-H…O hydrogen 
bonds. 
 
5.4.9 Crystal structure of 20F2BA 
The asymmetric unit of 20F2BA contains one molecule of 20, one molecule of 
F2BA and one water molecule. The structure is held together by hydrogen bonding 
between the pyridine nitrogen atom para to the carbonyl of 20 and the carboxylic acid, 
resulting in O-H…N interactions, Figure 5.20. 
 
Figure 5.20 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
20F2BA. 
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Unlike the previous structures, the water molecule forms a hydrogen bond with 
the pyridine nitrogen in the ortho-position of 20, and produces a step-like motif via 
interactions between the amide hydrogen and carbonyl group of 20, Figure 5.21. 
 
Figure 5.21 Unique hydrogen bond motif of 20F2BA involving a water molecule. 
 
5.4.10  Crystal structure of 20ABA 
In the crystal structure of 20ABA the asymmetric unit consists of one molecule of 
20, one molecule of ABA and one water molecule.  Similar to 20FBA, the carboxylic 
acid forms a hydrogen bond with the para-position pyridine nitrogen of 20, Figure 5.22. 
 
Figure 5.22 Thermal ellipsoids (50%) and labeling scheme of 20ABA. 
 
Further extension of the architecture of 20ABA, resulted in an interesting 
architecture, in that both the pyridine nitrogens participates in some form of hydrogen 
bond, with bond distances shown in Table 5.1.  Moreover, the amide hydrogen of ABA 
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forms a hydrogen bond with the carbonyl of 20, as well as a amine…acid N-H…O 
interaction, Figure 5.23.    
 
Figure 5.23 Extended architecture of 20ABA, formed through O-H…N, N-H…O 
interactions. 
 
5.4.11  Crystal structure of 21SUC 
The asymmetric unit of 21SUC consists of one molecule of 21, one molecule of 
SUC and two water molecules, with hydrogen bonds between the pyridine nitrogen of 21 
and the carboxylic acid, Figure 5.24. 
 
Figure 5.24 Thermal ellipsoids (50%) and labeling scheme of 21SUC. 
 
A 2-D sheet is produced by hydrogen bonds between the water molecule and the 
carbonyl and the amide hydrogen of 21, Figure 5.25. 
 
 
Figure 5.25 2-D motif of 21SUC, held together by O-H…N, N-H…O and O-H…O 
hydrogen bonds. 
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5.4.12  Crystal structure of 21ADI 
The asymmetric unit of 21ADI, contains one molecule of 21, one molecule of 
ADI and one water molecule, with hydrogen bond formation between the carboxylic acid 
the pyridine nitrogen of 21, Figure 5.26. 
 
Figure 5.26 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
21ADI. 
 
21ADI shows similar packing as 21SUC, with both ends of the acid forming 
hydrogen bonds with the pyridine nitrogen atoms. Also the structure forms a 2-D sheet 
via hydrogen bonding between the water and the carbonyl and amide hydrogen of 21, 
Figure 5.27. 
 
 
Figure 5.27 2-D architecture 21ADI, held together by O-H…N, N-H…O and O-H…O 
hydrogen bonds. 
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5.4.13  Crystal structure of 21SUB 
The asymmetric unit of 21SUB consists of one molecule of 21, one molecule of 
SUB and one water molecule. The architecture is similar to that of 21SUC and 21ADI, in 
that the carboxylic acid forms a hydrogen bond with the pyridine nitrogen, Figure 5.28. 
 
Figure 5.28 Thermal ellipsoids (50%) and labeling scheme of the supermolecule 
21SUB. 
 
The water molecule aids in the formation of the 2-D structure through hydrogen 
bonding between the amide hydrogen and carbonyl of 21, Figure 5.29. 
 
 
Figure 5.29 2-D sheet in 21SUB formed via O-H…N, N-H…O and O-H…O hydrogen 
bonds. 
 
5.4.14  Crystal structure of 23FUM 
The crystal structure of 23FUM has of one molecule of 23 and one molecule of 
FUM in the asymmetric unit. This structure is similar to 20FUM, in that the acid forms a 
hydrogen bond with the pyridine nitrogen, Figure 5.30. 
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Figure 5.30 Thermal ellipsoids (50%) and labeling scheme of 23FUM. 
 
The crystal structure does not contain any water molecules but displays a trimer 
formed through the interaction of both ends of the dicarboxylic acid groups, Figure 5.31. 
Additionally, no distinct non-covalent interaction was observed with the ortho-position 
nitrogen atom. 
 
 
Figure 5.31 Trimer of 23FUM held together by O-H…N interactions. 
5.4.15  Crystal structure of 23GLU 
The asymmetric unit of 23GLU consists of one molecule of 23 and one molecule 
of GLU, held together by hydrogen bonding between the carboxylic acid and the 
carbonyl of 23, Figure 5.32.  
 
Figure 5.32 Thermal ellipsoids (50%) and labeling scheme of 23GLU. 
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The overall 1-D zig-zag motif resulted from the hydrogen bonding interactions at 
both ends of the dicarboxylic acid and the pyridine nitrogen, Figure 5.33. 
 
 
Figure 5.33 1-D zig-zag motif of 23GLU held together via O-H…N and O-H…O 
hydrogen bonds. 
 
5.4.16  Crystal structure of 24ADI 
The crystal structure of 24ADI consists of one molecule of 24, one molecule of 
ADI and two water molecules in the asymmetric unit, however the structure also exhibits 
some disorder. The structure is held together via hydrogen bonds between the carboxylic 
acid and pyridine nitrogen, Figure 5.34. 
 
Figure 5.34 Thermal ellipsoids (50%) and labeling of 24ADI. 
 
A 2-D sheet-like array results from the water molecules hydrogen bonded to both 
the adjacent carbonyl and amide hydrogen of 24, Figure 5.35. 
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Figure 5.35 2-D array in 24ADI held together by O-H…N, N-H…O and O-H…O 
hydrogen bonds. 
 
5.4.17  Crystal structure of 24SUB 
The asymmetric unit cell of 24SUB consists of one molecule of 24, one molecule 
of SUB and one water molecule. The structure is held together by O-H…N hydrogen-
bond interactions between the acid and the pyridine nitrogen, Figure 5.36. 
 
Figure 5.36 Thermal ellipsoids (50%) and labeling of the supermolecule 24SUB. 
 
A 2-D array similar to that of 24ADI is formed through hydrogen bonds between 
the water molecules the carbonyl and amide hydrogen of 24, Figure 5.37. The water 
molecule also forms a hydrogen bond with the carbonyl of the acid, with bond distances 
listed in Table 5.1.     
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Figure 5.37 2-D array in 24SUB formed through O-H…N, N-H…O and O-H…O 
hydrogen bond interactions. 
 
5.5 Discussion 
5.5.1 Analyzing compounds via infrared spectroscopy 
The infrared spectra of the seventeen compounds prepared in this study indicate 
the formation of cocrystals in all cases. Broad stretches near 2450 and 1900 cm-1 were 
observed, which are characteristic of intermolecular O-H…N hydrogen bonds that can 
only come about if the two reactants form heteromeric supramolecular synthons. The 
vibrational spectra also suggest that the resulting products, in each case exist as molecular 
cocrystals and not as organic salts. All seventeen compounds, displayed a strong band 
around 1680 cm-1 and a weak band near 1275 cm-1 corresponding to C=O and C-O 
stretches of the carboxylic acid moiety.  
Single crystal X-ray data further supported the assignments made on the basis of 
vibrational spectroscopy. Each carboxylic acid contains two distinctly different C-O bond 
distances corresponding to the C=O and C-O(H) covalent bonds, and the C-N-C 
endocyclic bond angle of the heterocyclic moieties fall in the narrow range of 117.1-
119.1o, which is indicative of a non-ionized pyridine unit, Table 5.2.17 In contrast, the C-
N-C endocyclic bond angle of a pyridinium cation is 121.1o.17  
 
 
 
 127 
Table 5.2 Distribution of C-O bond lengths for carboxylic acid moieties and C-N-C 
bond angles for 20OCT, 20HEX, 20FUM, 20ADI, 20SUB, 20SEB, 20FBA, 20NBA, 
20F2BA, 20ABA, 21SUC, 21ADI, 21SUB, 23FUM, 23GLU, 24ADI, 24SUB 
Compound d(C=O) Å d(C-O) Å <(C-N-C) o 
20OCT 1.228(3) 1.303(3) 117.8(2) 
20HEX 1.229(3) 1.301(3) 116.8(2) 
20FUM 1.2295(16) 1.3184(15) 118.19(12) 
20ADI 1.210(2) 1.306(2) 118.13(14) 
20SUB 1.210(3) 1.297(3) 118.1(2) 
20SEB 1.2158(15) 1.3110(15) 117.87(11) 
20FBA 1.220(4) 1.291(4) 117.4(3) 
20NBA 1.213(4) 1.300(4) 117.8(3) 
20F2BA 1.2163(17) 1.3183(18) 117.98(12) 
20ABA 1.2217(18) 1.3104(18) 117.54(13) 
21SUC 1.203(2) 1.310(2) 118.18(14) 
21ADI 1.2112(19) 1.3044(19) 117.52(13) 
21SUB 1.215(3) 1.297(3) 117.58(19) 
23FUM 1.2228(9) 1.2922(9) 116.98(7) 
23GLU 1.204(2) 1.322(2) 116.79(15) 
24ADI 1.212(3) 1.325(3) 118.6(3) 
24SUB 1.2199(4) 1.3191(13) 118.62(10) 
 
5.5.2 Assessing the co-crystallizing ability of the hydrazones  
To better understand the co-crystallizing ability of the series of hydrazones in this 
study, it is important to look at the possible supramolecular synthons18 that is taking place 
when these molecules assemble into supermolecules. From the literature we know that 
pyridines and carboxylic acids tend to form robust synthons;19 therefore, the initial 
assembly of cocrystals should be achieved from interaction between the incoming acid 
and the pyridyl moiety on the hydrazone fragments.  However, each hydrazone has four 
possible acceptor sites and one donor site Figure 5.38.  
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Figure 5.38 Example of a hydrazone depicting the possible acceptor and donor sites. 
 
Therefore, the presence of so many acceptor sites creates some difficulty in 
accessing the competition of the incoming acid; however the seven possible synthons that 
can result from their interactions are shown in Figure 5.39. 
 
Figure 5.39 Expected acid…pyridine synthon (I). Four possible interactions involving 
N-H hydrogen bond donor: with the amide carbonyl (II), with acid carbonyl (III), with 
the pyridine nitrogen (IV), with imine nitrogen (V) and the carboxylic acid with the 
amide carbonyl (VI), and the imine nitrogen (VII). 
 
5.5.2.1          Formation of hydrazones/carboxylic acid cocrystals  
In every one of the seventeen cocrystals containing 20, 21, 23 and 24 and a 
carboxylic acid that we have obtained, the intermolecular interaction responsible for the 
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construction of  the main supramolecular assembly is the O-H…N motif between the 
carboxylic acid and the hydrazone pyridine moieties, Figure 5.40.  
 
cocrystals    17 
primary synthon   hydrazone pyridine/carboxylic acid 
# of occurrences   17/17 
supramolecular yield    100% 
Figure 5.40 Summary of primary hydrogen bonding between 20, 21, 23, 24 and 
various carboxylic acids. 
 
It is worth emphasizing that the carboxylic acid…pyridine interaction is very 
effective tool for the assembly of molecular cocrystals,20 and a search of the CSD7 
reveals forty-nine cocrystals having similar functionality as 20, 21, 23 and 24 all 
assembled via complementary carboxylic acid…pyridine interactions. Undoubtedly, this 
synthon is a suitable supramolecular tool, capable of bringing together a variety of 
discrete molecular building blocks into heteromeric molecular cocrystals.  
5.5.2.2  Secondary molecular interactions 
Other than the primary interaction that takes place between the carboxylic acid 
and the pyridine moieties, only synthon VI from the possible synthons Figure 5.39 was 
observed in 23GLU. However we were able to identify two other types of motifs in this 
series of compounds, Figure 5.41. For simplicity only the carboxylic acid/20 synthon will 
be shown.   
From the seventeen cocrystals obtained with 20, 21, 23, 24 and carboxylic acids, 
fourteen of those structures were hydrates, of the fourteen motif VIII was observed in 
twelve of the structures, whereas motif IX was only observed in 20F2BA and 20ABA. In 
these two examples water plays an important role in forming a hydrogen bond with the 
ortho-position nitrogen, suggesting that the nitrogen atom is active and should be able to 
participate in non-covalent interactions.  
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VIII    IX 
 
# of occurrences  12/14     2/14 
percentage   86%     14% 
Figure 5.41 Observed motifs between water molecule and cocrystal of 20, 21, 23, 24 
and carboxylic acids. 
 
Therefore cocrystals of 20 and 23 offer an excellent comparison of how altering 
the position of the nitrogen on the aryl ring affects co-crystallization outcome, as well as 
hydrogen-bond interactions. In 20 the carbonyl group is para to the pyridine nitrogen 
atom, whereas in 23 the carbonyl group is ortho to the pyridine nitrogen. However, in the 
two structures obtained with 23, not only was there no interaction at the ortho-position 
nitrogen atom, but there was no water molecule present in the structures. Therefore 
instead of a 2-D layered structure a trimer was observed in one case (23FUM) and a 1-D 
zigzag array in the other case (23GLU), Figure 5.42. 
 
 
   23GLU     23FUM 
Figure 5.42 Binding interactions in the absence of a water molecule. 
 
It is evident that water plays an important role in co-crystallization reactions with 
20, 21, 23 and 24. In each case where a water molecule is present in a 2-D layered 
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structure or step-like motif is formed, whereas in the absence of water the packing is 
either a 1-D chain or a trimer. These results suggest that the water molecule aids in the 
formation of the most favorable packing required for this series, a summary of all the 
observed interactions is shown in Table 5.3. 
 
Table 5.3 Molecular interaction of 20OCT, 20HEX, 20FBA, 20NBA, 20F2BA, 
20ABA, 20FUM, 20ADI, 20SUB, 20SEB, 21SUC, 21ADI, 21SUB, 23FUM, 23GLU, 
24ADI and 24SUB 
Compounds Para-position 
nitrogen atom 
Ortho-
position 
nitrogen atom 
Acid carbonyl API carbonyl Amide N-H Structural 
motif 
20OCT W X Y Y Y I, VIII 
20HEX W X Y Y Y I, VIII 
20FBA W X Y Y Y I, VIII 
20NBA W X Y Y Y I, VIII 
20F2BA W Y Y Y Y I, IX 
20ABA W Y Z Z Y I, IX 
20FUM W X X X X I 
20ADI W X Y Y Y I, VIII 
20SUB W X Y Y Y I, VIII 
20SEB W X Y Y Y I, VIII 
21SUC W - Y Y Y I, VIII 
21ADI W - Y Y Y I, VIII 
21SUB W - Y Y Y I, VIII 
23FUM W X X X X I 
23GLU W X X W V I, VI 
24ADI - W Y Y Y I, VIII 
24SUB - W Y Y Y I, VIII 
V = hydroxyl oxygen of acid; W = hydroxyl group of acid binds; X = no interactions; Y 
= water molecule binds; Z = binds with the N-H proton from the acid. 
 
5.5.3 Structural consistency of hydrazones 
The hydrazones we have studied have proven to be selective in their binding 
preferences, with only three out of the seventeen cases exhibiting the absence of a water 
molecule in the lattice of the structure. From the twelve cocrystals of 20 and 23 only two 
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times does the ortho-position nitrogen atom form a hydrogen bond. A summary of the 
binding between pyridine nitrogen and the carboxylic acids of the four APIs in the study 
is shown in Figure 5.43. 
 
 
 
Figure 5.43 Binding preferences of API with carboxylic acids. 
 
The cocrystals present in this study exemplify remarkable structural consistency, 
in that hydrates were observed fourteen out of seventeen times. The water molecule also 
formed hydrogen bonds thirteen out of seventeen times with both the API carbonyl as 
well as with the acid carbonyl, Figure 5.44. 
 
 
Figure 5.44 Classification of crystal structures obtained from supramolecular reactions 
between APIs and a variety of acids. The numbers obtained in each case are in brackets. 
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Although only two of the possible synthons were observed in this study, the 
hydrazone family of compounds tends to form cocrystals readily. Additionally, the water 
molecule demonstrates great selectively towards both the carbonyl of the API and acid as 
well as the N-H amide. 
5.5.4 Probing the ortho-position nitrogen in the formation of cocrystal 
Based on the cocrystals obtained for both 20 and 23, it begs the question, what 
would happen if the nitrogen atom para to the carbonyl was not present in the ring?  
Would that force the ortho-position nitrogen to participate in hydrogen bonding with 
incoming acids? Thus to answer these questions compound 25 was synthesized Figure 
5.45 and setup with the same series of acids used with 20 and 23.  
 
 
Figure 5.45 Comparison between 20 and 25. 
 
Cocrystal screening was carried out using FT-IR with particular attention focused 
to the 1900 and 2500 cm-1 region of the IR spectra, which is indicative of the formation 
of O-H…N hydrogen bonding.  Based on the FT-IR obtained eleven out of eleven times 
no O-H…N stretches were observed in the FT-IR; examples are shown in Figure 5.46 
(25NBA) and Figure 5.47 (25FUM). 
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Figure 5.46 FT-IR of 25NBA: 25(dark blue), 25NBA (red) and NBA (pink). 
 
 
Figure 5.47 FT-IR of 25FUM: 25(dark blue), 25FUM (red) and FUM (green). 
25 
25NBA 
NBA 
25 
25FUM 
FUM 
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From the two figures not only are the two prominent stretches missing but there 
are also no significant shifts of the carbonyl stretches in 25 or any of the acids observed 
in the 25NBA or 25FUM. Even though a water molecule is able to bind to the ortho-
position nitrogen, the incoming acid is unable to bind.  This may be as a result of the type 
of packing preferred by the molecule making it difficult for larger molecules to come in 
and interact with the ortho-position nitrogen atom. 
5.5.4 Probing the melting behavior of cocrystals of 20  
Melting point is a fundamental physical property and since we obtain structural 
consistency we decided to examine the melting behavior of cocrystals obtained with 
20OCT, 20NBA, 20FBA, 20F2BA, 20SUC, 20ADI, 20SUB, 20SEB. 
 
Figure 5.48 Melting point correlation profile of 20OCT, 20NBA, 20FBA and 
20F2BA. 
 
The melting points of the five cocrystals are plotted against the melting points of 
the corresponding monoacids. Melting point of 20 is 168-171oC and from the graph upon 
co-crystallization with F2BA and NBA an increase in melting point is observed, whereas 
the opposite is observed with cocrystal formed with OCT and FBA. This resulted in a 
positive correlation between the melting point of the acid and that of the corresponding 
cocrystal, Figure 5.48. 
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Figure 5.49 Melting point correlation for 20SUC, 20ADI, 20SUB and 20SEB. 
 
Likewise cocrystals with 20 and dicarboxylic acids also displayed similar trends, 
(Figure 5.49) as carbon chain length of the acids increases the melting point of the 
cocrystals decreases. Using linear regression, a correlation coefficient of 0.8611 was 
found, indicating that 86% of the variability in cocrystal melting points can be explained 
by variability in the melting point of the co-crystallizing agent. 
These findings suggest that the melting behavior of these crystalline solids are 
directly related to the melting points in the carboxylic acids.  The highest-melting 
cocrystal contains the dicarboxylic acid with the highest melting point, and the lowest-
melting acid produces the lowest melting cocrystal; suggesting that the melting behavior 
of the solid forms of this API can be modified over a considerable range (74-212oC) and 
(106-214oC), with mono-and di-carboxylic acids respectively. Moreover, the relationship 
between cocrystal and cocrystal former melting points has previously been reported for a 
series of 2-acetaminopyridine cocrystals with various acids.8 
 
5.6 Conclusion 
Four APIs were synthesized and seventeen cocrystals were obtained, resulting in 
fourteen hydrates. In 20 two of the ten crystal structures had the nitrogen atom ortho to 
the carbonyl participating in hydrogen bonding from a water molecule.  
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The absence of nitrogen atom from the aryl ring 25 resulted in no cocrystal 
formation, suggesting that maybe these types of compounds prefer to pack in a certain 
manner. Thus, in each case a water molecule is present in the crystalline lattice to satisfy 
or counter balance the acceptor to donor ratio present in the compounds. 
Nevertheless, this study highlighted the structural consistency as well as the 
capability of the hydrazones to form cocrystals.  It also highlights the difficulty in 
predicting the possible molecular interactions with any given acid. 
In addition, the results demonstrated that melting point behavior can be correlated 
to the molecular properties of the co-crystallizing agent, thus providing more insight into 
how we can fine-tune the melting behavior of a particular API without making or 
breaking of covalent bonds. 
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CHAPTER 6 - Using cocrystal to systematically modulate 
aqueous solubility and melting behavior of neoplasm inhibitors 
containing alkyenebisamides 
6.1 Introduction 
During development and formulation of any active pharmaceutical ingredient 
(API) that is to be delivered in a solid form, a wide range of stringent performance 
parameters such as solubility, dissolution rate, bioavailability, thermal stability, and 
hygroscopicity etc. needs to be carefully considered.1  It is therefore not surprising that 
poor biopharmaceutical properties (as opposed to toxicity or lack of efficacy) 2 is the 
main reason that less than one percent of active compounds eventually make it onto the 
market place.3 Poor solubility remains a key issue,4 and a number of approaches for 
addressing this issue have been pursued such as micronization which can increase surface 
area,5 the use of salt forms with enhanced dissolution profiles,6 solubilization of drugs in 
co-solvents7 and micellar solutions.8,9,10 Although these techniques can be effective, there 
is still a great need for a broader range of solid forms from which to choose a particular 
API in order to optimize physico-chemical properties without tampering with the intrinsic 
biological activity. 
Recent advances in crystal engineering11 have enabled the design of cocrystals 
where two or more molecular compounds are incorporated within the same crystalline 
lattices in specific stoichiometric amounts.12 Cocrystal synthesis does not involve 
making/breaking of covalent bonds, and it may therefore be possible to fine-tune physical 
properties by exercising precise control over the supramolecular assembly since the 
crystal structure determines the resulting physical properties of the compound.   
There have been several examples in literature where co-crystallization has been 
used as a tool for improving the physical properties of a given API.13 One notable 
example is 2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide co-
crystallized with glutaric acid, which showed an increase in the aqueous dissolution rate 
of eighteen times as compared to the homomeric crystalline form of the drug.14 
Additionally, single dose dog exposure studies confirmed that the cocrystal increased the 
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area under the plasma concentration-time curve (AUC) values by three times at two 
different dose levels.14 These results and others demonstrate the importance of cocrystals 
as an additional class of crystalline solid forms with desired physical properties. 
 Furthermore, structural and physical properties have been shown to be directly 
correlated in a series of even-chained aliphatic dicarboxylic acids, where the melting 
point decreases monotonically with increasing number of methylene groups in the chain. 
The structural consistency among these five compounds, Figure 6.1, translates to a 
predictable relationship between molecular structure (number of carbon atoms in the 
chain) and the melting point.15  
 
Figure 6.1 The melting points of even chain aliphatic acids as a function of carbon 
chain length. 
 
However, the melting point of odd-chain dicarboxylic acid is significantly lower 
than their even-numbered analogues as a result of significant differences in crystal 
structure/packing.15  
 Consequently, we hypothesize that if we can incorporate an API within a series 
of crystalline solids characterized by considerable structural consistency, we may be able 
to fine-tune melting behavior and aqueous solubility.  Changes to the physical properties 
could be achieved by varying the co-crystallizing agents in a systematic fashion without 
altering the precise nature of the molecular recognition events that drive the 
supramolecular assembly.  
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In this study we present a systematic structure-property study of a series of 
cocrystals with neoplasm inhibitors containing alkylenebisamide, which are capable of 
inhibiting the proliferation of lung cancer cells.16 Our strategy was to synthesize infinite 
API…acid…API…acid chains using the well-known carboxylic acid…pyridine 
hydrogen bond based synthon,17 Figure 6.2 (top), and these chains will subsequently be 
arranged into 2-D layers as a result of API-based self-complementary amide…amide 
hydrogen bonds,18 Figure 6.2(bottom). The FDA generally regards all the acids used in 
this study as safe.19  
 
 
Figure 6.2 Example of the robust and well-known acid…pyridine heterosynthon and 
amide…amide homosynthon as well as anticipated 2-D layer. 
 
Therefore with the above in mind we synthesized the target alkylene-
pyridinecarboxamide compounds 26-33, Figure 6.3. 
 
26 n = 0      30 n = 0 
27 n = 4      31 n = 4 
28 n = 6      32 n = 6 
29 n = 8      33 n = 8 
 
Figure 6.3  Target APIs 
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The main objectives of this study are: 
1. To determine whether we can synthesize a series of cocrystals with the desired 
structural consistency. 
2. To establish how well the melting point of the cocrystal can be correlated with 
the nature of the co-crystallizing agent. 
3. To establish whether the solubility can be modulated. 
 
6.2 Experimental  
6.2.1 Synthesis 
All chemicals, unless noted were purchased from Aldrich and Alfa Aesar and 
used without further purification. Column chromatography was carried out on silica gel 
(150 Å pore size) from Analtech Inc. Melting points were determined on a GallenKamp 
melting point apparatus in a capillary tube and are uncorrected. 1H and 13C NMR spectra 
were recorded on a Varian Unity plus 400 MHz or 200 MHz spectrometers in CDCl3 or 
DMSO-d6. Compounds were prepared for infrared spectroscopic (FT-IR) analysis as a 
mixture in KBr or on a ZnSe ATR crystal. 
 
6.2.1.1  Synthesis of N,N'-Bis(isonicotinic acid)hydrazide, 2620 
 
Isonicotinic acid (1.23g, 0.010 mol), pentafluorophenol (2.02g, 0.011 mol) and 
dicyclohexylcarbodimide (DCC) (2.06g, 0.010 mol) was dissolved in 40 mL of dry 1,4-
dioxane and allowed to stir at room temperature for 24 hrs, after which a white precipitate 
of dicyclohexylurea was observed, filtered off and discarded. The filtrate was evaporated 
to give a yellow oil of pentafluorophenol isonicotinate, which was not purified. To the oil 
30 mL of dimethylformamide (DMF) and isoniazid (1.51g, 0.011 mol) were added and 
left to stir at room temperature for 36 hrs. The solvent was then evaporated on a rotary 
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evaporator to produce the crude compound as a light brown solid, which was purified via 
column chromatography on silica with ethyl acetate as the eluant. The product 26 was 
isolated as a light yellow powder and recrystallization from ethanol gave microcrystalline 
particles, (1.98g, 66%). M.p.: 260-261oC; (Lit. m.p.: 267-268oC);21 1H NMR (δH; 200 
MHz, DMSO-d6): 10.97 (s, 2H), 8.82 (d, 4H, J = 4.8Hz) 7.83 (d, 4H, J = 4.8Hz); IR (KBr 
pellet): υ 3168, 1639, 1514, 1241, 1121, 997 cm-1. 
6.2.1.2  Synthesis of N,N'-1,4-butanediylbis-4-pyridinecarboxamide, 2722 
 
 
1,4-Diaminobutane (1.21g, 0.012 mol) was slowly added to a pyridine solution 
(50 mL) of isonicotinic acid (2.95g, 0.024 mol). The mixture was stirred for 15 minutes 
and triphenyl phosphite (TPP) (6.29 mL, 0.024 mol) was slowly added with a dropping 
funnel over a period of 15 minutes. The mixture was refluxed for 6 hrs at 70oC and the 
volume was reduced to 10 mL under vacuum. The solution was left to stand at room 
temperature for 24 hrs. After 24 hrs a light peach precipitate was observed and the solid 
was filtered off and washed numerous time with cold water. The solid obtained was 
recrystallized in ethanol to produce white microcrystalline particles (3.15g, 88%). M.p.: 
230-232oC, (Lit. m.p.: 230-232oC).23 1H NMR (δH; 200 MHz, DMSO-d6): 8.79 (s, 2H), 
8.73 (d, 2H, J = 4.8Hz), 7.76 (d, 2H, J = 4.8Hz), 3.33 (4H, m); IR (KBr pellet): υ 3301, 
3055, 2832, 1638, 1531, 1415, 1291, 1115, 997 cm-1. 
 
6.2.1.3  Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide, 2822 
 
1,6-Diaminohexane (1.98g, 0.017 mol) was slowly added to a pyridine solution 
(50 mL) of isonicotinic acid (4.20g, 0.034 mol). The mixture was stirred for 15 minutes 
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and TPP (9 mL, 0.034 mol) was slowly added with a dropping funnel over a period of 15 
minutes. The mixture was refluxed for 6 hrs at 70oC and the volume was reduced to 10 
mL under vacuum. The solution was left to stand at room temperature for 24 hrs after 
which a light peach precipitate was observed and the solid was filtered off and washed 
numerous times with cold water. The solid obtained was recrystallized in ethanol to 
produce white crystalline particles (2.717g, 50%). M.p.: 181-182oC, (Lit. m.p.: 178-
180oC).23 1H NMR (δH; 400 MHz, DMSO-d6): 8.72 (d, J =5.49Hz, 4H), 7.74 (d, J = 
5.49Hz, 4H), 3.26 (m, 4H), 1.53 (m, 4H), 1.34 (m, 4H); 13C NMR (δC; 200 MHz, DMSO-
d6): 163, 149, 140, 120, 28, 25; IR (KBr pellet): υ 3305, 2937, 2872, 1630, 1529, 1466, 
1409, 1293, 1070, 992 cm-1. 
6.2.1.4  Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide, 2922 
 
1,8-Diaminooctane (2.73g, 0.012 mol) was slowly added to a pyridine solution 
(50 mL) of isonicotinic acid (2.95g, 0.024 mol). The mixture was stirred for 15 minutes 
and triphenyl phosphite (TPP) (6.29 mL, 0.024 mol) was slowly added with a dropping 
funnel over a period of 15 minutes. The mixture was refluxed for 6 hrs at 70oC and the 
volume was reduced to 10 mL under vacuum. The solution was left to stand at room 
temperature for 24 hrs after a creamy precipitate was observed the solid was filtered off 
and washed with cold water (5 x 100 mL). The solid obtained was recrystallized in 
ethanol to produce off-white crystalline particles (2.41g, 57%). M.p.: 168-170oC, (Lit. 
m.p.: 165-166oC).23 1H NMR (δH; 400 MHz, DMSO-d6): 8.72 (d, 2H, J = 5.8Hz), 7.75 (d, 
2H, J = 5.8Hz), 3.27 (m, 4H), 1.51 (m, 4H); 13C NMR (δC; 400 MHz, D6-DMSO): 164, 
150, 141, 121, 28, 26; IR (KBr pellet): υ 3316, 2929, 1633, 1589, 1526, 1477, 1290, 
1183, 937 cm-1. 
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6.2.1.5  Synthesis of N,N'-Bis(nicotinic acid)hydrazide, 3020 
 
Nicotinic acid (1.23g, 0.010 mol), pentafluorophenol (2.02g, 0.011 mol) and 
dicyclohexylcarbodimide (DCC) (2.06g, 0.010 mol) was dissolved in 40 mL of dry 1,4-
dioxane and allowed to stir at room temperature for 24 hrs after which a white precipitate 
of dicyclohexylurea was observed and filtered off and discarded. The filtrate was 
evaporated to give a yellow oil of pentafluorophenol isonicotinate, which was not 
purified. To this oil, 30 mL of dimethylformamide (DMF) and nicotinic hydrazide (1.4g, 
0.01 mol) were added and left to stir at room temperature for 36 hrs. The solvent was 
then evaporated on a rotary evaporator to produce the crude compound as a light yellow 
solid. Product 30 was recrystallization from ethyl acetate as light yellow crystalline 
particles, (2.60g, 87%). M.p. 230-232oC; (Lit. m.p.: 229-232oC);24 1H NMR (δH; 200 
MHz, DMSO-d6): 10.85 (s, 2H), 9.0 3(s, 2H) 8.81 (d, 2H, J = 4.8Hz), 8.29 (d, 2H, J = 
6.2Hz), 7.62 (m, 2H); IR (KBr pellet): υ 3160, 2996, 1634, 1511, 1295, 1121, 997 cm-1. 
6.2.1.6  Synthesis of N,N'-1,4-butanediylbis-3-pyridinecarboxamide, 3122 
 
1,4-Diaminobutane (1.21g, 0.012 mol) was slowly added to a pyridine solution 
(50 mL) of nicotinic acid (2.95g, 0.024 mol). The mixture was stirred for 15 minutes and 
TPP (6.29 mL, 0.024 mol) was slowly added with a dropping funnel over a period of 15 
minutes. The mixture was refluxed for 6 hrs at 70oC and the volume was reduced to 10 
mL by vacuum evaporation. Solution was left to stand at room temperature for 24 hrs, at 
which time an off-white precipitate was observed and the solid was filtered off and 
washed with cold water (5 x 100 mL). The solid obtained was recrystallized in ethanol to 
produce off-white crystalline particles (1.00g, 28%). M.p.: 199-202oC, (Lit. m.p.: 199-
204oC).23 1H NMR (δH; 200 MHz, DMSO-d6): 8.99 (s, 1H), 8.69 (d, 2H, J = 4.8Hz), 8.19 
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(d, 2H, J = 8Hz), 7.52(m, 4H), 1.58 (m, 3H); IR (KBr pellet): υ 3297, 3074, 2952, 1633, 
1592, 1551, 1490, 1429, 1310, 1240, 989S cm-1. 
6.2.1.7  Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide, 3222 
 
1,6-Diaminohexane (1.98g, 0.017 mol) was slowly added to a pyridine solution 
(50 mL) of nicotinic acid (4.20g, 0.034 mol). The mixture was stirred for 15 minutes and 
TPP (9 mL, 0.034 mol) was slowly added with a dropping funnel over a period of 15 
minutes. The mixture was refluxed for 6 hrs at 70oC and the volume was reduced to 10 
mL by vacuum evaporation. The solution was left to stand at room temperature for 24 
hrs, producing a light peach precipitate, which was filtered and washed with cold water (5 
x 100 mL). The solid obtained was recrystallized in ethanol to produce white crystalline 
material (2.71g, 50%). M.p.: 167-170oC, (Lit. m.p. 168-170oC).25 1H NMR (δH; 200 
MHz, DMSO-d6): 13.47 (s, 1H), 9.07 (s, 2H), 8.97 (d, 2H, J = 2Hz), 8.30 (d, 2H, J = 
7.6Hz), 7.59 (m, 2H), 3.3 (m, 2H), 2.09 (m, 2H); 13C NMR (δC; 400 MHz, DMSO-d6): 
164, 151, 148, 134, 123, 29, 26; IR (KBr pellet): υ 3315, 1631, 1590, 1533, 1478, 1294, 
1193, 989 cm-1. 
6.2.1.8  Synthesis of N,N'-1,8-octanediylbis-3-pyridinecarboxamide, 3322 
 
1,8-Diaminooctane (2.73g, 0.012 mol) was slowly added to a pyridine solution 
(50 mL) of nicotinic acid (2.95g, 0.024 mol). The mixture was stirred for 15 minutes and 
TPP (6.29 mL, 0.024 mol) was slowly added with a dropping funnel over a period of 15 
minutes. The mixture was refluxed for 6 hrs at 70oC and the volume was reduced to 10 
mL by vacuum evaporation. The solution was left to stand at room temperature for 24 
hrs, producing a creamy precipitate, which was filtered and washed with cold water (5 x 
100 mL). The solid obtained was recrystallized in ethanol to produce off-white crystalline 
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particles (4.42g, 73%). M.p.: 154-156oC, (Lit. m.p.: 150-154 & 154-158oC).23,25 1H NMR 
(δH; 200 MHz, DMSO-d6): 8.99 (s, 1H), 8.69 (d, 2H, J = 3Hz), 8,19 (d, 1H, J = 8Hz), 
7.52(m, 1H), 3.30 (m, 3H) 1.51 (m, 5H); 13C NMR (δC; 400 MHz, D6-DMSO): 164, 151, 
148, 134, 130, 123, 29, 26; IR (KBr pellet): υ 3316, 2929, 1630, 1585, 1533, 1476, 1287, 
1180, 934 cm-1. 
6.2.2 Synthesis of cocrystals 
6.2.2.1  Synthesis of 4-(4-pyridinylcarbonyl)hydrazide succinic acid hydrate  
  (1:1), 26SUC 
26 (0.015g, 0.062 mmol) was dissolved in 4 mL of nitromethane and added to a 
beaker containing SUC (0.007g, 0.062 mmol) in 2 mL of nitromethane. The mixture was 
allowed to stand at ambient temperature for slow evaporation.  After five days, colorless 
needles were obtained. M.p.: 234-236oC. IR (ZnSe ATR crystal): υ 2402 cm-1, 1956 cm-1 
(O-H…N, br), 3415 cm-1 (N-H amide), 1687 cm-1 (C=O acid, s), 1638 cm-1 (C=O amide, 
s). 
6.2.2.2  Synthesis of 4-(4-pyridinylcarbonyl)hydrazide adipic acid (1:1), 26ADI 
26 (0.015g, 0.062 mmol) was dissolved in 4 mL of nitromethane and added to a 
beaker containing ADI (0.009g, 0.062 mmol) in 2 mL of nitromethane. The mixture was 
allowed to stand at ambient temperature for slow evaporation.  After ten days, orange 
plates were obtained. M.p.: 213-215oC. IR (ZnSe ATR crystal): υ 2533 cm-1, 1891 cm-1 
(O-H…N, br), 3400 cm-1 (N-H amide), 1706 cm-1 (C=O acid, s), 1634 cm-1 (C=O amide, 
s). 
6.2.2.3  Synthesis of 4-(4-pyridinylcarbonyl)hydrazide dodecanedioic acid (1:1),  
  26DOD 
26 (0.015g, 0.062 mmol) was dissolved in 4 mL of nitromethane and added to a 
beaker containing DOD (0.029g, 0.062 mmol) in 2 mL of nitromethane. The mixture was 
allowed to stand at ambient temperature for slow evaporation.  After five days, colorless 
plates were obtained. M.p.: 224-226oC. IR (ZnSe ATR crystal): υ 2516 cm-1, 1944 cm-1 
(O-H…N, br), 3166 cm-1 (N-H amide), 1699 cm-1 (C=O acid, s). 
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6.2.2.4  N,N'-1,4-butanediylbis-4-pyridinecarboxamide succinic acid hydrate  
  (1:2), 27SUC 
27 (0.015g, 0.053 mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which SUC (0.006g, 0.053 mmol) in 4 mL of ethanol-nitromethane (1:1) was added and 
allowed to stand at room temperature to slowly evaporate. Colorless needles were 
obtained after five days. Mp 227-229oC; (ZnSe ATR crystal) υ 2504 cm-1, 1973 cm-1 (O-
H…N, br), 3382 cm-1 (N-H amide), 1699 cm-1 (C=O, acid, s), 1625 cm-1 (C=O, amide, s). 
6.2.2.5  N,N'-1,4-butanediylbis-4-pyridinecarboxamide adipic acid (1:1), 27ADI 
27 (0.015g, 0.053 mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which ADI (0.007g, 0.053 mmol) in 4 mL of ethanol-nitromethane (1:1) was added and 
allowed to stand at room temperature to slowly evaporate. Colorless needles were 
obtained after five days. Mp 201-203oC; (ZnSe ATR crystal) ν 2537 cm-1, 1871 cm-1 (O-
H…N, br), 3382 cm-1 (N-H amide), 1699 cm-1 (C=O, acid, s), 1622 cm-1 (C=O, amide, s). 
6.2.2.6  N,N'-1,4-butanediylbis-4-pyridinecarboxamide suberic acid (1:1),  
  27SUB 
27 (0.015g, 0.053 mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which SUB (0.009g, 0.053 mmol) in 4 mL of ethanol-nitromethane (1:1) was added and 
allowed to stand at room temperature to slowly evaporate. Colorless needles were 
obtained after ten days. Mp 196-198oC; (ZnSe ATR crystal) ν 2500 cm-1, 1875 cm-1 (O-
H…N, br), 3313 cm-1 (N-H amide), 1703 cm-1 (C=O, acid, s), 1629 cm-1 (C=O, amide, s). 
6.2.2.7  Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide succinic  
  acid (1:1), 28SUC 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL of ethanol and ethyl acetate (1:1). 
To this solution was added SUC (0.011g, 0.092 mmol) in 5 mL of ethanol-ethyl acetate 
(1:1). The resulting solution was heated and allowed to stand at room temperature to 
slowly evaporate. Light pink plate-like crystals were obtained after ten days. M.p.: 186-
188oC; IR (ZnSe ATR crystal) ν 2488 cm-1, 1871 cm-1 (O-H…N, br), 3317 cm-1 (NH 
amide), 1702 cm-1 (C=O acid, s), 1636 cm-1 (C=O amide, s). 
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6.2.2.8  Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide adipic acid  
  (1:1), 28ADI 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL of ethanol. To this solution was 
added ADI (0.013g, 0.092 mmol) in 5 mL of ethanol. The resulting solution was heated 
and allowed to stand at room temperature to slowly evaporate. After 8 days, transparent 
needles were obtained. M.p.: 165-167oC; IR (ZnSe ATR crystal) ν 2512 cm-1, 1858 cm-1 
(O-H…N, br), 3309 cm-1 (NH amide), 1699 cm-1 (C=O acid, s), 1631 cm-1 (C=O amide, 
s). 
6.2.2.9  Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide suberic acid 
  (1:1), 28SUB 
28 (0.03g, 0.092 mmol) was dissolved in 7 mL methanol and mixed with a 
solution of SUB (0.016g, 0.092 mmol) in 5 mL of methanol.  The resulting solution was 
heated and allowed to stand at room temperature to slowly evaporate. Colorless prisms 
were obtained after fifteen days. M.p.: 158-160oC; (ZnSe ATR crystal) ν 2504 cm-1, 1879 
cm-1 (O-H…N, br), 3317 cm-1 (NH amide), 1707 cm-1 (C=O acid, s), 1632 cm-1 (C=O 
amide, s). 
6.2.2.10 Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide sebacic acid 
  (1:1), 28SEB 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL methanol and mixed with a 
solution of SEB (0.019g, 0.092 mmol) in 5 mL of methanol.  The resulting solution was 
heated and allowed to stand at room temperature to slowly evaporate. Transparent 
needles were observed after 8 days. M.p.: 148-150oC; (ZnSe ATR crystal) ν 2520 cm-1, 
1862 cm-1 (O-H…N, br), 3321 cm-1 (NH amide), 1707 cm-1 (C=O acid, s), 1632 cm-1 
(C=O amide, s). 
6.2.2.11 Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide   
  dodecanedioic acid (1:1), 28DOD 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL ethanol and mixed with a solution 
of DOD (0.022g, 0.092 mmol) in 5 mL of methanol.  The resulting solution was heated 
and allowed to stand at room temperature to slowly evaporate. After fifteen days 
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transparent needles were obtained. M.p.: 146-148oC; (ZnSe ATR crystal) ν 2508 cm-1, 
1866 cm-1 (O-H…N, br), 3325 cm-1 (NH amide), 1707 cm-1 (C=O acid, s), 1632 cm-1 
(C=O amide, s). 
6.2.2.12 Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide oxalic acid  
  (1:1), 28OXA 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL of ethanol-nitromethane (1:1) and 
mixed with a solution of OXA (0.008g, 0.092 mmol) in 5 mL of ethanol-nitromethane 
(1:1). The mixture was gently heated and allowed to stand at ambient temperature to 
slowly evaporate. After two days, colorless needles were obtained. M.p.: 188-190oC; 
(ZnSe ATR crystal) ν 2402 cm-1, 1862 cm-1 (O-H…N, br), 3305 cm-1 (NH amide), 1679 
cm-1 (C=O acid, s), 1633 cm-1 (C=O amide, s). 
6.2.2.13 Synthesis of N,N'-1,6-hexanediylbis-4-pyridinecarboxamide pimelic acid 
  (1:1), 28PIM 
28 (0.03g, 0.092 mmol) was dissolved in 5 mL of ethanol-nitromethane (1:1) and 
mixed with a solution of PIM (0.015g, 0.092 mmol) in 5 mL of ethanol-nitromethane 
(1:1). The mixture was gently heated and allowed to stand at ambient temperature to 
slowly evaporate. After six days colorless needles were obtained. M.p.: 173-175oC; 
(ZnSe ATR crystal) ν 2500 cm-1, 1928 cm-1 (O-H…N, br), 3297 cm-1 (NH amide), 1699 
cm-1 (C=O acid, s), 1634 cm-1 (C=O amide, s). 
6.2.2.14 Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide succinic acid 
  (1:1), 29SUC 
A solution of 29 (0.02g, 0.056 mmol) in 5 mL ethanol was mixed with a solution 
of SUC (0.007g, 0.056 mmol) in 5 mL of ethanol and was allowed to stand to slowly 
evaporate. Colorless plates were obtained at ten days. M.p.: 166-168oC; (KBr pellet) ν 
2495 cm-1, 1920 cm-1 (O-H...N, br), 3309 cm-1 (NH amide), 1704 cm-1 (C=O acid, s), 
1630 cm-1 (C=O amide, s). 
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6.2.2.15 Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide adipic acid  
  (1:1), 29ADI 
A solution of 29 (0.02g, 0.056 mmol) in 5 mL ethanol was mixed with a solution 
of adipic ADI (0.008g, 0.056 mmol) in 5 mL of ethanol and was allowed to stand to 
slowly evaporate. Light pink prisms were obtained after fifteen days. M.p.: 185-187oC; 
(KBr pellet) ν 2500 cm-1, 1926 cm-1 (O-H...N, br), 3320 cm-1 (NH amide), 1710 cm-1 
(C=O acid, s), 1638 cm-1 (C=O amide, s). 
6.2.2.16 Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide suberic acid  
  (1:1), 29SUB 
29 (0.02g, 0.056 mmol) was dissolved in 5 mL of ethanol. To this solution was 
added SUB (0.009, 0.056 mmol) in 5 mL of ethanol.  The resulting solution was allowed 
to stand at room temperature to slowly evaporate. Colorless needles were obtained after 
twenty days. M.p.: 163-165oC; (KBr pellet) ν 2501 cm-1, 1892 cm-1 (O-H...N, br), 3317 
cm-1 (NH amide), 1706 cm-1 (C=O acid, s), 1635 cm-1  (C=O amide, s). 
6.2.2.17 Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide sebacic acid  
  (1:1), 29SEB 
29 (0.015g, 0.0423 mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which SEB (0.009g, 0.0423 mmol) in 4 mL of ethanol-nitromethane (1:1) was added and 
allowed to stand at room temperature to slowly evaporate. Colorless needles were 
obtained after thirteen days.  M.p.: 162-164oC; (ZnSe ATR crystal) ν 2520 cm-1, 1871 
cm-1 (O-H…N, br), 3322 cm-1 (N-H amide), 1699 cm-1 (C=O acid, s), 1631cm-1 (C=O 
amide, s). 
6.2.2.18 Synthesis of N,N'-1,8-octanediylbis-4-pyridinecarboxamide malonic acid 
  (1:1), 29MAL 
29 (0.030g, 0.0847 mmol) was dissolved in 5 mL of ethanol-nitromethane (1:1) to 
which MAL (0.009g, 0.0847 mmol) in 5 mL of ethanol-nitromethane (1:1) was added 
and allowed to stand at ambient temperature to slowly evaporate. After ten days light 
pink plate-like crystals were obtained. M.p.: 146-148oC; (ZnSe ATR crystal) ν 2501 cm-1, 
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1971 cm-1 (O-H…N, br), 3317 cm-1 (N-H amide), 1690 cm-1 (C=O acid, s), 1635 cm-1 
(C=O amide, s). 
6.2.2.19 Synthesis of 3-(3-pyridinylcarbonyl)hydrazide sebacic acid (1:1), 30SEB 
30 (0.030g, 0.10 mmol) was dissolved in 4 mL ethanol to which SEB (0.020g, 
0.10 mmol) in 4 mL of ethanol was added and mixture was allowed to stand at room 
temperature to slowly evaporate. After ten days, orange plates were obtained. M.p.: 209-
210oC; (KBr pellet) ν 2496 cm-1, 1913 cm-1 (O-H…N, br), 3188 cm-1 (N-H amide), 1697 
cm-1 (C=O acid, s), 1605 cm-1 (C=O amide, s). 
6.2.2.20 Synthesis of N,N'-1,4-butanediylbis-3-pyridinecarboxamide succinic  
  acid (1:1), 31SUC 
A solution of 31 (0.015g, 0.050 mmol) in 2 mL ethanol-nitromethane (1:1) was 
mixed with a solution of SUC (0.006g, 0.050 mmol) in 2 mL of ethanol-nitromethane 
(1:1) and allowed to stand for slow evaporation. Colorless needles were obtained after ten 
days. M.p.: 168-170oC; (ZnSe ATR crystal) ν 2467 cm-1, 1916 cm-1 (O-H...N, br), 3301 
cm-1 (NH amide), 1700 cm-1 (C=O acid, s), 1630 cm-1 (C=O amide, s). 
6.2.2.21 Synthesis of N,N'-1,4-butanediylbis-3-pyridinecarboxamide suberic acid  
  (1:1), 31SUB 
31 (0.015g, 050 mmol) was dissolved in 2 mL of ethanol-nitromethane (1:1) and 
SUB (0.009g, 0.050 mmol) in 2 mL ethanol-nitromethane (1:1) was added and allowed to 
stand at room temperature to slowly evaporate. After five days prism-like crystals were 
obtained. M.p.: 166-168oC; (ZnSe ATR crystal) ν 2496 cm-1, 1887 cm-1 (O-H…N, br), 
3329 cm-1 (N-H, amide), 1697 cm-1 (C=O acid, s), 1628 cm-1 (C=O amide, s). 
6.2.2.22 Synthesis of N,N'-1,4-butanediylbis-3-pyridinecarboxamide   
  dodecanedioic acid (1:1), 31DOD 
31 (0.015g, 050 mmol) was dissolved in 2 mL of ethanol-nitromethane (1:1) and 
DOD (0.023g, 0.050 mmol) in 2 mL ethanol-nitromethane (1:1) was added and left at 
room temperature for slow evaporation. After seven days plate-like crystals were 
obtained. M.p.: 144-146oC; (ZnSe ATR crystal) ν 2500 cm-1, 1875 cm-1 (O-H…N, br), 
3305 cm-1 (N-H, amide), 1710 cm-1 (C=O acid, s), 1626 cm-1 (C=O amide, s). 
 154 
6.2.2.23 N,N'-1,6-hexanediylbis-3-pyridinecarboxamide succinic acid (1:1),  
  32SUC 
A solution of 32 (0.02g, 0.061 mmol) in 8 mL acetonitrile-ethyl acetate (1:1) was 
mixed with a solution of SUC (0.007g, 0.061 mmol) in 2 mL acetonitrile-ethyl acetate 
(1:1) and allowed to slowly evaporate at room temperature.  Colorless plate-like crystals 
were obtained after ten days. M.p.: 147-148oC; IR (KBr pellet) ν 2481 cm-1, 1924 cm-1 
(O-H…N, br), 3309 cm-1 (N-H amide), 1690 cm-1 (C=O acid, s), 1637 cm-1 (C=O amide, 
s). 
6.2.2.24 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide adipic acid  
  (1:1), 32ADI 
32 (0.015g, 0.046 mmol) was dissolved in 2 mL of ethanol-nitromethane (1:1) 
and ADI (0.007g, 0.046 mmol) in 2 mL ethanol-nitromethane (1:1). The resulting 
solution was gently heated and left at room temperature for slow evaporation. After 
twenty days, colorless needles were obtained. M.p.: 166-168oC; (ZnSe ATR crystal) ν 
2516 cm-1, 1895 cm-1 (O-H…N, br), 3309 cm-1 (N-H, amide), 1695 cm-1 (C=O acid, s), 
1629 cm-1 (C=O amide, s). 
6.2.2.25 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide suberic acid 
  (1:1), 32SUB 
32 (0.015g, 0.046 mmol) was dissolved in 10 mL nitromethane-ethyl acetate (1:1) 
and mixed with a solution of SUB (0.008g, 0.046 mmol) in 5 mL of nitromethane-ethyl 
acetate (1:1). The resulting solution was heated and allowed to stand at ambient 
temperature for slow evaporation.  Colorless prisms were obtained after four days. M.p.: 
182-184oC; (ZnSe ATR crystal) ν 2496 cm-1, 1896 cm-1 (O-H…N, br), 3329 cm-1 (NH  
amide), 1701 cm-1 (C=O acid, s), 1627 cm-1 (C=O amide, s). 
6.2.2.26 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide sebacic acid 
  (1:1), 32SEB 
32 (0.05g, 0.140 mmol) was dissolved in 10 mL nitromethane-ethyl acetate (1:1) 
and mixed with a solution of SEB (0.028g, 0.140 mmol) in 5 mL of nitromethane- ethyl 
acetate (1:1). The resulting solution was heated and allowed to stand at ambient 
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temperature for slow evaporation.  Colorless needles were obtained after ten days. M.p.: 
180-181oC; (KBr pellet) ν 2508 cm-1, 1905 cm-1 (O-H…N, br), 3305 cm-1 (NH  amide), 
1700 cm-1 (C=O acid, s), 1637 cm-1 (C=O amide, s). 
6.2.2.27 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide   
  dodecanedioic acid (1:1), 32DOD 
32 (0.015g, 0.046 mmol) was dissolved in 10 mL nitromethane-ethyl acetate (1:1) 
and mixed with a solution of DOD (0.011g, 0.046 mmol) in 5 mL of nitromethane-ethyl 
acetate (1:1). The resulting solution was heated and allowed to stand at ambient 
temperature for slow evaporation.  Colorless prisms were obtained after five days. M.p.: 
160-162oC; (ZnSe ATR crystal) ν 2500 cm-1, 1901 cm-1 (O-H…N, br), 3302 cm-1 (N-H 
amide), 1708 cm-1 (C=O acid, s), 1625 cm-1 (C=O amide, s). 
6.2.2.28 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide oxalic acid  
  (1:1), 32OXA 
A solution of 32 (0.030g, 0.092 mmol) in 5 mL ethanol-nitromethane (1:1) was 
mixed with a solution of OXA (0.008g, 0.092 mmol) in 5 mL ethanol-nitromethane (1:1) 
and allowed to stand at room temperature for slow evaporation.  Colorless needles were 
obtained after five days. M.p.: 179-181oC; IR (ZnSe ATR crystal) ν 2501 cm-1, 1928 cm-1 
(O-H…N, br), 3299 cm-1 (N-H amide), 1695 cm-1 (C=O acid, s), 1639 cm-1 (C=O amide, 
s). 
6.2.2.29 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide glutaric  
  acid (1:2), 32GLU 
A solution of 32 (0.023g, 0.070 mmol) in 5 mL ethanol was mixed with a solution 
of GLU (0.009g, 0.070 mmol) in 5 mL ethanol and allowed to stand at room temperature 
for slow evaporation.  Colorless needles were obtained after five days. M.p.: 142-144oC; 
IR (KBr pellet) ν 2474 cm-1, 1918 cm-1 (O-H…N, br), 3345 cm-1 (N-H amide), 1705 cm-1 
(C=O acid, s), 1630 cm-1 (C=O amide, s). 
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6.2.2.30 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide heptanoic  
  acid (1:1), 32HEP 
A solution of 32 (0.030g, 0.092 mmol) in 5 mL acetonitrile-nitromethane (1:1) 
was mixed with a solution of HEP (0.024g, 0.184 mmol) in 5 mL acetonitrile-
nitromethane (1:1) and allowed to stand at room temperature for slow evaporation.  
Colorless plates were obtained after five days. M.p.: 135-137oC; IR (KBr pellet) ν 2534 
cm-1, 1938 cm-1 (O-H…N, br), 3317 cm-1 (N-H amide), 1714 cm-1 (C=O acid, s), 1628 
cm-1 (C=O amide, s). 
6.2.2.31 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide octanoic  
  acid (1:1), 32OCT 
A solution of 32 (0.030g, 0.092 mmol) in 5 mL acetonitrile-nitromethane (1:1) 
was mixed a solution of OCT (0.027g, 0.184 mmol) in 5 mL acetonitrile-nitromethane 
(1:1) and allowed to stand at room temperature for slow evaporation.  Colorless plates 
were obtained after three days. M.p.: 136-138oC; IR (KBr pellet) ν 2509 cm-1, 1909 cm-1 
(O-H…N, br), 3328 cm-1 (N-H amide), 1707 cm-1 (C=O acid, s), 1629 cm-1 (C=O amide, 
s). 
6.2.2.32 Synthesis of N,N'-1,6-hexanediylbis-3-pyridinecarboxamide lauric acid  
  (1:1), 32LAU 
32 (0.030g, 0.092 mmol) was dissolved in 5 mL acetonitrile-nitromethane (1:1) 
and mixed with a solution of LAU (0.0369g, 0.184 mmol) in 5 mL of acetonitrile-
nitromethane (1:1). The resulting solution was heated and allowed to stand at ambient 
temperature for slow evaporation.  Colorless plates were obtained after fifteen days. M.p.: 
172-174oC; (KBr pellet) ν 2528 cm-1, 1904 cm-1 (O-H…N, br), 3306 cm-1 (N-H amide), 
1700 cm-1 (C=O acid, s), 1637 cm-1 (C=O amide, s).  
6.2.2.33  Synthesis of N,N'-1,8-octanediylbis-3-pyridinecarboxamide succinic acid 
  (1:1), 33SUC 
33 (0.015g, 0.042 mmol) was dissolved in 2 mL ethanol-nitromethane (1:1) and 
mixed with a solution of SUC (0.005g, 0.042 mmol) in 2 mL of ethanol-nitromethane 
(1:1). The resulting solution was heated and allowed to stand at ambient temperature for 
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slow evaporation.  Colorless plates were obtained after four days. M.p.: 160-162oC; 
(ZnSe ATR crystal) ν 2516 cm-1, 1891 cm-1 (O-H…N, br), 3301 cm-1 (N-H amide), 1694 
cm-1 (C=O acid, s), 1626 cm-1 (C=O amide, s).  
6.2.2.34 Synthesis of N,N'-1,8-octanediylbis-3-pyridinecarboxamide suberic acid  
  (1:1), 33SUB 
33 (0.015g, 0.042 mmol) was dissolved in 2 mL ethanol-nitromethane (1:1) and 
mixed with a solution of SUB (0.007g, 0.042 mmol) in 2 mL of ethanol-nitromethane 
(1:1). The resulting solution was heated and allowed to stand at ambient temperature for 
slow evaporation.  Colorless needles were obtained after ten days. M.p.: 152-154oC; 
(ZnSe ATR crystal) ν 2496 cm-1, 1891 cm-1 (O-H…N, br), 3329 cm-1 (N-H amide), 1699 
cm-1 (C=O acid, s), 1629 cm-1 (C=O amide, s).  
6.2.2.35 Synthesis of N,N'-1,8-octanediylbis-3-pyridinecarboxamide pimelic  
  (1:2), 33PIM 
33 (0.030g, 0.085 mmol) was dissolved in 5 mL ethanol-nitromethane (1:1) and 
mixed with a solution of PIM (0.014g, 0.085 mmol) in 5 mL of ethanol-nitromethane 
(1:1). The resulting solution was heated and allowed to stand at ambient temperature for 
slow evaporation.  Colorless needles were obtained after fifteen days. M.p.: 147-149oC; 
(ZnSe ATR crystal) ν 2508 cm-1, 1903 cm-1 (O-H…N, br), 3333 cm-1 (N-H amide), 1691 
cm-1 (C=O acid, s), 1625 cm-1 (C=O amide, s).  
6.3 Solubility studies 
6.3.1 Preparation of cocrystals for solubility studies 
Cocrystals of 28, 29 and dicarboxylic acid (1:1 molar ratio) were prepared via a 
solvothermal method.26 Supersaturation of 28 and SUC were created by cooling a 
solution of 28 (0.5112g, 1.566 mmol) and SUC (0.1849, 1.566 mmol) in 25.00 mL of 
ethanol from 40 to 25oC. The solid phase was harvested by vacuum filtration and dried at 
room temperature (22-23oC) on a Fisherbrand filter paper for 40 min to remove loosely 
bound solvent. The solid obtained was confirmed to be a cocrystal by FT-IR 
spectroscopy; also the IR obtained matched the previous IR of crystals submitted for X-
ray analysis. Cocrystals were stored in a desiccator over anhydrous calcium sulfate.  
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The remaining cocrystals in this study were made and analyzed following the 
same procedure. 
6.3.1.2  Aqueous solubility of APIs and cocrystals 
The solubility of 28, 29 and their respective cocrystals in water was determined 
from undersaturation by adding excess cocrystal solid phase in water.26 The suspensions 
were stirred with magnetic stirrers in a sealed 500 mL flask at constant temperature (25 ± 
0.5oC) maintained with a water bath. Samples were drawn at various time intervals over 
72hrs and filtered. Samples were diluted with the same solvent in which the solubility 
analysis was performed. The solutions equilibrated within 48hrs and average sample 
concentration differed by <3% at 24hrs and 48hrs. Concentrations of samples were 
obtained measuring the absorbance of 28, 29 and their respective cocrystals at λmax = 
236.4, and 234.8nm respectively. All UV-Visible measurements were carried out on a 
Shimadzu UV-1650 PC. 
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6.4 Results and Discussion 
6.4.1 Crystal structure descriptions 
Summaries of the crystallographic information are displayed in Table C.5 and all 
hydrogen-bond geometries are listed in Table 6.1. 
 
Table 6.1 Hydrogen-bond geometries for 26SUC, 26ADI, 26DOD, 27SUC, 27ADI, 
27SUB, 28SUC, 28ADI, 28SUB, 28SEB, 28DOD, 28OXA, 28PIM, 29SUC, 29ADI, 
29SUB, 29SEB, 29MAL, 30SEB, 31SUC, 31SUB, 31DOD, 32SUC, 32ADI, 32SUB, 
32SEB, 32DOD, 32OXA, 32GLU, 32HEP, 32OCT, 32LAU and 33UC, 33SUB, 
33PIM 
Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
26SUCi N(17)-H(17)...O(1W) 0.90(4) 1.86(4) 2.756(4) 173(4) 
 O(21)-H(21)...N(11) 1.04(4) 1.55(4) 2.588(3) 172(3) 
 O(1W)-H(1A)...O(22)#3 0.95(4) 1.83(4) 2.776(3) 172(3) 
 O(1W)-H(1B)...O(17)#4 0.79(5) 2.05(5) 2.828(3) 168(4) 
      
26ADIii O(21)-H(21)...N(11) 0.90(3) 1.82(3) 2.707(2) 166(2) 
 N(17)-H(17)...O(17)#3 0.82(3) 2.14(3) 2.949(2) 168(2) 
      
26DODiii O(21)-H(21)...N(11) 1.00(2) 1.71(2) 2.6746(16) 162.1(17) 
 N(17)-H(17)...O(17)#3 0.885(17) 1.986(17) 2.8121(16) 154.9(15) 
      
27SUCiv O(31)-H(31)...N(11) 1.064(16) 1.518(16) 2.5768(13) 173.0(14) 
 O(41)-H(41)...O(1W) 0.912(18) 1.676(18) 2.5832(13) 172.7(17) 
 O(1W)-H(1A)...O(32) 0.909(19) 1.91(2) 2.8067(15) 170.5(16) 
 O(1W)-H(1B)...O(17)#4 0.82(2) 1.93(2) 2.7422(14) 172.7(17) 
 N(17)-H(17)...O(42)#5 0.876(17) 2.030(17) 2.8625(15) 158.2(14) 
      
27ADIv O(31)-H(31)...N(11) 0.908(14) 1.788(14) 2.6940(9) 175.0(13) 
 N(17)-H(17)...O(17)#3 0.864(13) 2.139(13) 2.9876(9) 167.1(12) 
      
27SUBvi O(31)-H(31)...N(11) 0.938(15) 1.756(16) 2.6942(11) 178.7(14) 
 N(17)-H(17)...O(17)#3 0.880(14) 2.130(14) 2.9920(11) 166.1(12) 
      
28SUCvii O(31)-H(31)...N(11) 0.98(2) 1.73(2) 2.7094(19) 176(2) 
      
 N(17)-H(17)...O(17)#3 0.92(2) 2.11(2) 2.9902(19) 161.6(17) 
      
28ADIviii O(31)-H(31)...N(11) 0.929(16) 1.780(17) 2.7079(13) 177.6(15) 
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Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
 N(17)-H(17)...O(17)#3 0.902(15) 2.127(15) 3.0072(13) 165.0(13) 
      
28SUBix O(31)-H(31)...N(11) 0.977(13) 1.723(13) 2.6998(9) 179.8(13) 
 N(17)-H(17)...O(17)#3 0.898(12) 2.122(12) 3.0025(10) 166.5(11) 
      
28SEBx O(31)-H(31)...N(11) 0.962(14) 1.738(14) 2.6990(11) 177.2(13) 
 N(17)-H(17)...O(17)#3 0.926(15) 2.102(15) 3.0127(14) 167.4(11) 
      
28DODxi O(31)-H(31)...N(11) 0.92(2) 1.79(2) 2.7085(18) 177.6(19) 
 N(17)-H(17)...O(17)#3 0.836(18) 2.207(19) 3.0222(17) 165.3(18) 
      
28OXAxii O(31)-H(31)...N(11) 0.95(2) 1.71(2) 2.6521(10) 177.0(19) 
 N(17)-H(17)...O(17)#3 0.881(14) 2.102(14) 2.9509(10) 161.5(12) 
      
28PIMxiii O(51)-H(51)...N(11) 0.974(14) 1.743(14) 2.7138(10) 173.7(12) 
 O(57)-H(57)...N(21) 0.930(14) 1.761(14) 2.6756(11) 167.0(12) 
 N(17)-H(17)...O(17)#3 0.882(12) 2.044(12) 2.9193(10) 171.3(11) 
 N(27)-H(27)...O(27)#3 0.844(12) 2.253(12) 3.0922(10) 172.4(11) 
      
29SUCxiv O(31)-H(31)...N(11) 0.896(19) 1.817(19) 2.7128(15) 178.3(18) 
 N(17)-H(17)...O(17)#3 0.844(16) 2.150(16) 2.9834(14) 169.5(15) 
      
29ADIxv O(31)-H(31)...N(11) 0.925(15) 1.782(15) 2.7056(11) 176.3(13) 
 N(17)-H(17)...O(17)#3 0.848(14) 2.170(14) 3.0039(12) 167.9(13) 
      
29SUBxvi O(31)-H(31)...N(11) 0.905(18) 1.798(18) 2.7026(14) 177.2(17) 
 N(17)-H(17)...O(17)#3 0.853(17) 2.173(17) 3.0067(14) 165.5(15) 
      
29SEBxvii O(31)-H(31)...N(11) 0.96(2) 1.73(2) 2.6912(17) 178.6(18) 
 N(17)-H(17)...O(17)#3 0.899(19) 2.125(19) 2.9984(16) 163.5(16) 
      
29MALxviii N(17)-H(17)...O(17)#1 0.884(14) 2.115(15) 2.9904(13) 170.4(12) 
 N(27)-H(27)...O(27)#2 0.825(15) 2.168(15) 2.9401(14) 155.7(13) 
 O(41)-H(41)...N(11) 0.919(15) 1.801(15) 2.7079(13) 169.0(13) 
 O(43)-H(43)...N(21)#3 1.024(14) 1.613(14) 2.6353(12) 175.3(13) 
      
30SEBxix O(21)-H(21)...N(11) 0.84 1.83 2.663(2) 173.2 
 N(17)-H(17)...O(17)#3 0.88 2.08 2.8234(19) 141.5 
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Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
31SUCxx N(17)-H(17)...O(27)#3 0.889(14) 2.068(14) 2.9333(11) 164.3(12) 
 N(27)-H(27)...O(17)#4 0.908(14) 2.046(14) 2.9359(10) 166.3(12) 
 O(41)-H(41)...N(11) 0.836(17) 1.829(17) 2.6593(12) 172.2(15) 
 O(51)-H(51)...N(21) 0.878(16) 1.852(17) 2.7113(11) 165.4(14) 
      
31SUBxxi O(31)-H(31)...N(11) 0.974(17) 1.735(17) 2.7074(13) 175.9(14) 
 N(17)-H(17)...O(17)#3 0.891(15) 2.105(15) 2.9814(12) 167.4(13) 
      
31DODxxii O(31)-H(31)...N(11) 0.84 1.85 2.684(8) 171.4 
 N(17)-H(17A)...O(17)#3 0.88 2.09 2.935(10) 161.6 
      
32SUCxxiii O(31A)-H(31A)...N(11) 0.84 1.81 2.6488(10) 176.8 
 O(31B)-H(31B)...N(11) 0.84 2.06 2.894(7) 173.6 
 N(17)-H(17)...O(17)#3 0.852(12) 2.089(12) 2.9244(9) 166.8(11) 
      
32ADIxxiv O(31)-H(31)...N(11) 1.010(17) 1.704(17) 2.7137(15) 177.2(15) 
 N(17)-H(17)...O(17)#3 0.835(17) 2.110(18) 2.9394(14) 172.1(15) 
      
32SUBxxv O(31)-H(31)...N(11) 1.00(3) 1.73(3) 2.728(2) 175(2) 
 N(17)-H(17)...O(17)#3 0.80(2) 2.24(2) 3.021(2) 165.6(19) 
      
32SEBxxvi O(31)-H(31)...N(11) 0.935(19) 1.748(19) 2.6802(13) 175.0(15) 
 N(17)-H(17)...O(17)#3 0.913(16) 1.997(16) 2.8953(12) 167.6(13) 
      
32DODxxvii O(31)-H(31)...N(11) 0.862(19) 1.826(19) 2.6839(15) 173.7(17) 
 N(17)-H(17)...O(17)#3 0.851(18) 2.060(18) 2.8993(14) 169.1(15) 
      
32OXAxxviii N(17)-H(17)...O(17)#1 0.914(13) 2.033(13) 2.9172(11) 162.2(11) 
 N(27)-H(27)...O(27)#2 0.838(14) 2.138(14) 2.9656(11) 169.1(12) 
 O(41)-H(41)...N(11) 0.959(16) 1.645(16) 2.6021(11) 176.1(13) 
 O(43)-H(43)...N(21)#3 0.935(15) 1.674(15) 2.6030(12) 172.0(14) 
      
32GLUxxix N(17)-H(17)...O(17)#2 0.830(13) 2.292(13) 3.1019(10) 165.4(11) 
 O(31)-H(31)...N(11) 0.955(15) 1.726(15) 2.6731(10) 171.2(13) 
 O(35)-H(35)...O(36)#3 0.894(14) 1.725(14) 2.6154(9) 173.6(13) 
      
32HEPxxx O(31)-H(31)...N(11) 0.882(18) 1.836(19) 2.7123(14) 171.9(16) 
 N(17)-H(17)...O(17)#2 0.858(15) 2.124(16) 2.9674(12) 167.2(14) 
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Structure D-H…A d(D-H)/Å d(H…A)/ Å d(D…A)/ Å <(DHA)o 
      
32OCTxxxi N(17)-H(17)...O(17)#2 0.893(16) 2.118(16) 2.9903(13) 165.5(13) 
 O(31)-H(31)...N(11) 0.934(18) 1.785(18) 2.7188(13) 177.5(16) 
      
32LAUxxxii O(31)-H(31)...N(11) 0.86(3) 1.82(3) 2.671(2) 170(2) 
 N(17)-H(17)...O(17)#2 0.88(3) 2.02(3) 2.881(2) 168.8(19) 
      
33SUCxxxiii O(31)-H(31)...N(11) 0.94(3) 1.78(3) 2.717(2) 172(3) 
 N(17)-H(17)...O(17)#3 0.844(19) 2.12(2) 2.9555(17) 168.9(18) 
      
33SUBxxxiv N(17)-H(17)...O(17)#3 0.898(18) 2.016(18) 2.9012(17) 168.4(15) 
 O(31)-H(31)...N(11) 0.981(19) 1.69(2) 2.6694(16) 172.8(16) 
      
33PIMxxxv O(31)-H(31)...N(11) 0.939(16) 1.760(17) 2.6923(12) 171.6(14) 
 N(17)-H(17)...O(17)#2 0.834(14) 2.229(14) 3.0546(12) 170.6(13) 
 O(38)-H(38)...O(37)#3 0.907(16) 1.717(16) 2.6207(11) 174.3(14) 
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6.4.1.1 Crystal structure of 26SUC 
The primary motif in the crystal structure of 26SUC is composed of half a 
molecule of 26, half a molecule of SUC and one water molecule with interactions 
between the acid and the pyridyl moiety, as well as between the water molecule and 
amide moiety. The primary synthon is an acid…pyridine hydrogen bond, Figure 6.4. 
Instead of the typical amide…amide interaction, which is often observed the water 
molecule disrupts the architecture of the structure resulting in N-H…O and O-H…O 
interaction, Figure 6.5. 
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Figure 6.4 Thermal ellipsoid (50%) and labeling scheme of 26SUC. 
 
 
Figure 6.5 2-D sheet of 26SUC with N-H…O, O-H…N, and O-H…O hydrogen 
bonds. 
6.4.1.2 Crystal structures of 26ADI and 26DOD 
Unlike 26SUC, the crystal structure of 26ADI and 26DOD contain half a 
molecule of 26 and half a molecule of ADI and DOD respectively, with no water 
molecule observed in the crystalline lattice. The robust synthon of N-H…O is observed 
between the acid and the pyridine nitrogen in both cases Figure 6.6. 
   
 26ADI      26DOD 
Figure 6.6 Thermal ellipsoids (50%) and labeling scheme of the supermolecules in 
26ADI and 26DOD. 
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Furthermore, 26ADI contains amide…amide homosynthons, resulting in a 2-D 
sheet, Figure 6.7. However the overall architecture of 26DOD, displayed a slight twist in 
the structure resulting in a ribbon-like 2-D structure, via the amide…amide homosynthon, 
Figure 6.8. 
 
 
Figure 6.7 2-D sheet in 26ADI with both O-H…N and N-H…O hydrogen bonds. 
 
 
Figure 6.8 Slightly twisted 2-D architecture in 26DOD. 
 
6.4.1.3    Crystal structure of 27SUC 
Similar to 26SUC, the asymmetric unit of 27SUC contains one water molecule as 
well as one molecule of 27, however instead of one molecule of SUC the lattice contains 
two molecules of SUC. Furthermore, as with 26SUC the acid…pyridine heterosynthon is 
observed, along with the water molecule forming hydrogen bonds with the carbonyl of 
the API, as well as with the carbonyl of the acid and the hydroxy group of the other acid, 
Figure 6.9. The interesting thing about this structure is its unique packing resulting from 
the water molecule, which aids in the formation of 2-D layered structure, Figure 6.10. 
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Figure 6.9 Thermal ellipsoid (50%) and labeling of 27SUC. 
 
 
Figure 6.10 Unique packing of 27SUC resulting in O-H…N and O-H…O hydrogen 
bonding. 
 
6.4.1.4  Crystal structures of 27ADI and 27SUB 
The asymmetric unit of 27ADI and 27SUB contains half a molecule of 27 and 
half a molecule of ADI, and DOD respectively, with hydrogen bonds between the 
pyridine nitrogen and the dicarboxylic acid in both structures, Figure 6.11. 
   
 27ADI       27SUB 
Figure 6.11 Thermal ellipsoids (50%) and labeling scheme of 27ADI and 27SUB. 
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The N-H…O interactions result in a 1-D chain, which is expanded into a 2-D 
sheet via the aide of amide…amide (N-H…O) interactions, Figure 6.12 and Figure 6.13, 
respectively. 
 
 
Figure 6.12 2-D sheet in 27ADI, held together by O-H…N and N-H…O interactions. 
 
 
Figure 6.13 2-D sheet in 27SUB held together by O-H…N and N-H…O interactions. 
 
6.4.1.5  Crystal structures of 28SUC, 28ADI, 28SUB, 28SEB, 28DOD, 28OXA 
 and 28PIM 
The crystal structures of 28SUC, 28ADI, 28SUB, 28SEB, 28DOD, 28OXA and 
28PIM are all similar in that they are 1:1 cocrystals of 28 and the given dicarboxylic 
acids, all displaying the robust O-H…N heterosynthon between the pyridine nitrogen and 
the carboxylic acid, Figure 6.14. 
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  28SUC   28ADI 
  
 28SUB    28SEB 
 
28DOD                     28OXA 
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28PIM 
Figure 6.14 Thermal ellipsoids (50%) and labeling scheme of the 1:1 supermolecule of 
28SUC, 28ADI, 28SUB, 28SEB, 28DOD, 28OXA and 28PIM. 
 
These interactions result in the formation of 1-D chains Figures 6.15-6.21 
respectively, which in turn are organized into layers via inter-chain N-H…O hydrogen 
bonds; bond distances are shown in Table 6.1. Although the packing of the 28PIM is 
slightly different from the others in that the structure form this twisted 2-D layer instead 
of the linear array that was observed in the other structures. 
 
Figure 6.15 2-D sheet in 28SUC held together via O-H…N and N-H…O hydrogen 
bonds. 
 
 
Figure 6.16 2-D sheet in 28ADI held together via O-H…N and N-H…O hydrogen 
bonds. 
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Figure 6.17 2-D sheet in 28SUB held together via O-H…N and N-H…O hydrogen 
bonds. 
 
 
Figure 6.18 2-D sheet in 28SEB. 
 
 
Figure 6.19 2-D sheet in 28DOD. 
 
 
Figure 6.20 2-D sheet in 28OXA held together through O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.21 Slightly twisted 2-D sheet in 28PIM. 
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6.4.1.6  Crystal structures of 29SUC, 29SUC, 29ADI, 29SUB, 29SEB and  
  29MAL 
 The crystal structures of 29 are very similar in that each asymmetric unit consists 
of one molecule of 29 and one molecule of the corresponding dicarboxylic acid. Again 
the acid…pyridine supramolecular synthon is observed, Figure 6.22. 
   
 29SUC      29ADI 
 
  29SUB     29SEB 
 
 
29MAL 
Figure 6.22 The thermal ellipsoids (50%) and labeling scheme of 29SUC, 29ADI, 
29SUB, 29SEB and 29MAL. 
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The overall architecture in each case is a 2-D sheet-like structure via 
intermolecular interactions between the adjacent amides, Figures 6.23-27. In addition, 
even though the binding interactions are similar in all the structures with 29, the packing 
of 29MAL is different in that it formed a 2-D zig-zag array. 
 
 
Figure 6.23 2-D sheet-like structure in 29SUC. 
 
 
Figure 6.24 2-D sheet observed in 29ADI. 
 
 
Figure 6.25 2-D sheet-like structure in 29SUB. 
 
 
Figure 6.26 2-D sheet-like structure in 29SEB. 
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Figure 6.27 2-D zig-zag array in 29MAL formed through O-H…N and N-H…O 
hydrogen bonds. 
6.4.1.7    Crystal structure of 30SEB 
 The crystal structure of 30SEB consists of one molecule of 30 and one molecule 
of SEB in the asymmetric unit. The primary O-H…N supramolecule synthon is observed, 
resulting from the interaction between the pyridine nitrogen and the dicarboxylic acid, 
Figure 6.28.  
 
Figure 6.28 Thermal ellipsoids and labeling scheme for the supermolecule of 30SEB. 
 
The overall architecture is a 2-D zig-zag array via intermolecular interactions 
between the adjacent amides, Figure 6.29. 
 
Figure 6.29 2-D zig-zag array in 30SEB. 
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6.4.1.8  Crystal structures of 31SUC, 31SUB, 31DOD 
The crystal structures of 31 are very similar in that each asymmetric unit consists 
of half a molecule of 31 and half a molecule of the corresponding dicarboxylic acid. The 
structures are held together via acid…pyridine (O-H…N) Figure 6.30, bond distances, 
Table 6.1.  
   
  31SUC      31SUB 
 
      31DOD 
Figure 6.30 Thermal ellipsoids (50%) and labeling scheme for the supermolecules of 
31SUC, 31SUB and 31DOD. 
 
The 2-D array observed is held together via intermolecular interactions between 
the adjacent amides, Figures 6.31-6.33. The crystal packing in 31DOD was different 
from the other two structures, it formed a zig-zag array compare to the planar packing 
observed in both 31SUC and 31SUB. 
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Figure 6.31 2-D sheet-like structure in 31SUC. 
 
 
Figure 6.32 2-D array in 31SUB held together by both O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.33 Zig-zag array in 31DOD held together via O-H…N and N-H…O 
hydrogen bonds. 
 
6.4.1.9   Crystal structures of 32SUC, 32ADI, 32SUB, 32SEB, 32DOD, 32OXA,  
  32GLU, 32HEP, 32OCT, 32LAU 
The crystal structures of 32 consist of half a molecule of 32 and half a molecule of 
the corresponding mono or dicarboxylic acid in the asymmetric unit. The primary O-
H…N supramolecule synthon is observed, resulting from the interaction between the 
pyridine nitrogen and the dicarboxylic acid, Figure 6.34. In addition, the crystal structure 
of 32SUC is somewhat disordered. 
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 32SUC     32ADI 
       
32SUB        32SEB 
 
     
32DOD       32OXA 
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32GLU      32HEP 
    
32OCT       32LAU 
Figure 6.34 Thermal ellipsoids (50%) and labeling scheme for the supermolecules of 
32SUC, 32ADI, 32SUB, 32SEB, 32DOD, 32OXA, 32GLU, 32HEP, 32OCT and 
32LAU. 
 
The 2-D layer in these structures are held together via intermolecular interactions 
between the adjacent amides, Figures 6.35-6.44.  Although the connections in each of the 
molecules are the same, the packing is different, in that crystal structures 32SUC, 32ADI, 
32SEB, 32DOD, and 32OXA all packed in a zig-zag array, whereas the other crystal 
structures of 32 are packed in a planar fashion. Interestingly, although 32HEP, 32OCT 
and 32LAU are formed with monoacids they still result in the same intermolecular 
interactions, Figures 6.42-6.44. Additionally, of all the dicarboxylic acids, 32GLU 
packed in an exceptional fashion, not only is the robust O-H…N synthon observed, but 
the structure also forms an acid…acid dimer which aids in the extension of the linear 2-D 
sheet, Figure 6.41. 
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Figure 6.35 2-D zig-zag array in 32SUC held together via O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.36 2-D zig-zag array in 32ADI held together by O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.37 2-D sheet-like structure in 32SUB, formed through O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.38 Zig-zag array of 32SEB formed through O-H…N and N-H…O hydrogen 
bonds. 
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Figure 6.39 2-D zig-zag array in 32DOD formed through O-H…N and N-H…O 
hydrogen bonds. 
 
 
Figure 6.40 Zig-zag array in 32OXA, formed through O-H…N and N-H…O hydrogen 
bonds. 
 
 
Figure 6.41 Unique 2-D array in 32GLU held together via O-H…N, N-H…O and O-
H…O hydrogen bonds. 
 
 
Figure 6.42 1:1 cocrystal in 32HEP formed through O-H…N and N-H…O hydrogen 
bonds.  
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Figure 6.43 1:1 cocrystal in 32OCT formed via O-H…N and N-H…O hydrogen 
bonds. 
 
 
Figure 6.44 1:1 cocrystal in 32LAU forming a 2-D zig-zag array through O-H…N and 
N-H…O hydrogen bonds. 
 
6.4.1.10 Crystal structures of 33SUC, 33SUB, 33PIM 
The crystal structures of 33 consist of half a molecule of 33 and half a molecule of 
the corresponding dicarboxylic acid in the asymmetric unit. The primary O-H…N 
supramolecule synthon is observed, resulting from the interaction between the pyridine 
nitrogen and the dicarboxylic acid, Figure 6.45.  
               
   33SUC     33SUB 
 180 
 
33PIM 
Figure 6.45 Thermal ellipsoids (50%) and labeling scheme for the supermolecules of 
33SUC, 33SUB, and 33PIM. 
 
A 2-D array is formed via interactions between adjacent amides, Figures 6.46-
6.48.  Although the connections in each structure are the same, the packing is different. 
Crystal structures 33SUC and 33SUB both packed in a zig-zag array. Whereas, 33PIM 
not only packed in a planar fashion, but instead of a 1:1 structure, it is a 1:2 structure, 
which is similar to 32GLU, because it also forms an acid…acid dimer, resulting in a 
linear packing of the overall structure, Figure 6.48. 
 
 
Figure 6.46 2-D zig-zag array in 33SUC, formed through O-H…N and N-H…O 
hydrogen bonds. 
 
 181 
 
Figure 6.47 Zig-zag array in 33SUB formed through intermolecular interactions of O-
H…N and N-H…O hydrogen bonds. 
 
 
Figure 6.48 Unique 2-D array in 33PIM formed through O-H…N, N-H…O and O-
H…O hydrogen bonds. 
 
6.4.2 IR spectroscopy 
IR spectroscopy was used to screen all co-crystallization reactions in order to 
determine the formation of cocrystal. The solids obtained from co-crystallization 
reactions showed very similar stretches, at approximately 2450 cm-1 and 1900 cm-1 the 
formation of O-H…N(py) hydrogen bonds. Moreover, each cocrystal obtained showed a 
carbonyl stretch above 1670 cm-1 which further confirms cocrystal formation, not a salt, 
which would have a carbonyl shift below 1660 cm-1 suggesting the presence of COO- 
anions. Table 6.2 summarizes the vibrational stretch observed for each structure and 
Figure 6.49 depicts an example of cocrystal formed with 28; the remaining spectrum are 
shown in Table D.1 (Appendix D).  
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Table 6.2 Summary of IR data for compounds 26SUC, 26ADI, 26DOD, 27SUC, 
27ADI, 27SUB, 28SUC, 28ADI, 28SUB, 28SEB, 28DOD, 28OXA, 28PIM, 29SUC, 
29ADI, 29SUB, 29SEB, 29MAL, 30SEB, 31SUC, 31SUB, 31DOD, 32SUC, 32ADI, 
32SUB, 32SEB, 32DOD, 32OXA, 32GLU, 32HEP, 32OCT, 32LAU and 33SUC, 
33SUB, 33PIM 
Compounds Observed stretch (O-H..N) 
 cm-1 
Observe COOH 
cm-1 
Product 
26SUC 2402 & 1956 1687 cocrystal 
26ADI 2533 & 1891 1706 cocrystal 
26DOD 2516 & 1944 1699 cocrystal 
27SUC 2504 & 1973 1699 cocrystal 
27ADI 2537 & 1871 1699 cocrystal 
27SUB 2500 & 1875 1703 cocrystal 
28SUC 2488 & 1871 1702 cocrystal 
28ADI 2512 & 1858 1699 cocrystal 
28SUB 2504 & 1879 1707 cocrystal 
28SEB 2520 & 1862 1707 cocrystal 
28DOD 2508 & 1866 1707 cocrystal 
28OXA 2402 & 1862 1679 cocrystal 
28PIM 2500 & 1928 1699 cocrystal 
29SUC 2495 & 1920 1704 cocrystal 
29ADI 2500 & 1926 1710 cocrystal 
29SUB 2501 & 1892 1706 cocrystal 
29SEB 2520 & 1871 1699 cocrystal 
29MAL 2501 & 1971 1690 cocrystal 
20SEB 2496 & 1913 1697 cocrystal 
31SUC 2467 & 1916 1700 cocrystal 
31SUB 2496 & 1887 1697 cocrystal 
31DOD 2500 & 1875 1710 cocrystal 
32SUC 2481 & 1924 1690 cocrystal 
32ADI 2516 & 1895 1695 cocrystal 
32SUB 2496 & 1896 1701 cocrystal 
32SEB 2508 & 1905 1700 cocrystal 
32DOD 2500 & 1901 1708 cocrystal 
32OXA 2501 & 1928 1695 cocrystal 
32GLU 2474 & 1918 1705 cocrystal 
32HEP 2534 & 1938 1714 cocrystal 
32OCT 2509 & 1909 1707 cocrystal 
32LAU 2528 & 1904 1700 cocrystal 
33SUC 2516 & 1891 1694 cocrystal 
33SUB 2496 & 1891 1699 cocrystal 
33PIM 2508 & 1903 1691 cocrystal 
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Figure 6.49 IR spectra depicting cocrystal formation in 28SUC; 28 (blue), SUC 
(purple), 28SUC (red). 
 
The APIs formed cocrystals thirty-five out of thirty-five cases, given a 
supramolecular yield of 100%. In each case a broad stretch at approximately 2500 and 
1900 cm-1 was observed, which as previously mentioned is indicative of O-H…N 
(heterocyclic) hydrogen bonds. The formation of cocrystal in each case is driven by O-
H…N interactions. However, even though each compound was able to form a cocrystal, 
the structural consistency of each cocrystal can only be obtained from single crystal X-
ray crystallography data. 
6.4.3 Addressing structural consistency 
The intermolecular interactions observed in the series of cocrystals are 
remarkably consistent. In all thirty-five cases the pyridine nitrogen…acid heterosynthon 
was observed both in the IR spectra and X-ray structures. However, the amide…amide 
homosynthon was observed thirty-three out of thirty-five times with a 94% success rate. 
In the two exceptions 26SUC and 27SUC, this was due to disruption of the architecture 
28 
SUC 
28SUC 
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by a water molecule. A summary of the unit cell parameters for the crystal structures of 
28SUC, 28ADI, 28SUB, 28SEB, 28DOD are given in Table 6.3.  
 
Table 6.3 Comparison of structural data of cocrystals of 28 
 28SUC 28ADI 28SUB 28SEB 28DOD 
a (Å) 5.1754(4) 5.1412(4) 5.1392(5) 5.1506(4) 5.1519(4) 
b (Å) 10.9294(8) 5.2394(4) 5.2412(5) 5.2481(4) 5.2778(5) 
c (Å) 10.9423(8) 21.396(2) 23.145(2) 24.521(2) 26.148(3) 
α (deg) 118.826(4) 95.094(5) 94.959(3) 89.647(4) 86.023(6) 
β (deg) 91.381(5) 95.603(4) 95.222(2) 87.252(4) 89.386(6) 
γ (deg) 99.872(4) 91.076(5) 91.277(2) 88.505(5) 88.496(6) 
V (Å3) 530.11(7) 571.10(8) 619.0(1) 661.82(8) 709.0(1) 
 
As shown by the structural parameters, the five cocrystals of 28 are isostructural, 
and the increase in unit cell volume is a reflection of an increase in the size of the co-
crystallizing agent. Likewise, with the other structures obtained with 27, 29-33, they all 
are isostructural displaying similar increases in unit cell volume, Tables 6.4-6.5. 
Table 6.4 Comparison of structural data of cocrystals of 27 and 29 
 27ADI 27SUB 29SUC 29ADI 29SUB 29SEB 
a 5.1160(4) 5.1072(4) 5.1072(4) 5.1403(3) 5.1420(4) 5.1264(6) 
b  5.1957(4) 5.2045(4) 5.1171(4) 5.2489(3) 5.2541(4) 5.2432(6) 
c  19.5042(16) 21.5019(14) 22.119(2) 22.9829(15) 24.624(2) 26.127(3) 
α 90.704(2) 94.963(2) 96.134(6) 93.859(4) 89.785(4) 85.874(4) 
β 93.362(2) 95.404(2) 94.037(6) 95.267(4) 87.095(4) 89.354(4) 
γ 91.346(2) 91.630(2) 91.340(6) 91.289(4) 88.590(4) 88.356(4) 
V 517.36(7) 568.12(7) 573.05(8) 615.82(6) 664.209(9) 700.11(14) 
 
Table 6.5 Comparison of structural data of cocrystals of 31 and 32 
 31SUC 31SUB 31DOD 32SUC 32ADI 32SEB 32SUB 32DOD 
a 10.0264(7) 5.0982(5) 5.097(3) 5.0275(6) 5.0282(6) 5.1671(13) 4.9817(4) 4.9821(4) 
b  10.1248(7) 11.4639(10) 5.486(3) 6.9253(9) 6.7877(8) 11.646(3) 6.8634(6) 6.8797(6) 
c  11.0782(8) 11.4873(11) 23.823(13) 16.058(2) 17.522(2) 11.779(4) 20.0493(16) 21.4410(17) 
α 91.733(2) 115.707(3) 86.020(18) 89.749(6) 98.124(3) 67.873(11) 90.233(4) 87.936(6) 
β 107.922(2) 98.696(4) 86.521(18) 81.536(5) 97.604(3) 80.585(12) 90.233(4) 86.223(6) 
γ 110.922(2) 100.874(4) 87.553(18) 80.93(6) 94.605 79.827(12) 98.285(4) 81.469(5) 
V 493.555(12) 573.10(9) 662.8(6) 545.92(12) 583.82(12) 642.6(3) 677.32(10) 724.93(10) 
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Additionally, the crystal structures 32GLU and 33PIM both formed an 
acid…acid dimer along with the other excepted supramolecular synthons. This unique 
intermolecular interaction could be as a result of the structure wanting to form a linear 
network instead of a zigzag off-stack motif that was observed in the structures of 32 and 
33. 
6.4.4  Correlating melting behavior with the nature of the co-crystallizing 
 agent 
It has been demonstrated that co-crystallization can be used as a tool for 
improving the thermal stability27 as well as other physicochemical properties12,13 of 
variety of APIs. With this in mind and having achieved the required structural 
consistency, we subsequently examined whether the thermal behavior of cocrystals 
formed with 27, 28 and 29 could be correlated with any molecular feature of the five 
even numbered dicarboxylic acids. Melting point were recorded for the resulting 
cocrystals, and in the case of 27, 28 and 29 cocrystals, a graph of dicarboxylic acid 
melting point versus cocrystal melting point was plotted, Figure 6.50. The data clearly 
shows that the melting points of these five crystalline solids are directly related to the 
melting point of dicarboxylic acids.  
 
(a) 
 186 
 
      (b) 
 
 
(c) 
Figure 6.50 Melting points of cocrystals plotted vs. the melting point for the 
corresponding diacids; (a) 27SUC-27DOD; (b) 28SUC-28DOD; (c) 29SUC-29DOD. 
 
The cocrystals in each series displayed higher melting points than the 
corresponding pure diacids (Table 6.6); this is because of the strong hydrogen bonds and 
the efficient close packing, which stabilize the structures of the molecular complexes.  
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Table 6.6 Melting point of aliphatic dicarboxylic acids and their 1:1 cocrystals of 27, 
28, and 29. 
 Dicarboxylic 
acids 
M.p. of diacid M.p. of 
cocrystal of 27 
M.p. of 
cocrystal of 28 
M.p. of 
cocrystal of 29 
 SUC 186 229 188 187 
 ADI 154 203 167 162 
 SUB 144 198 160 165 
 SEB 137 189 150 163 
 DOD 129 184 148 156 
R2   0.9944 0.9844 0.8814 
Equation of line   y = 0.79x + 82 y = 0.72x + 54 y = 0.50x + 92 
 
Thus in each case the highest-melting cocrystal contains the dicarboxylic acid 
with the highest melting point, and the lowest-melting acid produces the lowest melting 
point cocrystal; demonstrating that the melting behavior of a given API can be modulated 
in a predictable and controlled manner.  Additionally, the melting point alteration in this 
co-crystalline series constitutes a readily explainable change in the physical properties of 
a pure component series as a consequence of cocrystal formation. 
6.4.5     Modulating aqueous solubility 
Although thermal properties are important; aqueous solubility is one of the key 
physicochemical parameters of a drug substance that needs to be assessed early on in the 
drug discovery and drug candidate selection process. Therefore the aqueous solubility of 
cocrystals of 28 and 29 (Figure 6.51 and Table E.1 Appendix E) were determined. 
 
(a) 
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     (b) 
Figure 6.51 Aqueous solubility of: (a) 28 and 28SUC-28DOD (b) 29 and 29SUC-
29DOD. 
 
The results show that the aqueous solubility of 28 and 29 can in fact be improved 
by a factor of 2.5 and 4.5 respectively, without altering the molecular structure of the API 
itself. Although the solubility of the cocrystals of 28 and 29 did not produce a linear 
correlation with the aliphatic even chain dicarboxylic acids, as did the melting points, the 
trend in physicochemical properties of the cocrystals can certainly be rationalized in 
terms of the aqueous solubility of the dicarboxylic acids. The cocrystals of the longer-
chain diacids, which are less polar and more hydrophobic in nature, show a decrease in 
aqueous solubility relative to that of the API itself. Even though a decrease in solubility is 
normally not desired within the pharmaceutical industry, a decreased solubility is 
preferred in some applications of specialty chemicals such as in the agrochemical 
industry.  
6.5 Conclusion 
Although it is obvious that not every cocrystal will deliver an improvement in 
physicochemical properties relative to that of the active ingredient, we have shown that 
systematic changes to the molecular nature of the co-crystallizing agent combined with 
control over the way that the individual building blocks are organized within crystalline 
lattice makes it possible to establish predictable links between molecular structure and 
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macroscopic physical properties. In this context, cocrystals may therefore offer unique 
opportunities for developing new solid forms in which a variety of desired physical 
properties can be tuned in a predictable manner. 
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CHAPTER 7 - Summary & Future Works 
7.1 Summary 
Supramolecular chemistry has come a long way, in providing chemist with a wide 
variety of reliable complementary interactions such as hydrogen and halogen bonds, 
allowing for the design and synthesis of supermolecules. The ability to synthesize 
supermolecules with predictable connectivities and stiochiometries can be accomplished 
by relying on established hierarchy of reliable intermolecular interactions.  
 We designed and synthesized three supramolecular reactants (SR’s) containing 
two distinct hydrogen bonding acceptor sites and one donor site (acetamidopyridine) in 
order to map out the behavior of the hydrogen-bonded sites during co-crystallization. 
These SR’s were allowed to react with various aliphatic and aromatic carboxylic acids 
producing both 1:1 molecular cocrystals as well as 1:2 ionic salts through O-H…N or 
charge-assisted N-H+…O- hydrogen bonds with the acetamidopyridine binding site, 
Figure 7.1.  
 
Figure 7.1 Summary of primary hydrogen bonding motifs between 4-
acetamidopyridine and aliphatic carboxylic acids. 
  
 The intermolecular interaction of pyridine…carboxylic acid observed in this study 
can be employed in subsequent supramolecular synthetic strategies, thus providing 
important information on the molecular recognition processes of small molecules, 
thereby allowing us to use this information in understanding larger and more complicated 
molecules. 
The ability to incorporate both a hydrogen and halogen-bonding moiety into the 
same crystalline lattice has provided supramolecular chemist with opportunity of 
designing new solid-state architectures. Therefore we design a system having two 
different acceptor sites and the molecular interaction preferences both a hydrogen and 
halogen bond is present as the donor molecules, Figure 7.2.  
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Figure 7.2 Possible interaction between two different acceptor moieties and a 
hydrogen and halogen bond donor, where A' is the best acceptor and A'' is second best 
acceptor; -X is the halogen bond donor and D-H is the hydrogen bond donor. 
 
In the attempt to determine the strength of the acceptor moieties, semi-empirical 
PM3 molecular electrostatic potential calculations were carried on the acceptor sites in 
mono N-oxide derivatives, Figure 7.3. 
 
Figure 7.3 Electrostatic potentials for acceptor moieties.  
 
Based on the electrostatic potential calculations of the two binding sites, the N-O 
moiety is the superior acceptor site for an incoming halogen or acid in comparison with 
the N atom. The ranking in binding sites strength was further supported by crystal 
structures that we obtained, in which of the eight structures obtained with the N-oxide 
moieties seven out of those structures had the best acceptor interaction with the best 
donor (88% supramolecular yield). 
Moreover, when halogenated benzoic acids were present in the same system 3/4 
times (75% supramolecular yield) halogen bonds the best donor (N…I or N…Br) aid in 
extending the architecture into polymeric networks, Figure 7.4 
N+-O-: -282 to -300kJmol-1 
N : -238 to -253kJmol-1 
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Figure 7.4 Polymeric network formed through hydrogen and halogen bonds (X = I, 
Br). 
 
This study has allowed us design new solid-state architectures incorporating both 
hydrogen and halogen bonds, furthering our understanding of molecular recognition. In 
addition, we have also learned that semi-empirical calculations can be use as a guide in 
determining the binding preferences of a variety of molecules as long as the charges on 
the molecules are significantly different. 
With our success in designing supermolecules with predictable connectivities 
using reliable intermolecular interactions as well as semi-empirical calculations; we can 
then use this knowledge in synthesizing pharmaceutical cocrystal, with the ultimate goal 
of fine-tuning both physical and chemical properties such as melting point, solubility, etc. 
Finally, we used our understanding of molecular recognition to construct 
pharmaceutical cocrystals. Consequently, we were able to incorporate an active 
pharmaceutical ingredient (API) within a new crystalline lattice in a controllable manner 
without make or breaking covalent bonds. The series of pharmaceutical cocrystals 
synthesized exhibit tremendous structural consistency, Figure 7.5. 
 
 
Figure 7.5 Example of a pharmaceutical cocrystal held together by hydrogen bonds. 
 
We were also able to show that both the melting behavior and solubility of a 
given API can be modulated in a controllable fashion. Moreover, form both the solubility 
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and melting behavior studies we can great a library of co-crystallizing agents that can be 
used to obtained the desire melting point or solubility of a given compound. 
Furthermore, we can also use our understanding to improve the poor 
biopharmaceutical properties of other drugs that did not make it onto the market or even 
drugs that are currently on the market. Instead of administrating a drug intravenously, we 
can move to orally administration and eventually transdermal patches. 
Additionally, molecular recognition can also be used in the agrochemical 
industry, in which a low soluble pesticide or herbicide is desired. So we can go back to 
the library of compounds that we have synthesized and use that knowledge to modulate 
the solubility of a variety of agrochemicals thereby creating longer lasting and more 
environmentally friendly chemicals. 
7.2 Future works 
Although our understanding of molecular recognition and intermolecular 
interactions has led us in designing new solid-state architectures with improved physical 
and chemical properties, there is still more work to be done, in order take each system to 
the next level. 
First, halogen bonding has aided in the expansion of molecular architectures. 
Therefore, we can use aliphatic dihalogenated species, analogous to the aliphatic 
dicarboxylic acids used in the studies herein and probe whether this type of non-covalent 
interactions can be use to form structurally consistent cocrystals, Figure 7.6. 
 
Figure 7.6 Proposed network formed through halogen bonds (X = I, Br).  
 
Consequently similar melting behavior and solubility studies can be carried and 
compared with the studies done with aliphatic dicarboxylic acids. This will then allow us 
to push this system further by incorporating both hydrogen and halogen bonded moieties 
into the same crystalline lattice and test which one of the three possible non-covalent 
interactions give us the optimal results in terms of fine-tuning the physical and chemical 
properties. 
 196 
Furthermore, to establish whether the bioactivity of APIs in this study is still in 
tact, biological studies will be carried out on both the pure API as well as the 
pharmaceutical cocrystal using both breast and lung cancer cell lines. First in vitro studies 
will be carried out, followed by in vivo studies to establish the lethal dose 50 of 
pharmaceutical cocrystals were synthesized. 
Finally, we can implement our understanding of molecular recognition on the 
poorly soluble drugs from top 300 drugs list. Thereby, providing a library of suitable co-
crystallizing agents to be used in modulating the physical and chemical properties. 
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Appendix A - Crystallographic Experimental Data 
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Chapter 2  Cocrystal and salt 
 
X-ray data for 2SEB was collected on a SMART APEX CCD diffractometer at 
100 K or a Bruker SMART 1000 four circle CCD diffractometer at 173 K (2HG) using a 
fine-focus molybdenum Ka tube. Data were collected using SMART.1 Initial cell 
constants were found by small widely separated ‘‘matrix’’ runs. Generally, an entire 
hemisphere of reciprocal space was collected regardless of Laue´ symmetry. Scan speed 
and scan width were chosen based on scattering power and peak rocking curves.  
Unit cell constants and orientation matrix were improved by least-squares 
refinement of reflections threshold from the entire dataset. Integration was performed 
with SAINT,2 using this improved unit cell as a starting point. Precise unit cell constants 
were calculated in SAINT from the final merged dataset. Lorenz and polarization 
corrections were applied. Laue´ symmetry, space group, and unit cell contents were 
found with XPREP.  
Data were reduced with SHELXTL.3 The structures were solved in all cases by 
direct methods without incident. In general, hydrogen atoms were assigned to idealized 
positions and were allowed to ride. Where possible, the coordinates of the amide 
hydrogen atoms were allowed to refine. Heavy atoms were refined with anisotropic 
thermal parameters. Unless otherwise noted, data were corrected for absorption. 
Compound 2SEB. The unique amide sits on a general position. The dicarboxylic 
acid sits on a crystallographic inversion center. Positional coordinates for the amide 
hydrogen (H17) and the carboxylic acid hydrogen (H21) were allowed to refine. 
Compound 2HG. The unique amide and unique carboxylic acid both sit on 
general positions. Positional coordinates for the pyridinium hydrogen H11, amide 
hydrogen H14, and carboxylic acid hydrogen H25 were allowed to refine. 
 
Chapter 2  Metal Complexes 
X-ray data were collected on a Bruker SMART 1000 four circle charge coupled 
device (CCD) diffractometer (1b, 2a), Bruker Kappa APEX II (5), or Bruker SMART 
APEX CCD diffractometer (1a) using, in each case, a fine-focus molybdenum Kα tube. 
Data were collected using SMART (1b, 2a)1 or APEX2 (1a)4 software. Initial cell 
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constants were found by small widely separated ‘matrix’ runs. Generally, an entire 
hemisphere of reciprocal space was collected regardless of Laué symmetry. Scan speed 
and scan width were chosen based on scattering power and peak rocking curves. 
Unit cell constants and orientation matrix were improved by least-squares 
refinement of reflections threshold from the entire dataset. Integration was performed 
with SAINT,2 using this improved unit cell as a starting point. Precise unit cell constants 
were calculated in SAINT from the final merged dataset. Lorenz and polarization 
corrections were applied. Laué symmetry, space group, and unit cell contents were found 
with XPREP. 
Data were reduced with SHELXTL.5 The structures were solved in all cases by 
direct methods without incident. In general, hydrogen atoms were assigned to idealized 
positions and were allowed to ride. Where possible, the coordinates of the amide 
hydrogen atoms were allowed to be refined. Heavy atoms were refined with anisotropic 
thermal parameters. Absorption correction was performed with SADABS where possible. 
Compound 1a: Data were corrected for absorption using SADABS. The position 
of the amide proton was allowed to be refined; all other hydrogen atoms were included in 
calculated positions and allowed to ride. 
Compound 1b: Data were corrected for absorption using SADABS. The 
asymmetric unit contains three species: a nickel complex, an ordered dichloromethane 
solvent molecule, and a disordered dichloromethane solvent molecule. Geometry of all 
three dichloromethane fragments was restrained with SAME commands. All non-
hydrogen atoms were given anisotropic thermal parameters. Thermal parameters for the 
two (closely located) disordered dichloromethane species were pair wise constrained 
using EADP commands. The position of the two-amide protons (H13 and H23) was 
allowed to be refined; all other hydrogen atoms were included in calculated positions and 
allowed to ride. 
Compound 2a: Data were corrected for absorption using SADABS. The 
asymmetric unit contains five species: a complete copper(II) complex on a general 
position, a half-complex (sitting on an inversion centre), and three ordered 
dichloromethane molecules. Five of the six –CF3 groups were disordered. Four were 
modeled with two species, and the fifth was modeled with three species. Geometry of all 
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–CF3 fragments was restrained to be similar to the first fragment (C41A, F41A-F41C) by 
the SAME command. The geometry of the first fragment (C41A, etc.) was idealized to 
tetrahedral by using DFIX restraints on the C–F bond distances and F–F distances. 
Thermal parameters for the set of three fluorine atoms on each species having occupancy 
<50% were constrained with EADP commands. The fluorine atoms having occupancy 
>60% were given isotropic thermal parameters (anisotropic refinement of other fluorine 
atoms was unstable). All hydrogen atoms were included in calculated positions and were 
allowed to ride. 
 
Chapter 6 
Data sets for 28SUC, 28ADI, 28SUB, 28SEB and 28DOD were collected on 
Bruker Kappa APEX II systems using MoKα radiation. Data were collected using 
APEX2 software.6 Initial cell constants were found by small widely separated “matrix” 
runs. Data collection strategies were determined using COSMO.7 Scan speed and scan 
width were chosen based on scattering power and peak rocking curves. All datasets were 
collected at – 153 °C using an Oxford Croystream low-temperature device. 
Unit cell constants and orientation matrix were improved by least-squares 
refinement of reflections threshold from the entire dataset. Integration was performed 
with SAINT,8 using this improved unit cell as a starting point. Precise unit cell constants 
were calculated in SAINT from the final merged dataset. Lorenz and polarization 
corrections were applied. A multi-scan absorption correction was performed with 
SADABS9 for 28SUB; absorption corrections were not applied for the other structures (µ 
≤ 0.1 mm-1 in each case). 
Data were reduced with SHELXTL.10 The structures were solved in all cases by 
direct methods without incident. In each case, both di-acid and di-pyridine molecules sit 
on inversion centers in space group P-1 to give one formula unit per unit cell. For each 
structure, the coordinates for the unique amide and carboxylic acid hydrogens were 
allowed to refine; all other hydrogen atoms were located in idealized positions and were 
treated with a riding model. All structures were fully ordered and none contained solvent 
or water of hydration. 
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Appendix B - 1H and 13C NMR 
 
 203 
 
Figure B.1 1H NMR of 1 
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Figure B.2 1H NMR of 2 
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Figure B.5 (a) 1H and (b) 13C NMR of 5 
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Figure B.6 (a) 1H and (b) 13C NMR of 6 
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Figure B.7 1H NMR of 7 
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Figure B.8 (a) 1H and (b) 13C NMR of 8 
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Figure B.9 (a) 1H and (b) 13C NMR of 9 
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Figure B.10 1H NMR of 10 
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Figure B.12 (a) 1H and (b) 13C NMR of 12 
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Figure B.13 (a) 1H and (b) 13C NMR of 13 
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Figure B.14 1H NMR of 14 
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Figure B.16 (a) 1H and (b) 13C NMR of 16 
N
S
 
200 MHz, CDCl3-d 
400 MHz, CDCl3-d 
 216 
 
(a) 
 
(b) 
Figure B.17 (a) 1H and (b) 13C NMR of 17 
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Figure B.18 1H NMR of 18 
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Figure B.19 (a) 1H and (b) 13C NMR of 19 
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Figure B.20 (a) 1H and 13C NMR of 20 
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Figure B.21 (a) 1H and 13C NMR of 21 
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Figure B.22 1H NMR of 22 
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Figure B.23 (a) 1H and (b) 13C NMR of 23 
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Figure B.24 (a) 1H and (b) 13C NMR of 24 
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Figure B.26 1H NMR of 26 
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Figure B.27 1H NMR of 27  
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Figure B.28 (a) 1H and 13C NMR of 28 
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Figure B.29 (a) 1H and 13C NMR of 29 
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Figure B.30 1H NMR of 30 
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Figure B.31 1H NMR of 31 
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Figure B.32 (a) 1H and 13C NMR of 32 
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Figure B.33 (a) 1H and 13C NMR of 33 
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Appendix C - Crystallographic Data Tables 
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 Table C.1  Crystal data and structure refinement for 2HG, 2SUB, 2SEB, 3SUC,  
  3HBA and 1a-b, 2a, 3a 
 
2HG  
Identification code  sf0601m 
Empirical formula  C12 H16 N2 O5 
Formula weight  268.27 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.1730(8) Å α= 80.462(7)°. 
 b = 7.6117(8) Å β= 75.807(7)°. 
 c = 11.9194(13) Å γ = 87.896(7)°. 
Volume 622.19(12) Å3 
Z 2 
Density (calculated) 1.432 g/cm3 
Absorption coefficient 0.112 mm-1 
F(000) 284 
Crystal size 0.35 x 0.30 x 0.15 mm3 
Theta range for data collection 1.79 to 26.37°. 
Index ranges -8<=h<=8, -9<=k<=9, -13<=l<=14 
Reflections collected 3381 
Independent reflections 2213 [R(int) = 0.0867] 
Completeness to theta = 26.37° 87.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2213 / 0 / 182 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0542, wR2 = 0.1396 
R indices (all data) R1 = 0.0664, wR2 = 0.1483 
Largest diff. peak and hole 0.442 and -0.291 e.Å-3 
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 Crystal data and structure refinement for 2SUB. 
Identification code  sf0918m 
Empirical formula  C22 H30 N4 O6 
Formula weight  446.50 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 10.0886(7) Å α= 90°. 
 b = 8.6108(6) Å β= 100.883(3)°. 
 c = 25.9765(19) Å γ = 90°. 
Volume 2216.0(3) Å3 
Z 4 
Density (calculated) 1.338 g/cm3 
Absorption coefficient 0.098 mm-1 
F(000) 952 
Crystal size 0.32 x 0.26 x 0.16 mm3 
Theta range for data collection 1.60 to 32.56°. 
Index ranges -15<=h<=11, -11<=k<=13, -39<=l<=38 
Reflections collected 50976 
Independent reflections 7909 [R(int) = 0.0243] 
Completeness to theta = 32.56° 98.2 %  
Absorption correction None 
Max. and min. transmission 0.9844 and 0.9692 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7909 / 0 / 307 
Goodness-of-fit on F2 1.052 
Final R indices [I>2sigma(I)] R1 = 0.0401, wR2 = 0.1134 
R indices (all data) R1 = 0.0471, wR2 = 0.1186 
Largest diff. peak and hole 0.415 and -0.220 e.Å-3 
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Crystal data and structure refinement for 2SEB. 
Identification code  sf0602 
Empirical formula  C24 H34 N4 O6 
Formula weight  474.55 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 28.532(3) Å α= 90°. 
 b = 8.2965(8) Å β= 101.987(2)°. 
 c = 10.6120(10) Å γ = 90°. 
Volume 2457.2(4) Å3 
Z 4 
Density (calculated) 1.283 g/cm3 
Absorption coefficient 0.093 mm-1 
F(000) 1016 
Crystal size 0.22 x 0.32 x 0.42 mm3 
Theta range for data collection 2.56 to 30.53°. 
Index ranges -39<=h<=40, -11<=k<=11, -15<=l<=15 
Reflections collected 14481 
Independent reflections 3740 [R(int) = 0.0727] 
Completeness to theta = 30.53° 99.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3740 / 0 / 161 
Goodness-of-fit on F2 1.066 
Final R indices [I>2sigma(I)] R1 = 0.0555, wR2 = 0.1544 
R indices (all data) R1 = 0.0661, wR2 = 0.1600 
Largest diff. peak and hole 0.510 and -0.418 e.Å-3 
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Crystal data and structure refinement for 3SUC. 
Identification code  sf0801m 
Empirical formula  C20 H26 N4 O6 
Formula weight  418.45 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.6600(4) Å α= 90°. 
 b = 4.9276(2) Å β= 110.7620(10)°. 
 c = 16.3965(5) Å γ = 90°. 
Volume 1031.99(6) Å3 
Z 2 
Density (calculated) 1.347 g/cm3 
Absorption coefficient 0.101 mm-1 
F(000) 444 
Crystal size 0.30 x 0.25 x 0.20 mm3 
Theta range for data collection 2.57 to 32.58°. 
Index ranges -19<=h<=19, -7<=k<=7, -24<=l<=24 
Reflections collected 11571 
Independent reflections 3694 [R(int) = 0.0229] 
Completeness to theta = 32.58° 98.2 %  
Absorption correction None 
Max. and min. transmission 0.9801 and 0.9704 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3694 / 0 / 143 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0403, wR2 = 0.1138 
R indices (all data) R1 = 0.0461, wR2 = 0.1192 
Largest diff. peak and hole 0.516 and -0.265 e.Å-3 
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Crystal data and structure refinement for 3HBA. 
Identification code  sf0937m 
Empirical formula  C15 H16 N2 O4 
Formula weight  288.30 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 5.6869(3) Å α= 90°. 
 b = 7.2012(4) Å β= 93.882(2)°. 
 c = 33.5028(18) Å γ = 90°. 
Volume 1368.88(13) Å3 
Z 4 
Density (calculated) 1.399 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 608 
Crystal size 0.32 x 0.24 x 0.14 mm3 
Theta range for data collection 0.61 to 32.57°. 
Index ranges -8<=h<=6, -10<=k<=7, -50<=l<=50 
Reflections collected 17775 
Independent reflections 4684 [R(int) = 0.0291] 
Completeness to theta = 30.00° 97.9 %  
Absorption correction None 
Max. and min. transmission 0.9858 and 0.9679 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4684 / 0 / 204 
Goodness-of-fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0484, wR2 = 0.1318 
R indices (all data) R1 = 0.0560, wR2 = 0.1383 
Largest diff. peak and hole 0.666 and -0.278 e.Å-3 
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Crystal data and structure refinement for 1a. 
Identification code  sf0909m 
Empirical formula  C44 H38 Co N4 O6 
Formula weight  777.71 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.5058(5) Å α= 90°. 
 b = 22.1284(11) Å β= 113.088(2)°. 
 c = 9.7478(5) Å γ = 90°. 
Volume 1886.20(17) Å3 
Z 2 
Density (calculated) 1.369 g/cm3 
Absorption coefficient 0.510 mm-1 
F(000) 810 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.45 to 31.50°. 
Index ranges -13<=h<=13, -31<=k<=32, -14<=l<=14 
Reflections collected 21981 
Independent reflections 6142 [R(int) = 0.0260] 
Completeness to theta = 31.50° 97.8 %  
Absorption correction None 
Max. and min. transmission 0.9274 and 0.8830 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6142 / 152 / 292 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0419, wR2 = 0.1117 
R indices (all data) R1 = 0.0473, wR2 = 0.1162 
Largest diff. peak and hole 0.642 and -0.447 e.Å-3 
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Crystal data and structure refinement for 1b. 
Identification code  sf0806m 
Empirical formula  C44 H38 N4 Ni O6 
Formula weight  777.49 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.3654(6) Å α= 90°. 
 b = 22.1464(15) Å β= 112.103(2)°. 
 c = 9.8255(6) Å γ = 90°. 
Volume 1888.1(2) Å3 
Z 2 
Density (calculated) 1.368 g/cm3 
Absorption coefficient 0.569 mm-1 
F(000) 812 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 2.35 to 33.14°. 
Index ranges -14<=h<=13, -34<=k<=34, -14<=l<=15 
Reflections collected 57124 
Independent reflections 7129 [R(int) = 0.0295] 
Completeness to theta = 33.14° 99.1 %  
Absorption correction None 
Max. and min. transmission 0.9453 and 0.8708 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7129 / 1 / 251 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0506, wR2 = 0.1466 
R indices (all data) R1 = 0.0571, wR2 = 0.1535 
Largest diff. peak and hole 1.472 and -0.804 e.Å-3 
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Crystal data and structure refinement for 2a. 
Identification code  sf0810m 
Empirical formula  C28 H26 Cu F12 N5 O7 
Formula weight  836.08 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.6722(5) Å α= 90°. 
 b = 24.6667(14) Å β= 96.700(4)°. 
 c = 9.5859(6) Å γ = 90°. 
Volume 2036.6(2) Å3 
Z 2 
Density (calculated) 1.363 g/cm3 
Absorption coefficient 0.635 mm-1 
F(000) 844 
Crystal size 0.20 x 0.08 x 0.04 mm3 
Theta range for data collection 2.29 to 30.51°. 
Index ranges -12<=h<=12, -35<=k<=33, -11<=l<=13 
Reflections collected 23919 
Independent reflections 6224 [R(int) = 0.0691] 
Completeness to theta = 30.51° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9751 and 0.8836 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6224 / 42 / 269 
Goodness-of-fit on F2 1.524 
Final R indices [I>2sigma(I)] R1 = 0.0899, wR2 = 0.2423 
R indices (all data) R1 = 0.1497, wR2 = 0.2649 
Largest diff. peak and hole 1.162 and -0.911 e.Å-3 
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Crystal data and structure refinement for 3a. 
Identification code  sf0823m 
Empirical formula  C46 H42 Co N4 O6 
Formula weight  805.77 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 12.5711(6) Å α= 90°. 
 b = 15.5146(8) Å β= 97.011(2)°. 
 c = 10.0698(5) Å γ = 90°. 
Volume 1949.28(17) Å3 
Z 2 
Density (calculated) 1.373 g/cm3 
Absorption coefficient 0.496 mm-1 
F(000) 842 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.42 to 32.37°. 
Index ranges -18<=h<=18, -20<=k<=23, -15<=l<=14 
Reflections collected 31101 
Independent reflections 6869 [R(int) = 0.0249] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9293 and 0.8859 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6869 / 0 / 263 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0317, wR2 = 0.0861 
R indices (all data) R1 = 0.0375, wR2 = 0.0899 
Largest diff. peak and hole 0.489 and -0.212 e.Å-3 
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 Table C.2 Crystal data and structure refinement for 4IF4BA, 4I3F3BA, 4HBA,  
  5IF4BA, 5BrF4BA, 5ABA, 6IBA, and 6ABA 
 
4IF4BA 
Identification code  sf0832m 
Empirical formula  C11 H5 F4 I N2 O3 
Formula weight  416.07 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.2494(2) Å α= 110.254(2)°. 
 b = 11.6205(6) Å β= 96.027(2)°. 
 c = 13.8376(7) Å γ = 98.468(2)°. 
Volume 625.04(5) Å3 
Z 2 
Density (calculated) 2.211 g/cm3 
Absorption coefficient 2.625 mm-1 
F(000) 396 
Crystal size 0.46 x 0.28 x 0.22 mm3 
Theta range for data collection 3.18 to 39.38°. 
Index ranges -7<=h<=7, -19<=k<=20, -23<=l<=24 
Reflections collected 23438 
Independent reflections 7076 [R(int) = 0.0188] 
Completeness to theta = 30.00° 99.4 %  
Absorption correction None 
Max. and min. transmission 0.5959 and 0.3814 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7076 / 0 / 190 
Goodness-of-fit on F2 1.013 
Final R indices [I>2sigma(I)] R1 = 0.0200, wR2 = 0.0518 
R indices (all data) R1 = 0.0220, wR2 = 0.0528 
Largest diff. peak and hole 1.436 and -0.852 e.Å-3 
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 Crystal data and structure refinement for 4I3F3B. 
Identification code  sf0911m 
Empirical formula  C16 H4 F6 I6 N2 O 
Formula weight  1115.61 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Cc 
Unit cell dimensions a = 12.3402(19) Å α= 90°. 
 b = 13.476(2) Å β= 110.979(4)°. 
 c = 15.223(2) Å γ = 90°. 
Volume 2363.7(6) Å3 
Z 4 
Density (calculated) 3.135 g/cm3 
Absorption coefficient 7.945 mm-1 
F(000) 1976 
Crystal size 0.24 x 0.12 x 0.08 mm3 
Theta range for data collection 2.33 to 31.51°. 
Index ranges -13<=h<=18, -19<=k<=19, -22<=l<=22 
Reflections collected 22414 
Independent reflections 3902 [R(int) = 0.0334] 
Completeness to theta = 31.51° 99.1 %  
Absorption correction None 
Max. and min. transmission 0.5690 and 0.2515 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3902 / 0 / 149 
Goodness-of-fit on F2 1.114 
Final R indices [I>2sigma(I)] R1 = 0.0201, wR2 = 0.0440 
R indices (all data) R1 = 0.0223, wR2 = 0.0449 
Largest diff. peak and hole 0.780 and -0.833 e.Å-3 
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 Crystal data and structure refinement for 4HBA. 
Identification code  sf0803m 
Empirical formula  C11 H10 N2 O4 
Formula weight  234.21 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6865(3) Å α= 85.253(3)°. 
 b = 7.2166(4) Å β= 86.577(3)°. 
 c = 10.5803(5) Å γ = 83.773(3)°. 
Volume 505.12(4) Å3 
Z 2 
Density (calculated) 1.540 g/cm3 
Absorption coefficient 0.120 mm-1 
F(000) 244 
Crystal size 0.25 x 0.25 x 0.15 mm3 
Theta range for data collection 1.93 to 31.51°. 
Index ranges -9<=h<=9, -10<=k<=10, -15<=l<=15 
Reflections collected 14329 
Independent reflections 3245 [R(int) = 0.0241] 
Completeness to theta = 31.51° 96.2 %  
Absorption correction None 
Max. and min. transmission 0.9823 and 0.9707 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3245 / 0 / 160 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0395, wR2 = 0.1105 
R indices (all data) R1 = 0.0503, wR2 = 0.1209 
Largest diff. peak and hole 0.531 and -0.234 e.Å-3 
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 Crystal data and structure refinement for 5IF4BA. 
Identification code  sf0829m 
Empirical formula  C15 H13 F4 I N2 O3 
Formula weight  472.17 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.9049(10) Å a= 90°. 
 b = 7.9564(9) Å b= 93.772(4)°. 
 c = 23.142(3) Å g = 90°. 
Volume 1636.1(3) Å3 
Z 4 
Density (calculated) 1.917 Mg/m3 
Absorption coefficient 2.018 mm-1 
F(000) 920 
Crystal size 0.25 x 0.18 x 0.12 mm3 
Theta range for data collection 2.71 to 32.58°. 
Index ranges -13<=h<=13, -12<=k<=10, -34<=l<=31 
Reflections collected 20666 
Independent reflections 5886 [R(int) = 0.0205] 
Completeness to theta = 32.58° 98.8 %  
Absorption correction None 
Max. and min. transmission 0.7938 and 0.6324 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5886 / 94 / 334 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0283, wR2 = 0.0677 
R indices (all data) R1 = 0.0323, wR2 = 0.0702 
Largest diff. peak and hole 0.936 and -0.874 e.Å-3 
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Crystal data and structure refinement for 5BrF4BA. 
Identification code  sf0824m 
Empirical formula  C15 H13 Br F4 N2 O3 
Formula weight  425.18 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.9124(13) Å α= 90°. 
 b = 7.9267(10) Å β= 95.717(7)°. 
 c = 22.746(3) Å γ = 90°. 
Volume 1598.9(4) Å3 
Z 4 
Density (calculated) 1.766 g/cm3 
Absorption coefficient 2.633 mm-1 
F(000) 848 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.72 to 32.57°. 
Index ranges -13<=h<=12, -12<=k<=11, -33<=l<=34 
Reflections collected 17551 
Independent reflections 5657 [R(int) = 0.0273] 
Completeness to theta = 25.00° 99.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5657 / 125 / 317 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0468, wR2 = 0.1298 
R indices (all data) R1 = 0.0604, wR2 = 0.1372 
Largest diff. peak and hole 0.945 and -1.030 e.Å-3 
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Crystal data and structure refinement for 5ABA. 
Identification code  sf0908m 
Empirical formula  C22 H26 N4 O5 
Formula weight  426.47 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.0405(8) Å α= 90°. 
 b = 7.2636(5) Å β= 101.902(3)°. 
 c = 23.2647(15) Å γ = 90°. 
Volume 2156.3(2) Å3 
Z 4 
Density (calculated) 1.314 g/cm3 
Absorption coefficient 0.095 mm-1 
F(000) 904 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.60 to 32.03°. 
Index ranges -14<=h<=19, -10<=k<=10, -34<=l<=34 
Reflections collected 26805 
Independent reflections 7304 [R(int) = 0.0336] 
Completeness to theta = 32.03° 97.3 %  
Absorption correction None 
Max. and min. transmission 0.9859 and 0.9722 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7304 / 0 / 302 
Goodness-of-fit on F2 1.095 
Final R indices [I>2sigma(I)] R1 = 0.0492, wR2 = 0.1307 
R indices (all data) R1 = 0.0722, wR2 = 0.1435 
Largest diff. peak and hole 0.331 and -0.476 e.Å-3 
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Crystal data and structure refinement for 6IBA. 
Identification code  sf0917m 
Empirical formula  C17 H13 I N2 O3 
Formula weight  420.19 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.1002(7) Å α= 90°. 
 b = 10.7028(8) Å β= 107.850(3)°. 
 c = 15.3637(11) Å γ = 90°. 
Volume 1580.9(2) Å3 
Z 4 
Density (calculated) 1.765 g/cm3 
Absorption coefficient 2.042 mm-1 
F(000) 824 
Crystal size 0.28 x 0.24 x 0.16 mm3 
Theta range for data collection 2.12 to 33.14°. 
Index ranges -15<=h<=15, -16<=k<=10, -22<=l<=23 
Reflections collected 27337 
Independent reflections 5790 [R(int) = 0.0237] 
Completeness to theta = 33.14° 96.0 %  
Absorption correction None 
Max. and min. transmission 0.7359 and 0.5986 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5790 / 0 / 208 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0321, wR2 = 0.0882 
R indices (all data) R1 = 0.0379, wR2 = 0.0919 
Largest diff. peak and hole 1.744 and -1.081 e.Å-3 
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Crystal data and structure refinement for 6ABA. 
Identification code  sf0805 
Empirical formula  C17 H15 N3 O3 
Formula weight  309.32 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 10.6939(5) Å α= 90°. 
 b = 3.9716(2) Å β= 92.444(3)°. 
 c = 33.8720(19) Å γ = 90°. 
Volume 1437.30(13) Å3 
Z 4 
Density (calculated) 1.429 g/cm3 
Absorption coefficient 0.101 mm-1 
F(000) 648 
Crystal size 0.32 x 0.203 x 0.188 mm3 
Theta range for data collection 2.02 to 27.11°. 
Index ranges -13<=h<=13, -5<=k<=5, -43<=l<=42 
Reflections collected 34351 
Independent reflections 3158 [R(int) = 0.0513] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3158 / 0 / 217 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0437, wR2 = 0.0942 
R indices (all data) R1 = 0.0895, wR2 = 0.1120 
Largest diff. peak and hole 0.177 and -0.273 e.Å-3 
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 Table C.3 Crystal data and structure refinement for 9, 17, 8SUC, 8IBA 
9 
Identification code  sf0720m 
Empirical formula  C11 H10 N2 O S 
Formula weight  218.27 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 5.8014(9) Å α= 90°. 
 b = 24.959(4) Å β= 111.200(7)°. 
 c = 7.4141(10) Å γ = 90°. 
Volume 1000.9(2) Å3 
Z 4 
Density (calculated) 1.449 g/cm3 
Absorption coefficient 0.294 mm-1 
F(000) 456 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 1.63 to 32.03°. 
Index ranges -8<=h<=8, -37<=k<=37, -11<=l<=10 
Reflections collected 18161 
Independent reflections 3434 [R(int) = 0.0433] 
Completeness to theta = 32.03° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9712 and 0.9301 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3434 / 0 / 140 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0447, wR2 = 0.1229 
R indices (all data) R1 = 0.0590, wR2 = 0.1318 
Largest diff. peak and hole 0.606 and -0.486 e.Å-3 
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Crystal data and structure refinement for 17. 
Identification code  sf0807m 
Empirical formula  C13 H14 N2 O S 
Formula weight  246.32 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.4109(3) Å α= 90.542(3)°. 
 b = 7.3580(4) Å β= 91.181(3)°. 
 c = 15.6259(7) Å γ = 108.345(3)°. 
Volume 590.29(5) Å3 
Z 2 
Density (calculated) 1.386 g/cm3 
Absorption coefficient 0.258 mm-1 
F(000) 260 
Crystal size 0.25 x 0.05 x 0.02 mm3 
Theta range for data collection 2.61 to 33.67°. 
Index ranges -7<=h<=8, -9<=k<=11, -23<=l<=23 
Reflections collected 12962 
Independent reflections 4077 [R(int) = 0.0304] 
Completeness to theta = 25.00° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9961 and 0.9383 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4077 / 0 / 160 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0396, wR2 = 0.1075 
R indices (all data) R1 = 0.0573, wR2 = 0.1175 
Largest diff. peak and hole 0.537 and -0.293 e.Å-3 
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Crystal data and structure refinement for 8SUC. 
Identification code  sf0802m 
Empirical formula  C22 H20 N2 O4 S2 
Formula weight  440.52 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.9134(3) Å α= 90°. 
 b = 5.2495(2) Å β= 92.786(2)°. 
 c = 24.7635(10) Å γ = 90°. 
Volume 1027.49(7) Å3 
Z 2 
Density (calculated) 1.424 g/cm3 
Absorption coefficient 0.292 mm-1 
F(000) 460 
Crystal size 0.25 x 0.15 x 0.08 mm3 
Theta range for data collection 3.13 to 34.97°. 
Index ranges -12<=h<=11, -6<=k<=8, -39<=l<=38 
Reflections collected 18428 
Independent reflections 4280 [R(int) = 0.0224] 
Completeness to theta = 34.97° 94.6 %  
Absorption correction None 
Max. and min. transmission 0.9770 and 0.9306 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4280 / 10 / 155 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0352, wR2 = 0.1003 
R indices (all data) R1 = 0.0405, wR2 = 0.1048 
Largest diff. peak and hole 0.513 and -0.184 e.Å-3 
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 Crystal data and structure refinement for 8IBA. 
Identification code  sf0723 
Empirical formula  C16 H12 I N O2 S 
Formula weight  409.23 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 16.6606(13) Å α= 90°. 
 b = 6.9866(6) Å β= 90°. 
 c = 25.659(2) Å γ = 90°. 
Volume 2986.7(4) Å3 
Z 8 
Density (calculated) 1.820 g/cm3 
Absorption coefficient 2.287 mm-1 
F(000) 1600 
Crystal size 0.18 x 0.10 x 0.02 mm3 
Theta range for data collection 2.44 to 30.53°. 
Index ranges -23<=h<=23, -9<=k<=9, -36<=l<=35 
Reflections collected 35794 
Independent reflections 4539 [R(int) = 0.0954] 
Completeness to theta = 30.53° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9557 and 0.6836 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4539 / 10 / 201 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0461, wR2 = 0.0849 
R indices (all data) R1 = 0.0765, wR2 = 0.0938 
Largest diff. peak and hole 1.807 and -1.901 e.Å-3 
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 Table C.4 Crystal data and structure refinement for 20OCT, 20HEX, 20FUM,  
  20ADI, 20SUB, 20SEB, 20FBA, 20NBA, 20F2BA, 20ABA, 21SUC,  
  21ADI, 21SUB, 23ADI, 23F5BA, 23FUM, 23GLU, 24ADI, 24SUB 
 
20OCT 
Identification code  sf0603m 
Empirical formula  C20 H28 N4 O4 
Formula weight  388.46 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6610(8) Å α= 99.459(8)°. 
 b = 8.4541(11) Å β= 94.349(9)°. 
 c = 19.684(2) Å γ = 107.887(8)°. 
Volume 1031.1(2) Å3 
Z 2 
Density (calculated) 1.251 g/cm3 
Absorption coefficient 0.088 mm-1 
F(000) 416 
Crystal size 0.40 x 0.10 x 0.10 mm3 
Theta range for data collection 2.12 to 27.70°. 
Index ranges -8<=h<=8, -9<=k<=10, -24<=l<=25 
Reflections collected 7356 
Independent reflections 4563 [R(int) = 0.0998] 
Completeness to theta = 27.70° 94.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4563 / 0 / 265 
Goodness-of-fit on F2 0.847 
Final R indices [I>2sigma(I)] R1 = 0.0679, wR2 = 0.1609 
R indices (all data) R1 = 0.1322, wR2 = 0.1858 
Largest diff. peak and hole 0.290 and -0.245 e.Å-3 
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 Crystal data and structure refinement for 20HEX. 
Identification code  sf0608m 
Empirical formula  C18 H24 N4 O4 
Formula weight  360.41 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6573(13) Å α= 95.391(10)°. 
 b = 8.1256(14) Å β= 97.999(12)°. 
 c = 18.128(3) Å γ = 104.439(14)°. 
Volume 931.9(3) Å3 
Z 2 
Density (calculated) 1.284 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 384 
Crystal size 0.40 x 0.25 x 0.10 mm3 
Theta range for data collection 1.14 to 27.51°. 
Index ranges -8<=h<=7, -10<=k<=9, -23<=l<=21 
Reflections collected 6561 
Independent reflections 4031 [R(int) = 0.0855] 
Completeness to theta = 27.51° 94.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4031 / 0 / 247 
Goodness-of-fit on F2 0.894 
Final R indices [I>2sigma(I)] R1 = 0.0630, wR2 = 0.1541 
R indices (all data) R1 = 0.1249, wR2 = 0.1825 
Largest diff. peak and hole 0.272 and -0.341 e.Å-3 
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 Crystal data and structure refinement for 20FUM. 
Identification code  sf0712m 
Empirical formula  C28 H24 N8 O6 
Formula weight  568.55 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.6444(2) Å a= 90°. 
 b = 26.8514(13) Å b= 102.395(3)°. 
 c = 10.8139(5) Å g = 90°. 
Volume 1317.15(10) Å3 
Z 2 
Density (calculated) 1.434 Mg/m3 
Absorption coefficient 0.105 mm-1 
F(000) 592 
Crystal size 0.25 x 0.20 x 0.10 mm3 
Theta range for data collection 2.07 to 30.51°. 
Index ranges -6<=h<=6, -38<=k<=38, -15<=l<=15 
Reflections collected 33731 
Independent reflections 4030 [R(int) = 0.0631] 
Completeness to theta = 30.51° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9896 and 0.9743 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4030 / 0 / 196 
Goodness-of-fit on F2 1.083 
Final R indices [I>2sigma(I)] R1 = 0.0464, wR2 = 0.1072 
R indices (all data) R1 = 0.0712, wR2 = 0.1191 
Largest diff. peak and hole 0.375 and -0.300 e.Å-3 
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Crystal data and structure refinement for 20ADI. 
Identification code  sf0607m 
Empirical formula  C30 H34 N8 O8 
Formula weight  634.65 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6047(8) Å a= 98.182(6)°. 
 b = 8.0678(9) Å b= 101.688(8)°. 
 c = 15.3573(18) Å g = 104.436(9)°. 
Volume 759.84(15) Å3 
Z 1 
Density (calculated) 1.387 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 334 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.38 to 28.30°. 
Index ranges -7<=h<=8, -10<=k<=10, -20<=l<=20 
Reflections collected 9931 
Independent reflections 3529 [R(int) = 0.1503] 
Completeness to theta = 28.30° 93.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3529 / 0 / 220 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0589, wR2 = 0.1523 
R indices (all data) R1 = 0.0780, wR2 = 0.1713 
Largest diff. peak and hole 0.385 and -0.299 e.Å-3 
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Crystal data and structure refinement for 20SUB. 
Identification code  sf0605m 
Empirical formula  C32 H38 N8 O8 
Formula weight  662.70 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6283(9) Å α= 81.455(11)°. 
 b = 8.1784(11) Å β= 83.602(8)°. 
 c = 15.902(2) Å γ = 74.806(8)°. 
Volume 820.29(19) Å3 
Z 1 
Density (calculated) 1.342 g/cm3 
Absorption coefficient 0.099 mm-1 
F(000) 350 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 2.60 to 27.49°. 
Index ranges -8<=h<=7, -9<=k<=10, -20<=l<=20 
Reflections collected 6027 
Independent reflections 3569 [R(int) = 0.1203] 
Completeness to theta = 27.49° 94.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3569 / 0 / 229 
Goodness-of-fit on F2 1.096 
Final R indices [I>2sigma(I)] R1 = 0.0731, wR2 = 0.2228 
R indices (all data) R1 = 0.0990, wR2 = 0.2502 
Largest diff. peak and hole 0.321 and -0.373 e.Å-3 
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 Crystal data and structure refinement for 20SEB. 
Identification code  sf0703m 
Empirical formula  C34 H42 N8 O8 
Formula weight  690.76 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.5516(4) Å α= 94.293(3)°. 
 b = 8.1666(5) Å β= 93.041(3)°. 
 c = 33.7458(19) Å γ = 105.225(3)°. 
Volume 1732.32(18) Å3 
Z 2 
Density (calculated) 1.324 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 732 
Crystal size 0.25 x 0.20 x 0.08 mm3 
Theta range for data collection 1.82 to 32.58°. 
Index ranges -9<=h<=9, -12<=k<=12, -51<=l<=51 
Reflections collected 75728 
Independent reflections 12391 [R(int) = 0.0540] 
Completeness to theta = 32.58° 98.2 %  
Absorption correction None 
Max. and min. transmission 0.9923 and 0.9763 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12391 / 0 / 475 
Goodness-of-fit on F2 1.013 
Final R indices [I>2sigma(I)] R1 = 0.0508, wR2 = 0.1141 
R indices (all data) R1 = 0.1133, wR2 = 0.1388 
Largest diff. peak and hole             0.508 and -0.254 e.Å-3  
 261 
 Crystal data and structure refinement for 20FBA. 
Identification code  sf0606m 
Empirical formula  C19 H17 F N4 O4 
Formula weight  384.37 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.6065(14) Å a= 92.457(13)°. 
 b = 7.2295(17) Å b= 97.668(14)°. 
 c = 21.354(4) Å g = 116.706(15)°. 
Volume 896.8(3) Å3 
Z 2 
Density (calculated) 1.423 Mg/m3 
Absorption coefficient 0.109 mm-1 
F(000) 400 
Crystal size 0.40 x 0.20 x 0.05 mm3 
Theta range for data collection 1.94 to 27.47°. 
Index ranges -8<=h<=8, -9<=k<=9, -27<=l<=27 
Reflections collected 6657 
Independent reflections 3951 [R(int) = 0.1136] 
Completeness to theta = 27.47° 95.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3951 / 0 / 270 
Goodness-of-fit on F2 0.885 
Final R indices [I>2sigma(I)] R1 = 0.0624, wR2 = 0.1467 
R indices (all data) R1 = 0.1720, wR2 = 0.1947 
Extinction coefficient 0.013(4) 
Largest diff. peak and hole 0.285 and -0.258 e.Å-3 
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 Crystal data and structure refinement for 20NBA. 
Identification code  sf0604m 
Empirical formula  C19 H17 N5 O6 
Formula weight  411.38 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.5983(13) Å α= 81.922(11)°. 
 b = 7.2343(14) Å β= 84.772(14)°. 
 c = 19.755(4) Å γ = 80.711(16)°. 
Volume 919.1(3) Å3 
Z 2 
Density (calculated) 1.486 g/cm3 
Absorption coefficient 0.114 mm-1 
F(000) 428 
Crystal size 0.40 x 0.40 x 0.20 mm3 
Theta range for data collection 1.04 to 27.45°. 
Index ranges -8<=h<=8, -9<=k<=8, -25<=l<=25 
Reflections collected 6545 
Independent reflections 3966 [R(int) = 0.0969] 
Completeness to theta = 27.45° 93.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3966 / 19 / 306 
Goodness-of-fit on F2 0.924 
Final R indices [I>2sigma(I)] R1 = 0.0866, wR2 = 0.2181 
R indices (all data) R1 = 0.1363, wR2 = 0.2475 
Largest diff. peak and hole 0.784 and -0.291 e.Å-3 
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Crystal data and structure refinement for 20F2BA. 
Identification code  sf0702m 
Empirical formula  C19 H16 F2 N4 O4.10 
Formula weight  403.96 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 7.4376(2) Å α= 90°. 
 b = 12.3798(4) Å β= 93.396(2)°. 
 c = 39.3480(11) Å γ = 90°. 
Volume 3616.64(18) Å3 
Z 8 
Density (calculated) 1.484 g/cm3 
Absorption coefficient 0.120 mm-1 
F(000) 1670 
Crystal size 0.25 x 0.25 x 0.04 mm3 
Theta range for data collection 3.11 to 30.51°. 
Index ranges -10<=h<=6, -17<=k<=17, -56<=l<=56 
Reflections collected 34501 
Independent reflections 5339 [R(int) = 0.0500] 
Completeness to theta = 30.51° 96.5 %  
Absorption correction None 
Max. and min. transmission 0.9952 and 0.9706 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5339 / 0 / 286 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0540, wR2 = 0.1381 
R indices (all data) R1 = 0.0713, wR2 = 0.1528 
Largest diff. peak and hole 0.570 and -0.571 e.Å-3 
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Crystal data and structure refinement for 20ABA. 
Identification code  sf0722m 
Empirical formula  C19 H19 N5 O4 
Formula weight  381.39 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.8995(2) Å α= 90°. 
 b = 14.6202(4) Å β= 93.198(2)°. 
 c = 14.0267(3) Å γ = 90°. 
Volume 1822.21(8) Å3 
Z 4 
Density (calculated) 1.390 g/cm3 
Absorption coefficient 0.101 mm-1 
F(000) 800 
Crystal size 0.27 x 0.25 x 0.22 mm3 
Theta range for data collection 3.60 to 27.12°. 
Index ranges -10<=h<=11, -18<=k<=18, -17<=l<=17 
Reflections collected 23993 
Independent reflections 4009 [R(int) = 0.0552] 
Completeness to theta = 27.12° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9787 and 0.9736 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4009 / 0 / 271 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0420, wR2 = 0.0997 
R indices (all data) R1 = 0.0673, wR2 = 0.1129 
Largest diff. peak and hole 0.228 and -0.238 e.Å-3 
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Crystal data and structure refinement for 21SUC. 
Identification code  sf0710m 
Empirical formula  C16 H20 N4 O7 
Formula weight  380.36 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.844(2) Å a= 90°. 
 b = 6.8807(14) Å b= 98.561(2)°. 
 c = 26.413(5) Å g = 90°. 
Volume 1769.1(6) Å3 
Z 4 
Density (calculated) 1.428 Mg/m3 
Absorption coefficient 0.114 mm-1 
F(000) 800 
Crystal size 0.20 x 0.15 x 0.08 mm3 
Theta range for data collection 8.14 to 30.38°. 
Index ranges -13<=h<=14, -5<=k<=9, -37<=l<=37 
Reflections collected 26114 
Independent reflections 5152 [R(int) = 0.0792] 
Completeness to theta = 30.38° 96.8 %  
Absorption correction None 
Max. and min. transmission 0.9910 and 0.9776 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5152 / 0 / 265 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.0580, wR2 = 0.1391 
R indices (all data) R1 = 0.0970, wR2 = 0.1577 
Largest diff. peak and hole 0.436 and -0.270 e.Å-3 
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Crystal data and structure refinement for 21ADI. 
Identification code  sf0709m 
Empirical formula  C18 H22 N4 O6 
Formula weight  390.40 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.8908(3) Å α= 66.395(2)°. 
 b = 11.3841(6) Å β= 89.086(2)°. 
 c = 12.6504(6) Å γ = 84.907(2)°. 
Volume 905.54(8) Å3 
Z 2 
Density (calculated) 1.432 g/cm3 
Absorption coefficient 0.109 mm-1 
F(000) 412 
Crystal size 0.20 x 0.10 x 0.10 mm3 
Theta range for data collection 1.76 to 30.50°. 
Index ranges -5<=h<=9, -16<=k<=16, -18<=l<=18 
Reflections collected 15411 
Independent reflections 5258 [R(int) = 0.0366] 
Completeness to theta = 30.50° 95.3 %  
Absorption correction None 
Max. and min. transmission 0.9892 and 0.9785 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5258 / 0 / 273 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0550, wR2 = 0.1322 
R indices (all data) R1 = 0.0848, wR2 = 0.1458 
Largest diff. peak and hole              0.307 and -0.301 e.Å-3 
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Crystal data and structure refinement for 21SUB. 
Identification code  sf0721m 
Empirical formula  C20 H26 N4 O6 
Formula weight  418.45 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.918(2) Å a= 67.522(16)°. 
 b = 11.800(4) Å b= 79.851(16)°. 
 c = 13.910(5) Å g = 84.973(16)°. 
Volume 1032.6(6) Å3 
Z 2 
Density (calculated) 1.346 Mg/m3 
Absorption coefficient 0.101 mm-1 
F(000) 444 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.60 to 29.57°. 
Index ranges -9<=h<=9, -12<=k<=16, -19<=l<=19 
Reflections collected 23107 
Independent reflections 5306 [R(int) = 0.0634] 
Completeness to theta = 25.00° 93.8 %  
Absorption correction None 
Max. and min. transmission 0.9851 and 0.9704 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5306 / 0 / 286 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0629, wR2 = 0.1621 
R indices (all data) R1 = 0.1177, wR2 = 0.2042 
Largest diff. peak and hole 0.373 and -0.220 e.Å-3 
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Crystal data and structure refinement for 23FUM. 
Identification code  sf0819m 
Empirical formula  C28 H24 N8 O6 
Formula weight  568.55 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.4782(3) Å a= 97.053(2)°. 
 b = 8.8918(4) Å b= 102.589(2)°. 
 c = 11.7133(5) Å g = 90.066(2)°. 
Volume 653.24(5) Å3 
Z 1 
Density (calculated) 1.445 Mg/m3 
Absorption coefficient 0.105 mm-1 
F(000) 296 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.31 to 32.55°. 
Index ranges -9<=h<=9, -13<=k<=13, -17<=l<=17 
Reflections collected 15112 
Independent reflections 4625 [R(int) = 0.0199] 
Completeness to theta = 32.55° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.9844 and 0.9741 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4625 / 0 / 196 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0386, wR2 = 0.1139 
R indices (all data) R1 = 0.0438, wR2 = 0.1184 
Largest diff. peak and hole 0.508 and -0.423 e.Å-3 
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Crystal data and structure refinement for 23GLU. 
Identification code  sf0932m 
Empirical formula  C17 H18 N4 O5 
Formula weight  358.35 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 10.4837(6) Å α= 90°. 
 b = 12.1023(8) Å β= 90°. 
 c = 26.5805(16) Å γ = 90°. 
Volume 3372.5(4) Å3 
Z 8 
Density (calculated) 1.412 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 1504 
Crystal size 0.28 x 0.24 x 0.12 mm3 
Theta range for data collection 1.53 to 32.58°. 
Index ranges -15<=h<=14, -17<=k<=17, -39<=l<=36 
Reflections collected 34857 
Independent reflections 5877 [R(int) = 0.0862] 
Completeness to theta = 30.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9874 and 0.9709 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5877 / 0 / 244 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0704, wR2 = 0.1354 
R indices (all data) R1 = 0.1261, wR2 = 0.1562 
Largest diff. peak and hole 0.334 and -0.258 e.Å-3 
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Crystal data and structure refinement for 24ADI. 
Identification code  sf0816m 
Empirical formula  C18 H20 N4 O6 
Formula weight  388.38 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.9702(8) Å a= 82.412(6)°. 
 b = 7.2951(8) Å b= 86.955(6)°. 
 c = 19.794(2) Å g = 66.582(6)°. 
Volume 915.49(17) Å3 
Z 2 
Density (calculated) 1.409 Mg/m3 
Absorption coefficient 0.108 mm-1 
F(000) 408 
Crystal size 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 2.08 to 32.04°. 
Index ranges -10<=h<=10, -10<=k<=10, -29<=l<=27 
Reflections collected 18462 
Independent reflections 6037 [R(int) = 0.1117] 
Completeness to theta = 25.00° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9893 and 0.9684 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6037 / 2 / 267 
Goodness-of-fit on F2 0.940 
Final R indices [I>2sigma(I)] R1 = 0.0693, wR2 = 0.1703 
R indices (all data) R1 = 0.2056, wR2 = 0.2142 
Largest diff. peak and hole 0.479 and -0.335 e.Å-3 
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Crystal data and structure refinement for 24SUB. 
Identification code  sf0815m 
Empirical formula  C20 H26 N4 O6 
Formula weight  418.45 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.8479(8) Å α= 92.343(2)°. 
 b = 7.5486(8) Å β= 93.002(2)°. 
 c = 21.280(2) Å γ = 113.883(2)°. 
Volume 1002.12(19) Å3 
Z 2 
Density (calculated) 1.387 g/cm3 
Absorption coefficient 0.104 mm-1 
F(000) 444 
Crystal size 0.15 x 0.15 x 0.10 mm3 
Theta range for data collection 1.92 to 31.46°. 
Index ranges -10<=h<=9, -10<=k<=11, -31<=l<=30 
Reflections collected 13812 
Independent reflections 6525 [R(int) = 0.0232] 
Completeness to theta = 31.46° 98.1 %  
Absorption correction None 
Max. and min. transmission 0.9897 and 0.9846 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6525 / 0 / 286 
Goodness-of-fit on F2 1.011 
Final R indices [I>2sigma(I)] R1 = 0.0452, wR2 = 0.1208 
R indices (all data) R1 = 0.0671, wR2 = 0.1341 
Largest diff. peak and hole 0.487 and -0.323 e.Å-3 
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 Table C.5 Crystal data and structure refinement for 26SUC, 26ADI, 26DOD,  
  27SUC, 27ADI, 27SUB, 28SUC, 28ADI, 28SUB, 28SEB, 28DOD,  
  28OXA, 28PIM, 29SUC, 29ADI, 29SUB, 29SEB, 29MAL, 30SEB,  
  31SUC, 31SUB, 31DOD, 32SUC, 32ADI, 32SUB, 32SEB, 32DOD,  
  32OXA, 32GLU, 32HEP, 32OCT, 32LAU and 33UC, 33SUB, 33PIM 
 
26SUC 
Identification code  sf0944m 
Empirical formula  C16 H20 N4 O8 
Formula weight  396.36 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 18.6319(16) Å α= 90°. 
 b = 3.7424(3) Å β= 99.566(5)°. 
 c = 25.545(2) Å γ = 90°. 
Volume 1756.4(3) Å3 
Z 4 
Density (calculated) 1.499 g/cm3 
Absorption coefficient 0.122 mm-1 
F(000) 832 
Crystal size 0.28 x 0.16 x 0.08 mm3 
Theta range for data collection 1.62 to 30.45°. 
Index ranges -22<=h<=26, -5<=k<=5, -36<=l<=35 
Reflections collected 9062 
Independent reflections 2401 [R(int) = 0.0906] 
Completeness to theta = 25.00° 95.0 %  
Absorption correction None 
Max. and min. transmission 0.9903 and 0.9667 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2401 / 78 / 140 
Goodness-of-fit on F2 1.503 
Final R indices [I>2sigma(I)] R1 = 0.1013, wR2 = 0.2416 
R indices (all data) R1 = 0.1282, wR2 = 0.2609 
Largest diff. peak and hole 0.772 and -0.588 e.Å-3 
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 Crystal data and structure refinement for 26ADI. 
Identification code  sf1004m 
Empirical formula  C18 H20 N4 O6 
Formula weight  388.38 
Temperature  298(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.8804(3) Å α= 95.710(4)°. 
 b = 7.9736(6) Å β= 90.985(4)°. 
 c = 12.0838(8) Å γ = 103.099(5)°. 
Volume 455.34(5) Å3 
Z 1 
Density (calculated) 1.416 g/cm3 
Absorption coefficient 0.108 mm-1 
F(000) 204 
Crystal size 0.28 x 0.22 x 0.12 mm3 
Theta range for data collection 2.64 to 30.03°. 
Index ranges -6<=h<=6, -11<=k<=11, -17<=l<=17 
Reflections collected 9499 
Independent reflections 2629 [R(int) = 0.0430] 
Completeness to theta = 30.03° 98.7 %  
Absorption correction None 
Max. and min. transmission 0.9871 and 0.9703 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2629 / 0 / 133 
Goodness-of-fit on F2 1.723 
Final R indices [I>2sigma(I)] R1 = 0.0651, wR2 = 0.2399 
R indices (all data) R1 = 0.0798, wR2 = 0.2486 
Largest diff. peak and hole 0.343 and -0.253 e.Å-3 
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Crystal data and structure refinement for 26DOD. 
Identification code  sf1001m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.6641(12) Å α= 95.406(6)°. 
 b = 7.1147(18) Å β= 95.778(6)°. 
 c = 18.067(5) Å γ = 91.815(6)°. 
Volume 593.3(3) Å3 
Z 1 
Density (calculated) 1.323 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 252 
Crystal size 0.28 x 0.16 x 0.08 mm3 
Theta range for data collection 2.28 to 31.50°. 
Index ranges -6<=h<=5, -10<=k<=10, -25<=l<=26 
Reflections collected 11248 
Independent reflections 3909 [R(int) = 0.0607] 
Completeness to theta = 31.50° 98.8 %  
Absorption correction None 
Max. and min. transmission 0.9924 and 0.9736 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3909 / 0 / 160 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0560, wR2 = 0.1279 
R indices (all data) R1 = 0.0942, wR2 = 0.1437 
Largest diff. peak and hole 0.436 and -0.367 e.Å-3 
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 Crystal data and structure refinement for 27SUC. 
Identification code  sf1003m 
Empirical formula  C24 H34 N4 O12 
Formula weight  570.55 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.7321(4) Å α= 74.877(3)°. 
 b = 9.0931(8) Å β= 85.703(4)°. 
 c = 16.0232(14) Å γ = 76.887(4)°. 
Volume 648.15(10) Å3 
Z 1 
Density (calculated) 1.462 g/cm3 
Absorption coefficient 0.118 mm-1 
F(000) 302 
Crystal size 0.32 x 0.24 x 0.10 mm3 
Theta range for data collection 2.38 to 32.57°. 
Index ranges -6<=h<=7, -13<=k<=13, -23<=l<=20 
Reflections collected 13621 
Independent reflections 4352 [R(int) = 0.0424] 
Completeness to theta = 30.00° 98.8 %  
Absorption correction None 
Max. and min. transmission 0.9883 and 0.9632 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4352 / 0 / 196 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0513, wR2 = 0.1306 
R indices (all data) R1 = 0.0739, wR2 = 0.1443 
Largest diff. peak and hole 0.425 and -0.425 e.Å-3 
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Crystal data and structure refinement for 27ADI. 
Identification code  sf0946m 
Empirical formula  C22 H28 N4 O6 
Formula weight  444.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1160(4) Å α= 90.704(2)°. 
 b = 5.1957(4) Å β= 93.362(2)°. 
 c = 19.5042(16) Å γ = 91.346(2)°. 
Volume 517.36(7) Å3 
Z 1 
Density (calculated) 1.427 g/cm3 
Absorption coefficient 0.105 mm-1 
F(000) 236 
Crystal size 0.32 x 0.22 x 0.14 mm3 
Theta range for data collection 3.14 to 32.56°. 
Index ranges -7<=h<=6, -6<=k<=7, -29<=l<=26 
Reflections collected 8119 
Independent reflections 3505 [R(int) = 0.0163] 
Completeness to theta = 30.00° 98.6 %  
Absorption correction None 
Max. and min. transmission 0.9854 and 0.9671 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3505 / 0 / 151 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0375, wR2 = 0.1069 
R indices (all data) R1 = 0.0437, wR2 = 0.1132 
Largest diff. peak and hole              0.507 and -0.245 e.Å-3 
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 Crystal data and structure refinement for 27SUB. 
Identification code  sf1002m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1221(4) Å α= 94.963(2)°. 
 b = 5.2045(4) Å β= 95.404(2)°. 
 c = 21.5019(14) Å γ = 91.630(2)°. 
Volume 568.12(7) Å3 
Z 1 
Density (calculated) 1.381 g/cm3 
Absorption coefficient 0.100 mm-1 
F(000) 252 
Crystal size 0.32 x 0.24 x 0.08 mm3 
Theta range for data collection 3.93 to 32.58°. 
Index ranges -6<=h<=7, -7<=k<=6, -32<=l<=32 
Reflections collected 10539 
Independent reflections 3669 [R(int) = 0.0198] 
Completeness to theta = 27.50° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.9920 and 0.9686 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3669 / 0 / 160 
Goodness-of-fit on F2 1.064 
Final R indices [I>2sigma(I)] R1 = 0.0429, wR2 = 0.1227 
R indices (all data) R1 = 0.0529, wR2 = 0.1303 
Largest diff. peak and hole 0.458 and -0.237 e.Å-3 
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 Crystal data and structure refinement for 28SUC. 
Identification code  sf0716m 
Empirical formula  C22 H28 N4 O6 
Formula weight  444.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1754(4) Å α= 118.826(4)°. 
 b = 10.9294(8) Å β= 91.381(5)°. 
 c = 10.9423(8) Å γ = 99.872(4)°. 
Volume 530.11(7) Å3 
Z 1 
Density (calculated) 1.392 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 236 
Crystal size 0.15 x 0.15 x 0.10 mm3 
Theta range for data collection 2.14 to 30.49°. 
Index ranges -7<=h<=6, -15<=k<=15, -15<=l<=15 
Reflections collected 12293 
Independent reflections 3228 [R(int) = 0.0513] 
Completeness to theta = 30.49° 99.5 %  
Absorption correction None 
Max. and min. transmission 0.9898 and 0.9848 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3228 / 0 / 151 
Goodness-of-fit on F2 1.063 
Final R indices [I>2sigma(I)] R1 = 0.0605, wR2 = 0.1509 
R indices (all data) R1 = 0.0993, wR2 = 0.1761 
Largest diff. peak and hole 0.528 and -0.294 e.Å-3 
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 Crystal data and structure refinement for 28ADI. 
Identification code  sf0901m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1412(4) Å α= 95.094(5)°. 
 b = 5.2394(4) Å β= 95.603(4)°. 
 c = 21.3961(17) Å γ = 91.076(5)°. 
Volume 571.10(8) Å3 
Z 1 
Density (calculated) 1.374 g/cm3 
Absorption coefficient 0.100 mm-1 
F(000) 252 
Crystal size 0.24 x 0.14 x 0.06 mm3 
Theta range for data collection 2.88 to 31.49°. 
Index ranges -7<=h<=6, -7<=k<=7, -31<=l<=31 
Reflections collected 9707 
Independent reflections 3695 [R(int) = 0.0336] 
Completeness to theta = 31.49° 97.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3695 / 0 / 160 
Goodness-of-fit on F2 1.095 
Final R indices [I>2sigma(I)] R1 = 0.0470, wR2 = 0.1167 
R indices (all data) R1 = 0.0691, wR2 = 0.1293 
Largest diff. peak and hole 0.442 and -0.258 e.Å-3 
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Crystal data and structure refinement for 28SUB. 
Identification code  sf0705m 
Empirical formula  C26 H36 N4 O6 
Formula weight  500.59 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1392(5) Å α= 94.050(3)°. 
 b = 5.2412(5) Å β= 95.222(2)°. 
 c = 23.145(2) Å γ = 91.277(2)°. 
Volume 619.02(10) Å3 
Z 1 
Density (calculated) 1.343 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 268 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 1.77 to 30.51°. 
Index ranges -6<=h<=7, -7<=k<=7, -32<=l<=32 
Reflections collected 17489 
Independent reflections 3780 [R(int) = 0.0297] 
Completeness to theta = 30.51° 99.3 %  
Absorption correction None 
Max. and min. transmission 0.9905 and 0.9764 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3780 / 0 / 169 
Goodness-of-fit on F2 1.090 
Final R indices [I>2sigma(I)] R1 = 0.0372, wR2 = 0.1086 
R indices (all data) R1 = 0.0424, wR2 = 0.1137 
Largest diff. peak and hole 0.495 and -0.278 e.Å-3 
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Crystal data and structure refinement for 28SEB. 
Identification code  sf0830m 
Empirical formula  C28 H40 N4 O6 
Formula weight  528.64 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1506(4) Å α= 89.647(4)°. 
 b = 5.2481(4) Å β= 87.252(4)°. 
 c = 24.5206(16) Å γ = 88.505(5)°. 
Volume 661.82(8) Å3 
Z 1 
Density (calculated) 1.326 g/cm3 
Absorption coefficient 0.094 mm-1 
F(000) 284 
Crystal size 0.24 x 0.14 x 0.08 mm3 
Theta range for data collection 3.33 to 33.14°. 
Index ranges -7<=h<=7, -7<=k<=8, -37<=l<=37 
Reflections collected 16445 
Independent reflections 4947 [R(int) = 0.0338] 
Completeness to theta = 33.14° 98.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4947 / 0 / 178 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0493, wR2 = 0.1271 
R indices (all data) R1 = 0.0827, wR2 = 0.1420 
Largest diff. peak and hole 0.451 and -0.254 e.Å-3 
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Crystal data and structure refinement for 28DOD. 
Identification code  sf0928m 
Empirical formula  C30 H44 N4 O6 
Formula weight  556.69 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1519(4) Å α= 86.023(6)°. 
 b = 5.2778(5) Å β= 89.386(6)°. 
 c = 26.148(3) Å γ = 88.496(6)°. 
Volume 708.99(11) Å3 
Z 1 
Density (calculated) 1.304 g/cm3 
Absorption coefficient 0.091 mm-1 
F(000) 300 
Crystal size 0.28 x 0.04 x 0.04 mm3 
Theta range for data collection 2.34 to 32.58°. 
Index ranges -7<=h<=7, -7<=k<=7, -39<=l<=37 
Reflections collected 16574 
Independent reflections 5028 [R(int) = 0.0726] 
Completeness to theta = 32.58° 97.8 %  
Absorption correction None 
Max. and min. transmission 0.9964 and 0.9749 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5028 / 0 / 187 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0650, wR2 = 0.1632 
R indices (all data) R1 = 0.1159, wR2 = 0.1937 
Largest diff. peak and hole 0.403 and -0.358 e.Å-3 
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Crystal data and structure refinement for 28OXA. 
Identification code  sf0920m 
Empirical formula  C20 H24 N4 O6 
Formula weight  416.43 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1134(6) Å α= 95.992(7)°. 
 b = 5.3528(7) Å β= 91.615(7)°. 
 c = 17.611(2) Å γ = 91.021(7)°. 
Volume 479.11(10) Å3 
Z 1 
Density (calculated) 1.443 g/cm3 
Absorption coefficient 0.108 mm-1 
F(000) 220 
Crystal size 0.26 x 0.16 x 0.08 mm3 
Theta range for data collection 4.91 to 32.58°. 
Index ranges -7<=h<=7, -7<=k<=8, -26<=l<=26 
Reflections collected 10093 
Independent reflections 3452 [R(int) = 0.0303] 
Completeness to theta = 25.00° 98.7 %  
Absorption correction None 
Max. and min. transmission 0.9914 and 0.9724 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3452 / 0 / 143 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0402, wR2 = 0.1099 
R indices (all data) R1 = 0.0500, wR2 = 0.1159 
Largest diff. peak and hole 0.472 and -0.236 e.Å-3 
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Crystal data and structure refinement for 28PIM. 
Identification code  sf0927m 
Empirical formula  C25 H34 N4 O6 
Formula weight  486.56 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0330(4) Å α= 82.823(4)°. 
 b = 11.9025(9) Å β= 89.008(4)°. 
 c = 20.6795(16) Å γ = 79.850(4)°. 
Volume 1209.86(16) Å3 
Z 2 
Density (calculated) 1.336 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 520 
Crystal size 0.26 x 0.14 x 0.12 mm3 
Theta range for data collection 2.12 to 32.70°. 
Index ranges -7<=h<=7, -17<=k<=18, 0<=l<=31 
Reflections collected 17249 
Independent reflections 17249 [R(int) = 0.0000] 
Completeness to theta = 32.70° 97.6 %  
Absorption correction None 
Max. and min. transmission 0.9885 and 0.9754 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 17249 / 0 / 329 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0547, wR2 = 0.1419 
R indices (all data) R1 = 0.0810, wR2 = 0.1590 
Largest diff. peak and hole 0.527 and -0.291 e.Å-3 
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Crystal data and structure refinement for 29SUC. 
Identification code  sf0831m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1072(4) Å α= 96.134(6)°. 
 b = 5.1171(4) Å β= 94.037(6)°. 
 c = 22.119(2) Å γ = 91.340(6)°. 
Volume 573.05(8) Å3 
Z 1 
Density (calculated) 1.369 g/cm3 
Absorption coefficient 0.099 mm-1 
F(000) 252 
Crystal size 0.24 x 0.14 x 0.08 mm3 
Theta range for data collection 2.79 to 31.64°. 
Index ranges -7<=h<=7, -7<=k<=7, 0<=l<=32 
Reflections collected 5484 
Independent reflections 5484 [R(int) = 0.0000] 
Completeness to theta = 31.64° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9921 and 0.9765 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5484 / 0 / 161 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0471, wR2 = 0.1143 
R indices (all data) R1 = 0.0597, wR2 = 0.1230 
Largest diff. peak and hole 0.403 and -0.250 e.Å-3 
 286 
Crystal data and structure refinement for 29ADI. 
Identification code  sf0813m 
Empirical formula  C26 H36 N4 O6 
Formula weight  500.59 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1403(3) Å α= 93.859(4)°. 
 b = 5.2489(3) Å β= 95.267(4)°. 
 c = 22.9829(15) Å γ = 91.289(4)°. 
Volume 615.82(6) Å3 
Z 1 
Density (calculated) 1.350 g/cm3 
Absorption coefficient 0.097 mm-1 
F(000) 268 
Crystal size 0.25 x 0.10 x 0.05 mm3 
Theta range for data collection 2.68 to 31.41°. 
Index ranges -7<=h<=7, -7<=k<=7, -33<=l<=33 
Reflections collected 10595 
Independent reflections 3955 [R(int) = 0.0263] 
Completeness to theta = 31.41° 97.0 %  
Absorption correction None 
Max. and min. transmission 0.9952 and 0.9763 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3955 / 0 / 169 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0402, wR2 = 0.1061 
R indices (all data) R1 = 0.0570, wR2 = 0.1154 
Largest diff. peak and hole 0.439 and -0.213 e.Å-3 
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Crystal data and structure refinement for 29SUB. 
Identification code  sf0808m 
Empirical formula  C28 H40 N4 O6 
Formula weight  528.64 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1420(4) Å α= 89.785(4)°. 
 b = 5.2541(4) Å β= 87.095(4)°. 
 c = 24.624(2) Å γ = 88.590(4)°. 
Volume 664.20(9) Å3 
Z 1 
Density (calculated) 1.322 g/cm3 
Absorption coefficient 0.093 mm-1 
F(000) 284 
Crystal size 0.20 x 0.15 x 0.10 mm3 
Theta range for data collection 0.83 to 31.88°. 
Index ranges -7<=h<=7, -7<=k<=7, -27<=l<=36 
Reflections collected 11236 
Independent reflections 4009 [R(int) = 0.0293] 
Completeness to theta = 25.00° 97.2 %  
Absorption correction None 
Max. and min. transmission 0.9907 and 0.9816 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4009 / 0 / 178 
Goodness-of-fit on F2 1.005 
Final R indices [I>2sigma(I)] R1 = 0.0473, wR2 = 0.1230 
R indices (all data) R1 = 0.0706, wR2 = 0.1384 
Largest diff. peak and hole 0.420 and -0.235 e.Å-3 
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Crystal data and structure refinement for 29SEB. 
Identification code  sf0936m 
Empirical formula  C30 H44 N4 O6 
Formula weight  556.69 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1264(6) Å a= 85.874(4)°. 
 b = 5.2432(6) Å b= 89.354(4)°. 
 c = 26.127(3) Å g = 88.356(4)°. 
Volume 700.11(14) Å3 
Z 1 
Density (calculated) 1.320 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 300 
Crystal size 0.32 x 0.18 x 0.06 mm3 
Theta range for data collection 3.90 to 33.11°. 
Index ranges -7<=h<=5, -7<=k<=7, -40<=l<=38 
Reflections collected 11866 
Independent reflections 4577 [R(int) = 0.0393] 
Completeness to theta = 27.50° 96.7 %  
Absorption correction None 
Max. and min. transmission 0.9945 and 0.9711 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4577 / 0 / 187 
Goodness-of-fit on F2 1.084 
Final R indices [I>2sigma(I)] R1 = 0.0614, wR2 = 0.1655 
R indices (all data) R1 = 0.0956, wR2 = 0.1827 
Largest diff. peak and hole 0.555 and -0.342 e.Å-3 
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Crystal data and structure refinement for 29MAL. 
Identification code  sf0828m 
Empirical formula  C23 H30 N4 O6 
Formula weight  458.51 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 42.2708(18) Å α= 90°. 
 b = 5.1015(2) Å β= 115.572(2)°. 
 c = 22.9436(10) Å γ = 90°. 
Volume 4463.0(3) Å3 
Z 8 
Density (calculated) 1.365 g/cm3 
Absorption coefficient 0.100 mm-1 
F(000) 1952 
Crystal size 0.25 x 0.15 x 0.15 mm3 
Theta range for data collection 4.67 to 32.72°. 
Index ranges -64<=h<=57, 0<=k<=7, 0<=l<=34 
Reflections collected 15642 
Independent reflections 15642 [R(int) = 0.0000] 
Completeness to theta = 30.00° 98.7 %  
Absorption correction None 
Max. and min. transmission 0.9852 and 0.9755 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15642 / 0 / 311 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0570, wR2 = 0.1297 
R indices (all data) R1 = 0.1087, wR2 = 0.1540 
Largest diff. peak and hole 0.479 and -0.323 e.Å-3 
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Crystal data and structure refinement for 30SEB. 
Identification code  sf0708m 
Empirical formula  C22 H28 N4 O6 
Formula weight  444.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.7236(5) Å α= 85.161(3)°. 
 b = 6.7563(6) Å β= 82.746(3)°. 
 c = 16.9532(16) Å γ = 89.911(3)°. 
Volume 534.78(9) Å3 
Z 1 
Density (calculated) 1.380 g/cm3 
Absorption coefficient 0.102 mm-1 
F(000) 236 
Crystal size 0.20 x 0.20 x 0.08 mm3 
Theta range for data collection 3.03 to 30.51°. 
Index ranges -6<=h<=6, -3<=k<=9, -24<=l<=24 
Reflections collected 8968 
Independent reflections 3155 [R(int) = 0.0575] 
Completeness to theta = 30.51° 96.2 %  
Absorption correction None 
Max. and min. transmission 0.9919 and 0.9799 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3155 / 18 / 158 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0652, wR2 = 0.1612 
R indices (all data) R1 = 0.1205, wR2 = 0.1900 
Largest diff. peak and hole 0.273 and -0.329 e.Å-3 
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Crystal data and structure refinement for 31SUC. 
Identification code  sf0945m 
Empirical formula  C20 H24 N4 O6 
Formula weight  416.43 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.0264(7) Å α= 91.733(2)°. 
 b = 10.1248(7) Å β= 107.904(2)°. 
 c = 11.0782(8) Å γ = 110.922(2)°. 
Volume 987.11(12) Å3 
Z 2 
Density (calculated) 1.401 g/cm3 
Absorption coefficient 0.105 mm-1 
F(000) 440 
Crystal size 0.38 x 0.32 x 0.14 mm3 
Theta range for data collection 2.49 to 32.58°. 
Index ranges -8<=h<=15, -15<=k<=14, -16<=l<=16 
Reflections collected 16313 
Independent reflections 6661 [R(int) = 0.0212] 
Completeness to theta = 30.00° 98.2 %  
Absorption correction None 
Max. and min. transmission 0.9854 and 0.9612 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6661 / 0 / 283 
Goodness-of-fit on F2 1.239 
Final R indices [I>2sigma(I)] R1 = 0.0525, wR2 = 0.1571 
R indices (all data) R1 = 0.0645, wR2 = 0.1720 
Largest diff. peak and hole 0.661 and -0.368 e.Å-3 
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Crystal data and structure refinement for 31SUB. 
Identification code  sf0939m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0982(5) Å α= 115.707(3)°. 
 b = 11.4639(10) Å β= 98.696(4)°. 
 c = 11.4873(11) Å γ = 100.874(4)°. 
Volume 573.10(9) Å3 
Z 1 
Density (calculated) 1.369 g/cm3 
Absorption coefficient 0.099 mm-1 
F(000) 252 
Crystal size 0.36 x 0.16 x 0.10 mm3 
Theta range for data collection 2.06 to 31.00°. 
Index ranges -7<=h<=5, -16<=k<=16, -16<=l<=16 
Reflections collected 9022 
Independent reflections 3570 [R(int) = 0.0278] 
Completeness to theta = 30.00° 98.6 %  
Absorption correction None 
Max. and min. transmission 0.9901 and 0.9651 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3570 / 0 / 160 
Goodness-of-fit on F2 1.074 
Final R indices [I>2sigma(I)] R1 = 0.0445, wR2 = 0.1220 
R indices (all data) R1 = 0.0601, wR2 = 0.1316 
Largest diff. peak and hole 0.355 and -0.298 e.Å-3 
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Crystal data and structure refinement for 31DOD. 
Identification code  sf0941m 
Empirical formula  C28 H40 N4 O6 
Formula weight  528.64 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.097(3) Å α= 86.020(18)°. 
 b = 5.486(3) Å β= 86.521(18)°. 
 c = 23.823(13) Å γ = 87.553(18)°. 
Volume 662.8(6) Å3 
Z 1 
Density (calculated) 1.324 g/cm3 
Absorption coefficient 0.094 mm-1 
F(000) 284 
Crystal size 0.38 x 0.04 x 0.04 mm3 
Theta range for data collection 2.58 to 28.28°. 
Index ranges -6<=h<=6, -7<=k<=7, -31<=l<=26 
Reflections collected 10139 
Independent reflections 3194 [R(int) = 0.3225] 
Completeness to theta = 28.28° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.9963 and 0.9653 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3194 / 0 / 65 
Goodness-of-fit on F2 1.446 
Final R indices [I>2sigma(I)] R1 = 0.2077, wR2 = 0.4158 
R indices (all data) R1 = 0.3885, wR2 = 0.4703 
Largest diff. peak and hole 0.949 and -1.211 e.Å-3 
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Crystal data and structure refinement for 32SUC. 
Identification code  sf0809m 
Empirical formula  C22 H28 N4 O6 
Formula weight  444.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0275(6) Å α= 89.749(6)°. 
 b = 6.9253(9) Å β= 81.536(5)°. 
 c = 16.058(2) Å γ = 80.893(6)°. 
Volume 545.92(12) Å3 
Z 1 
Density (calculated) 1.352 g/cm3 
Absorption coefficient 0.100 mm-1 
F(000) 236 
Crystal size 0.25 x 0.25 x 0.15 mm3 
Theta range for data collection 2.57 to 34.34°. 
Index ranges -7<=h<=7, -10<=k<=10, -25<=l<=25 
Reflections collected 14151 
Independent reflections 4361 [R(int) = 0.0241] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9852 and 0.9755 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4361 / 6 / 161 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.1222 
R indices (all data) R1 = 0.0533, wR2 = 0.1305 
Largest diff. peak and hole 0.473 and -0.225 e.Å-3 
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Crystal data and structure refinement for 32ADI. 
Identification code  sf1005m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0282(6) Å a= 98.124(3)°. 
 b = 6.7877(8) Å b= 97.604(3)°. 
 c = 17.522(2) Å g = 94.605(3)°. 
Volume 583.82(12) Å3 
Z 1 
Density (calculated) 1.344 Mg/m3 
Absorption coefficient 0.098 mm-1 
F(000) 252 
Crystal size 0.36 x 0.16 x 0.08 mm3 
Theta range for data collection 2.37 to 30.49°. 
Index ranges -7<=h<=6, -8<=k<=9, -24<=l<=24 
Reflections collected 8477 
Independent reflections 3487 [R(int) = 0.0333] 
Completeness to theta = 30.49° 97.8 %  
Absorption correction None 
Max. and min. transmission 0.9922 and 0.9657 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3487 / 0 / 160 
Goodness-of-fit on F2 1.084 
Final R indices [I>2sigma(I)] R1 = 0.0487, wR2 = 0.1270 
R indices (all data) R1 = 0.0688, wR2 = 0.1400 
Largest diff. peak and hole 0.367 and -0.281 e.Å-3 
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Crystal data and structure refinement for 32SUB. 
Identification code  sf0934m 
Empirical formula  C26 H36 N4 O6 
Formula weight  500.59 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1671(13) Å α= 67.873(11)°. 
 b = 11.646(3) Å β= 80.585(12)°. 
 c = 11.779(4) Å γ = 79.827(12)°. 
Volume 642.6(3) Å3 
Z 1 
Density (calculated) 1.294 g/cm3 
Absorption coefficient 0.093 mm-1 
F(000) 268 
Crystal size 0.28 x 0.18 x 0.08 mm3 
Theta range for data collection 1.88 to 29.57°. 
Index ranges -7<=h<=5, -16<=k<=12, -16<=l<=12 
Reflections collected 9851 
Independent reflections 3328 [R(int) = 0.0395] 
Completeness to theta = 27.50° 96.2 %  
Absorption correction None 
Max. and min. transmission 0.9926 and 0.9745 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3328 / 0 / 169 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0563, wR2 = 0.1407 
R indices (all data) R1 = 0.1002, wR2 = 0.1599 
Largest diff. peak and hole 0.251 and -0.293 e.Å-3 
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Crystal data and structure refinement for 32SEB. 
Identification code  sf0820m 
Empirical formula  C28 H40 N4 O6 
Formula weight  528.64 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.9817(4) Å a= 93.097(4)°. 
 b = 6.8634(6) Å b= 90.233(4)°. 
 c = 20.0493(16) Å g = 98.285(4)°. 
Volume 677.32(10) Å3 
Z 1 
Density (calculated) 1.296 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 284 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 2.03 to 31.64°. 
Index ranges -7<=h<=7, -10<=k<=10, -22<=l<=29 
Reflections collected 11823 
Independent reflections 4462 [R(int) = 0.0296] 
Completeness to theta = 31.64° 97.6 %  
Absorption correction None 
Max. and min. transmission 0.9909 and 0.9775 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4462 / 0 / 178 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0517, wR2 = 0.1446 
R indices (all data) R1 = 0.0676, wR2 = 0.1571 
Largest diff. peak and hole 0.626 and -0.322 e.Å-3 
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Crystal data and structure refinement for 32DOD. 
Identification code  sf0833m 
Empirical formula  C30 H44 N4 O6 
Formula weight  556.69 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.9821(4) Å α= 87.936(6)°. 
 b = 6.8797(6) Å β= 86.223(6)°. 
 c = 21.4410(17) Å γ = 81.469(5)°. 
Volume 724.93(10) Å3 
Z 1 
Density (calculated) 1.275 g/cm3 
Absorption coefficient 0.089 mm-1 
F(000) 300 
Crystal size 0.28 x 0.12 x 0.06 mm3 
Theta range for data collection 2.86 to 31.50°. 
Index ranges -7<=h<=7, -10<=k<=9, -31<=l<=31 
Reflections collected 14792 
Independent reflections 4826 [R(int) = 0.0450] 
Completeness to theta = 31.50° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9947 and 0.9755 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4826 / 0 / 187 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0510, wR2 = 0.1297 
R indices (all data) R1 = 0.0854, wR2 = 0.1478 
Largest diff. peak and hole 0.479 and -0.300 e.Å-3 
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Crystal data and structure refinement for 32OXA. 
Identification code  sf0926m 
Empirical formula  C20 H24 N4 O6 
Formula weight  416.43 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0759(3) Å α= 77.759(2)°. 
 b = 11.9049(8) Å β= 88.428(3)°. 
 c = 16.5104(11) Å γ = 84.804(2)°. 
Volume 970.97(11) Å3 
Z 2 
Density (calculated) 1.424 g/cm3 
Absorption coefficient 0.107 mm-1 
F(000) 440 
Crystal size 0.32 x 0.26 x 0.20 mm3 
Theta range for data collection 1.26 to 32.52°. 
Index ranges -7<=h<=7, -17<=k<=15, -22<=l<=24 
Reflections collected 20512 
Independent reflections 6627 [R(int) = 0.0266] 
Completeness to theta = 30.00° 98.9 %  
Absorption correction None 
Max. and min. transmission 0.9790 and 0.9666 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6627 / 0 / 283 
Goodness-of-fit on F2 1.088 
Final R indices [I>2sigma(I)] R1 = 0.0447, wR2 = 0.1295 
R indices (all data) R1 = 0.0565, wR2 = 0.1379 
Largest diff. peak and hole 0.403 and -0.280 e.Å-3 
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Crystal data and structure refinement for 32GLU. 
Identification code  sf0907m 
Empirical formula  C28 H38 N4 O10 
Formula weight  590.62 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.2223(3) Å α= 92.069(3)°. 
 b = 11.4288(7) Å β= 100.203(3)°. 
 c = 12.4175(7) Å γ = 102.989(3)°. 
Volume 708.52(7) Å3 
Z 1 
Density (calculated) 1.384 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 314 
Crystal size 0.26 x 0.22 x 0.15 mm3 
Theta range for data collection 3.34 to 32.57°. 
Index ranges -7<=h<=7, -17<=k<=17, -18<=l<=17 
Reflections collected 14555 
Independent reflections 5113 [R(int) = 0.0240] 
Completeness to theta = 32.57° 99.2 %  
Absorption correction None 
Max. and min. transmission 0.9843 and 0.9730 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5113 / 0 / 199 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0406, wR2 = 0.1169 
R indices (all data) R1 = 0.0539, wR2 = 0.1267 
Largest diff. peak and hole 0.441 and -0.279 e.Å-3 
 301 
Crystal data and structure refinement for 32HEP. 
Identification code  sf0916m 
Empirical formula  C32 H50 N4 O6 
Formula weight  586.76 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0819(4) Å a= 71.273(4)°. 
 b = 12.1581(11) Å b= 87.334(4)°. 
 c = 13.7060(11) Å g = 80.885(4)°. 
Volume 791.87(11) Å3 
Z 1 
Density (calculated) 1.230 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 318 
Crystal size 0.32 x 0.24 x 0.14 mm3 
Theta range for data collection 1.57 to 31.49°. 
Index ranges -7<=h<=7, -10<=k<=17, -19<=l<=20 
Reflections collected 12589 
Independent reflections 4649 [R(int) = 0.0222] 
Completeness to theta = 27.50° 95.1 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4649 / 0 / 197 
Goodness-of-fit on F2 1.113 
Final R indices [I>2sigma(I)] R1 = 0.0496, wR2 = 0.1411 
R indices (all data) R1 = 0.0643, wR2 = 0.1513 
Largest diff. peak and hole 0.301 and -0.315 e.Å-3 
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Crystal data and structure refinement for 32OCT. 
Identification code  sf0922m 
Empirical formula  C34 H54 N4 O6 
Formula weight  614.81 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1476(9) Å α= 71.870(5)°. 
 b = 11.756(2) Å β= 89.300(6)°. 
 c = 14.714(3) Å γ = 79.313(5)°. 
Volume 830.6(3) Å3 
Z 1 
Density (calculated) 1.229 g/cm3 
Absorption coefficient 0.084 mm-1 
F(000) 334 
Crystal size 0.22 x 0.16 x 0.12 mm3 
Theta range for data collection 4.03 to 32.58°. 
Index ranges -7<=h<=7, -17<=k<=17, -22<=l<=21 
Reflections collected 12360 
Independent reflections 5396 [R(int) = 0.0319] 
Completeness to theta = 30.00° 95.7 %  
Absorption correction None 
Max. and min. transmission 0.9900 and 0.9817 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5396 / 0 / 206 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0521, wR2 = 0.1385 
R indices (all data) R1 = 0.0764, wR2 = 0.1544 
Largest diff. peak and hole 0.392 and -0.243 e.Å-3 
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Crystal data and structure refinement for 32LAU. 
Identification code  sf0914m 
Empirical formula  C42 H70 N4 O6 
Formula weight  727.02 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.9566(9) Å α= 86.710(7)°. 
 b = 6.8438(12) Å β= 88.938(8)°. 
 c = 30.988(6) Å γ = 80.797(7)°. 
Volume 1035.9(3) Å3 
Z 1 
Density (calculated) 1.165 g/cm3 
Absorption coefficient 0.077 mm-1 
F(000) 398 
Crystal size 0.26 x 0.14 x 0.04 mm3 
Theta range for data collection 2.63 to 31.00°. 
Index ranges -7<=h<=7, -5<=k<=9, -43<=l<=44 
Reflections collected 21462 
Independent reflections 6407 [R(int) = 0.0664] 
Completeness to theta = 31.00° 97.4 %  
Absorption correction None 
Max. and min. transmission 0.9969 and 0.9802 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6407 / 0 / 241 
Goodness-of-fit on F2 1.179 
Final R indices [I>2sigma(I)] R1 = 0.0760, wR2 = 0.1926 
R indices (all data) R1 = 0.1217, wR2 = 0.2117 
Largest diff. peak and hole 0.464 and -0.308 e.Å-3 
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Crystal data and structure refinement for 33SUC. 
Identification code  sf0935m 
Empirical formula  C24 H32 N4 O6 
Formula weight  472.54 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 5.6265(5) Å a= 90°. 
 b = 5.0514(4) Å b= 93.156(5)°. 
 c = 41.791(4) Å g = 90°. 
Volume 1185.98(18) Å3 
Z 2 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 504 
Crystal size 0.36 x 0.14 x 0.06 mm3 
Theta range for data collection 3.84 to 30.11°. 
Index ranges -5<=h<=7, -7<=k<=5, -58<=l<=58 
Reflections collected 12813 
Independent reflections 3407 [R(int) = 0.0609] 
Completeness to theta = 30.11° 97.6 %  
Absorption correction None 
Max. and min. transmission 0.9943 and 0.9663 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3407 / 0 / 160 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0547, wR2 = 0.1379 
R indices (all data) R1 = 0.1196, wR2 = 0.1632 
Largest diff. peak and hole 0.208 and -0.198 e.Å-3 
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Crystal data and structure refinement for 33SUB. 
Identification code  sf0919m 
Empirical formula  C28 H40 N4 O6 
Formula weight  528.64 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.9897(14) Å α= 94.517(9)°. 
 b = 6.8639(18) Å β= 92.960(10)°. 
 c = 20.045(5) Å γ = 99.537(9)°. 
Volume 673.5(3) Å3 
Z 1 
Density (calculated) 1.303 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 284 
Crystal size 0.28 x 0.14 x 0.08 mm3 
Theta range for data collection 3.10 to 32.58°. 
Index ranges -7<=h<=6, -10<=k<=8, -30<=l<=29 
Reflections collected 11396 
Independent reflections 4516 [R(int) = 0.0399] 
Completeness to theta = 30.00° 97.2 %  
Absorption correction None 
Max. and min. transmission 0.9927 and 0.9747 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4516 / 0 / 178 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0547, wR2 = 0.1314 
R indices (all data) R1 = 0.0957, wR2 = 0.1495 
Largest diff. peak and hole 0.325 and -0.259 e.Å-3 
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Crystal data and structure refinement for 33PIM. 
Identification code  sf0925m 
Empirical formula  C34 H50 N4 O10 
Formula weight  674.78 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1587(3) Å α= 86.165(3)°. 
 b = 11.5313(7) Å β= 80.328(3)°. 
 c = 14.8862(9) Å γ = 78.897(3)°. 
Volume 856.06(9) Å3 
Z 1 
Density (calculated) 1.309 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 362 
Crystal size 0.28 x 0.20 x 0.12 mm3 
Theta range for data collection 2.78 to 31.50°. 
Index ranges -7<=h<=7, -16<=k<=16, -21<=l<=21 
Reflections collected 20473 
Independent reflections 5667 [R(int) = 0.0416] 
Completeness to theta = 31.50° 99.3 %  
Absorption correction None 
Max. and min. transmission 0.9885 and 0.9735 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5667 / 0 / 226 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0459, wR2 = 0.1279 
R indices (all data) R1 = 0.0657, wR2 = 0.1411 
Largest diff. peak and hole 0.435 and -0.250 e.Å-3 
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Appendix D - Infrared Spectra of cocrystals of 27-29 
 308 
 
Figure D.1 FT-IR of 27 (green), 27SUC (turquoise), 27ADI (red) and 27SUB (blue). 
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Figure D.2 FT-IR of 27 (red), 27SEB (green) and 27DOD (orange). 
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Figure D.3 FT-IR of 28 (blue), 28SUC (purple) and 28ADI (red). 
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Figure D.4 FT-IR of 28 (blue), 28SUB (green), 28SEB (orange) and 28DOD (red). 
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Figure D.5 FT-IR of 29 (blue), 29SUC (purple), 29ADI (red). 
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Figure D.6 FT-IR of 29SUB (turquoise), 29SEB (pink), 29DOD (red).  
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Appendix E - Solubility data for cocrystals of 28 and 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 315 
 
 
Figure E.1 UV-Vis profile for 28 
 
 
Figure E.2 Calibration curve of 28 
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Table E.1 Solubility of cocrystals 28SUC-28DOD and single component crystals, 28 
in water at T = 25oC 
Sample Solubility (g/L) 
28 0.2151± 0.0209 
28SUC 0.5122± 0.0024 
28ADI 0.3594± 0.0052 
28SUB 0.2820± 0.0038 
28SEB 0.0371± 0.0032 
28DOD 0.0222± 0.0001 
Solubility values are the mean ± standard deviation of n = 4 
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Figure E.3 UV-Vis profile of 29 
 
 
Figure E.4 Calibration curve of 29 
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Table E.2 Solubility of cocrystals 29SUC-29DOD and single component crystals, 29 
in water at T = 25oC 
Sample Solubility (g/L) 
29 0.0412 ± 0.04118 
29SUC 0.1786± 0.001 
29ADI 0.1076± 0.002 
29SUB 0.0877± 0.002 
29SEB 0.0523± 0.002 
29DOD 0.0530± 0.001 
Solubility of values are the mean ± standard deviation n = 4. 
 
